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Abstract 
For many tissues fatty acids represent the major source of fuel. In the past few decades it 
has become evident that in addition to their role as energy substrates, fatty acids also have 
an important signaling function by modulating transcription of genes. An important group 
of transcription factors involved in mediating the effects of dietary fatty acids on gene 
transcription are the Peroxisome Proliferator-Activated Receptors (PPARs). PPARs are 
members of the superfamily of nuclear hormone receptors and regulate genes involved in 
numerous important biological processes, ranging from lipid metabolism to inflammation 
and wound healing. In the liver the dominant PPAR isoform has been show to be PPARα, 
although PPARβ/δ and PPARγ are expressed in liver as well. 
 
The aim of this thesis was to further characterize the role of PPARα and PPARβ/δ in 
hepatic metabolism and study their activation by fatty acids. Even though PPARα as gene 
regulator in liver has been well described, a complete overview of its target genes has been 
lacking so far. By combining several nutrigenomics tools, we succeeded in creating a 
comprehensive list of PPARα-regulated genes involved in lipid metabolism in liver. 
Additionally, by using a unique design where mice were fed synthetic triglycerides 
consisting of one type of fatty acid, we could distinguish between different types of dietary 
unsaturated fatty acids in their ability to activate PPARα. Although it is well known that 
PPARα plays an important role in liver during fasting, no direct in vivo evidence exists that 
circulating free fatty acids are able to ligand activate hepatic PPARα. In our studies, we 
found that upregulation of gene expression by PPARβ/δ is sensitive to circulating plasma 
free fatty acids whereas this is not the case for PPARα. Not much is known about the 
function of PPARβ/δ in the liver. In order to better understand the role of this nuclear 
receptor, we compared the effects of PPARα and PPARβ/δ deletion on whole genome gene 
regulation and plasma and liver metabolites. Our results revealed that PPARβ/δ does not 
mediate an adaptive response to fasting, and pointed to a role for PPARβ/δ in hepatic 
glucose- and lipoprotein metabolism. 
 
In conclusion, this thesis contributes to the important work of mapping the molecular 
mechanisms dictating lipid metabolism in the liver. By using several nutrigenomics tools, 
we are able to show that PPARα is a key mediator of the effect of dietary fatty acids on 
hepatic gene expression. In addition, we better define the roles of PPARα and PPARβ/δ in 
hepatic metabolism and provide a new concept for functional differentiation between 
PPARs in liver. 
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Nutrigenomics – a combination of molecular nutrition and 
genomics 
Obesity is increasing world wide and has become one of the major health challenges 
globally. Several metabolic abnormalities are associated with obesity, including insulin 
resistance, high blood pressure, high blood cholesterol and high triglyceride levels. These 
conditions are collectively referred to as metabolic syndrome or syndrome X (1, 2). One of 
the important challenges for nutritional science today is to find effective solutions for this 
increasing problem of obesity and its related conditions. 
 
Until recently, nutrition research focused mainly on physiological and epidemiological 
aspects of human health. The introduction of nutrigenomics has created large opportunities 
to increase our understanding of nutrition on a molecular level. Nutrigenomics, or 
nutritional genomics, studies the genome-wide influences of nutrition, and can be seen as a 
combination of molecular nutrition and genomics (3, 4). Within the field of nutrigenomics, 
nutrients are perceived as dietary signal molecules that bring about changes in gene-, 
protein- and metabolite expression. Presently, nutrigenomics research mainly targets 
disease prevention rather than curing already developed illnesses. A major focus is on 
chronic diseases, such as cardiovascular disease, metabolic syndrome and cancer, which are 
generally related to overconsumption of certain nutrients or food components. With the 
help of nutrigenomics, biomarker profiles can be created that allow separation of healthy 
and (early-) diseased states. The expectation is that in these early disease states nutritional 
intervention will suffice to restore health without the need for pharmacological therapy. 
 
In order to reach the ambitious goals that nutrigenomics pursues, various genomics 
techniques are applied, including transcriptomics, proteomics, and metabolomics, as well as 
functional genomics tools such as transgenic and knockout mouse models. Genes that are 
particularly interesting to knockout in these models are those whose products function as 
nutrient sensors, including many members of the nuclear receptor superfamily. 
Transcriptomics has become a very important tool for the large scale analysis of biological 
processes. This technique measures the amounts of the various mRNAs that are being 
transcribed at any given moment in a cell or tissue. A transcriptome constitutes the basis for 
its corresponding proteome, and can vary a great deal in response to external stimuli such 
as exposure to certain nutrients or chemicals, or as a response to disease. 
 
In the past decade, microarray technology has developed into a major tool for high-
throughput transcriptomics. High-density oligonucleotide arrays, such as the Affymetrix 
GeneChip® Arrays, are able to measure the expression of the entire genome of an organism 
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in a single hybridization assay (5, 6). Affymetrix uses photolithography to attach millions 
of DNA probes onto a glass surface, creating an array with a massive amount of 
information on a small surface area (5). Each transcript in an RNA sample is represented by 
a set of 20 probe-pairs on the array, each probe built up of 25 nucleotides (7, 8). A probe-
pair consists of a perfect match (PM) probe and a mismatch (MM) probe, which is identical 
to the PM probe with the exception that the middle nucleotide is substituted with its 
complement (7). The purpose of this design is to detect non-specific hybridization with the 
MM probe, whereas the PM probe will detect specific hybridization of transcripts from the 
gene of interest. Reliable results from microarray analyses are highly dependent on good 
quality control of the arrays and sound statistical tests of the outcome measurements (9). 
 
The liver as metabolic regulator 
The liver is of major importance in maintaining whole body metabolic homeostasis. In the 
fed state, a variety of substrates originating from the diet reach the liver, including glucose 
and fatty acids. The uptake of glucose from the hepatic portal vein into the hepatocyte 
occurs with the help of the GLUT2 transporter (10). When blood glucose levels rise after a 
meal, the pancreatic β-cells start producing and secreting insulin into the blood. The 
subsequent rise in plasma insulin stimulates several enzymes in the liver involved in the 
formation of glycogen, which functions as a storage form of glucose. This process will 
continue as long as there is enough glucose and insulin in the blood and until the glycogen 
storage in the liver has been saturated (11). An additional response to excess glucose is de 
novo synthesis of fatty acids by the liver. These fatty acids are excreted in the form of very 
low density lipoprotein (VLDL) particles into the blood stream to be used by other tissues 
such as adipose tissue (for storage in the form of triglycerides) and muscle, eventually 
returning to the liver as VLDL remnants. 
 
The majority of fatty acids taken up by the liver are derived from endogenous triglyceride 
stores in the adipose tissue and circulate as free fatty acids. The remainder of fatty acids 
taken up are derived from the diet and arrive in the liver as free fatty acids via the portal 
vein in the case of short- or medium chain fatty acids, or as triglycerides incorporated into 
chylomicron remnants in the case of long chain fatty acids. Uptake of fatty acids into the 
hepatocyte occurs through the transporters fatty acid transport protein (FATP), fatty acid 
translocase (FAT/CD36), and possibly by diffusion, although the relative contribution of 
each of these processes remains to be determined (12). 
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The liver is a major site for fatty acid beta oxidation, which operates in both the 
mitochondria and peroxisomes of the hepatocyte and yields energy in the form of ATP. In 
certain obese individuals, excess hepatic uptake of fatty acids cannot be properly 
compensated by increased fatty acid breakdown or increased triglyceride secretion, giving 
rise to fatty liver or steatosis. This abnormal fat storage has been correlated with the 
metabolic syndrome and represents the early stage of non-alcoholic fatty liver disease 
(NAFLD). For reasons that are poorly understood, in some individuals the hepatic steatosis 
progresses towards the more severe non-alcoholic steatohepatitis (NASH), which may be 
followed by cirrhosis and ultimately liver failure. 
 
In the fasted state, glucose and insulin levels in the blood decline and the liver will start 
using up the stored glycogen via a process called glycogenolysis (13). The high activity of 
glucose 6 phosphatase allows the liver to release glucose in the blood stream, which can be 
used by other tissues in the body as fuel. It is estimated that liver glycogen storage is 
sufficient to maintain glucose homeostasis in the blood for up to 10 hours (11). Once the 
glycogen reserves have been exhausted, the body relies upon the liver in particular to make 
glucose via the process of gluconeogenesis using lactate, gluconeogenic amino acids, and 
glycerol as substrate (11). 
 
In response to low plasma insulin levels and high rates of hepatic fatty acid uptake, another 
process is initiated in the liver, which is ketogenesis. Ketogenesis describes the production 
of ketone bodies in the mitochondria from fatty acids released from white adipose tissue 
during fasting. The ketone bodies, which include β–hydroxybutyrate, acetoacetate and 
acetone, are transported from the liver to especially the brain, where they serve as 
important alternative substrates for energy production. 
 
Nuclear receptors function as nutrient sensors 
Nuclear receptors are transcription factors that mediate the effects of nutrients on gene 
expression. Upon binding of a ligand, which can be a natural or pharmacological 
compound, the receptor is activated, leading to binding of the receptor-ligand complex to 
DNA and increased transcription of specific target genes. 
 
The superfamily of nuclear hormone receptors consists of 48 members and represents the 
most important group of nutrient sensors (3). Many members of this group bind nutrients 
and their metabolites, including retinoic acid (retinoic acid receptor RAR and retinoid X 
receptor RXR), vitamin D (vitamin D receptor VDR), bile salts (farnesoid X receptor 
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FXR), and fatty acids (peroxisome proliferator activated receptors PPARs). Chapter 2 
describes in more detail the function of nuclear receptors in general and the PPAR family 
in particular. 
 
Fatty acids – major biological regulators 
Fat has traditionally been regarded exclusively as a way for the body to store energy. In the 
past decades it has become evident, however, that fatty acids function as signaling 
molecules with the ability to alter the regulation of genes involved in important biological 
processes. 
 
Our diet consists mainly of saturated (SFA) and monounsaturated (MUFA) fatty acids, with 
a much smaller amount of polyunsaturated fatty acids (PUFA). A growing body of 
evidence indicates that an increased PUFA consumption can result in several health 
benefits, such as a decreased risk of cardiovascular disease, increased insulin sensitivity 
and protection of age-related neurological degeneration (14-16). Important dietary sources 
of PUFAs include fatty fish (eicosapentaenoic acid, EPA, and docosahexaenoic acid, 
DHA), and numerous vegetable oils. 
 
However, it has been shown that dietary fatty acids have the ability to directly regulate 
genes involved in several inflammatory processes, lipid metabolism and energy utilization 
(17). PUFAs are able to increase fat oxidation via activation of peroxisome proliferator 
activated receptors, as well as suppress lipogenic genes via inhibition of sterol regulatory 
element-binding protein 1 (SREBP-1) (18, 19). Whether these mechanisms account for the 
beneficial effects of PUFAs on human health requires further investigation. 
 
Outline of this thesis 
The aim of the research described in this thesis is to determine the importance of the 
nuclear receptors PPARα and PPARβ/δ in fatty acid dependent gene regulation in liver, and 
to better characterize their functional roles in hepatic lipid metabolism. To this end, a 
nutrigenomics approach is followed using several common tools such as transgenic- and 
knockout mouse models and expression microarrays. 
 
In Chapter 2 a detailed overview is presented of the three members of the PPAR family 
and their important roles in metabolism and inflammation. Chapter 3 is a descriptive 
profiling study designed for two purposes: 1) to generate a comprehensive overview of 
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PPARα-regulated genes relevant to lipid metabolism in liver and 2) to identify possible 
novel PPARα target genes and –pathways involved in lipid metabolism. Chapter 4 
addresses the overall role of PPARα in gene regulation by dietary fatty acids in liver using 
a unique experimental design based on synthetic triglycerides in combination with 
transcriptomics. In Chapter 5, we compare the activation of PPARα and PPARβ/δ in 
mouse liver during fasting and find that PPARβ/δ, but not PPARα, responds to increased 
plasma free fatty acid levels. In Chapter 6 a comparative transcriptomics analysis is 
presented of the impact of PPARα and PPARβ/δ inactivation on liver gene expression 
during fasting. In Chapter 7 the results of an in silico method for the screening of putative 
PPREs in the mouse genome are compared with results from gene expression analysis. 
Finally, in Chapter 8 the general discussion and conclusions are presented. 
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Abstract 
The ligand-activated family of peroxisome proliferator activated receptors (PPARs) 
consists of three members named PPARα, PPARδ and PPARγ. Each PPAR subtype is 
characterized by a specific tissue expression pattern, partially accounting for distinct 
biological functions. Analogous to many other nuclear receptors, PPARs form heterodimers 
with the retinoid X receptor and regulate DNA transcription by binding to specific response 
elements present in target genes. 
 
PPARα (NR1C1) is highly expressed in liver, heart, intestine, skeletal muscle, and various 
immune cells. Agonists for PPARα include the lipid-lowering fibrate drugs as well as 
numerous fatty acids and eicosanoids. PPARα is known to play an important role in many 
different metabolic processes, especially under conditions of fasting, and has proven to be 
an extremely important regulator of inflammation via inhibition of gene expression. 
 
PPARδ (NR1C2) is ubiquitously expressed but its function has mainly been studied in skin, 
heart, and skeletal muscle. In the past few years, it has become evident that PPARδ is 
involved in numerous biological processes including lipid metabolism, wound healing and 
inflammation. 
 
The most studied PPAR subtype is PPARγ (NR1C3), which is expressed at high levels in 
adipose tissue, macrophages and vascular cells. PPARγ drives adipocyte differentiation, 
has important regulatory roles during fat storage and glucose metabolism, and is an 
important suppressor of inflammation. Importantly, it serves as the molecular target for the 
thiazolidionedione drugs. 
 
In this chapter we provide an overview of the major functions of the three PPAR subtypes, 
and focus on their role in metabolic and inflammatory processes. 
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Introduction 
The peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription 
factors that belong to the superfamily of nuclear hormone receptors, and more specifically 
to the class II nuclear receptors. Three subtypes encoded by separate genes can be 
distinguished: PPARα, PPARβ/δ and PPARγ (20, 21). Until now, PPARs have been cloned 
from several species, including human, mouse, rat, chicken, fish, guinea pig, hamster and 
amphibian (21, 22). 
 
PPARs, like many other nuclear receptors, bind to DNA and regulate transcription in the 
form of a heterodimer with the nuclear receptor retinoid X receptor (RXR) (Figure 1A). 
Recent evidence suggests that to a large extent PPARs and retinoid X receptors are 
associated even in the absence of ligand (23). Activation of target genes occurs through 
direct binding of the PPAR:RXR heterodimer to specific nucleotide sequences called 
peroxisome proliferator response elements (PPREs) (24). These response elements are of 
the direct repeat 1 (DR-1) type, which is defined by a direct repetition of the consensus 
sequence AGGTCA with a single nucleotide insertion between the two repeats (24). PPAR 
will bind to the 5’ part of the response element, whereas RXR binds to the 3’ half-site (24). 
A PPRE is commonly present as one or multiple copies located in or close to the promoter 
region of a target gene (24). 
 
Members of the nuclear hormone receptor family are related to each other with respect to 
amino acid sequence and their molecular mode of function within cells. They share a 
highly conserved DNA binding domain (DBD) responsible for binding to the response 
element sequence in target genes. A reasonably well conserved ligand-binding domain 
(LBD) is present at the C-terminal end of the receptors, which binds ligands and interacts 
with coactivators. Crystallographic structures of PPARs reveal an exceptionally spacious 
ligand-binding pocket compared to other nuclear receptors, thereby explaining the 
promiscuity in ligand binding (25-27). Ligands of PPARs include numerous fatty acids and 
their derivates, as well as a large number of industrially synthesized compounds. 
 
The ability of PPARs to regulate transcription is controlled by complex interactions 
involving coactivators and corepressors (Figure 1). PPARs are present in the nucleus of the 
cell, both in the presence and absence of ligand. In the latter case, compression of the 
chromatin is caused by corepressor proteins such as nuclear corepressors (NCoRs) and 
silencing mediator for retinoid and thyroid hormone receptor (SMRT), which connect 
PPARs with enzymes expressing histone deacetylase activity (28-30). Once ligand binding 
occurs, these corepressor protein complexes dissociate, and subsequent recruitment of 
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several coactivator proteins leads to a conformational change within the ligand-binding 
domain of the receptor (29, 30). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic depiction of the mechanism of gene regulation by PPARs. 
Transcriptional regulation and the interplay between PPARs and cofactors. PPARs bind to DNA and 
regulate transcription as a heterodimer with the nuclear receptor retinoid X receptor (RXR). In the 
absence of ligand, corepressor proteins such as nuclear corepressor (NCoR) and silencing mediator 
for retinoid and thyroid hormone receptor (SMRT) connect the PPAR:RXR complex with enzymes 
expressing histone deacetylase activity (HDAC). This causes compression of the chromatin structure 
and a subsequent repression of gene transcription. Ligand binding is followed by a dissociation of the 
corepressor complexes and recruitment of coactivator proteins. CREB binding protein (CBP) and 
adenovirus E1A-associated protein (p300) are coactivators that possess histone acetyltransferase 
(HAT) activity, leading to remodeling of the chromatin structure and a facilitation of gene 
transcription. Steroid receptor coactivator 1 (SRC-1) forms a complex with CBP/p300 proteins, 
thereby recruiting HAT activity. PPAR gamma coactivator 1 (PGC-1) has the ability to recruit 
enzymes that posses HAT activity. PPAR binding protein (PBP) serves as an anchor within multi-
subunit coactivator complexes, called TRAP complexes, which may function as docking platforms 
for RNA polymerase II during the transcriptional process. 
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Figure 2. The regulatory role of PPARs in different tissues. Overview of tissue distribution 
and different processes where PPARs have proven to play an important regulatory role. 
 
 
 
 
 
Several nuclear receptor coactivators have been identified in recent years. Coactivators 
contain a so-called LXXLL (L: leucine; X: any amino acid) motif, where direct binding 
with the ligand binding domain of the nuclear receptor takes place. Coactivators often have 
several different LXXLL motifs, suggesting that they are able to bind to several different 
nuclear receptors simultaneously. 
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Some coactivators possess histone acetyltransferase (HAT) activity (Figure 1). This group 
of coactivators is able to remodel chromatin structure and in this way facilitate gene 
transcription (30, 31). Examples of this type of coactivators are CBP (CREB binding 
protein) and p300 (adenovirus E1A-associated protein). SRC-1 (steroid receptor 
coactivator) is a coactivator that binds to the LBD on the receptor in a ligand-dependent 
manner and forms a complex with CBP/p300 proteins, thereby recruiting HAT activity. 
 
A different group of coactivators consists of proteins that form multi-subunit coactivator 
complexes. These coactivators are recruited to the nuclear receptor in a ligand-dependent 
manner, and may function as docking platforms for RNA polymerase II during the 
transcriptional process. The most important protein in this context is the coactivator PBP 
(PPAR binding protein) which serves as an anchor inside the complex. Experiments 
involving liver specific knockouts of this gene showed a dysfunctional PPARα-mediated 
transcriptional response (32). Another important coactivator is PGC-1 (PPAR gamma 
coactivator 1). PGC-1 interacts with PPARγ to induce mitochondrial biogenesis and 
induction of a brown adipocyte-specific gene expression program (33). Additionally, it is 
able to coactivate PPARα-dependent gene regulation, especially towards fatty acid 
oxidation processes (34). This protein thus plays an important role during fasting in the 
liver by upregulating genes involved in gluconeogenesis, and fatty acid 
oxidation/ketogenesis (35, 36). 
 
Each PPAR subtype is characterized by a specific tissue expression pattern (Figure 2), 
thereby accounting for their distinct biological functions. Within a tissue, PPARs exhibit 
differential activity towards target genes, which is partly due to differential availability of 
receptor-specific ligands and coactivators (24, 37, 38). Nevertheless, studies using PPAR 
agonists have shown considerable overlaps in gene regulation between PPARs, even within 
a certain tissue. To what extent this is an artifact of pharmacological activation of PPARs 
or reflects the limited receptor specificity of synthetic agonists remains to be determined. In 
this chapter we provide an overview of the major functions of PPARs, separated by PPAR 
subtype, and focus on their role in metabolic and inflammatory processes. 
 
PPARα (NR1C1) 
Of the three PPAR subtypes, PPARα was discovered first (20). Since then it has been 
cloned in several different species, including human (39, 40), rat (41), frog (42) and rabbit 
(43). Human PPARα is situated on chromosome 22, and its mouse namesake has been 
mapped to chromosome 15. 
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In rodent as well as in human, PPARα is expressed in many tissues that actively metabolize 
fatty acids (Figure 2). It is highly expressed in liver, with expression levels in mouse 
reportedly exceeding those in human (44, 45). In addition, PPARα is relatively well 
expressed in heart, kidney, intestine, skeletal muscle and brown adipose tissue (20, 38, 46-
50). PPARα has also been found in different types of immune cells, such as macrophages 
and T and B cells (51-59). Finally, PPARα has been detected in vascular endothelial, 
vascular smooth muscle cells, and atherosclerotic lesions (51, 52, 60-62). 
 
PPARα serves as a receptor for a structurally diverse set of compounds, both natural and 
synthetic. A major group of synthetic PPARα agonists are the fibrates, which comprises a 
cluster of lipid-lowering drugs used for treatment of dyslipidemia, including gemfibrozil, 
bezafibrate, clofibrate, fenofibrate and WY14643 (21, 24, 63-66). In addition, PPARα is 
activated by a variety of plasticizers, insecticides, and other rodent hepatic carcinogens. 
Endogenous ligands for PPARα include a variety of (long-chain polyunsaturated) fatty 
acids and eicosanoids (41, 67, 68). Recently, it was shown that the effects of dietary 
unsaturated fatty acids on hepatic gene expression are almost entirely mediated by PPARα 
and mimic those of synthetic PPARα agonists (69). 
 
Metabolism 
PPARα plays an important regulatory role in many different metabolic processes, 
especially under conditions of fasting (70-72) (Figure 2). In addition, it governs the 
metabolic response in liver to acute and chronic dietary fat feeding (69, 73). Here, we 
summarize the involvement of PPARα in nutrient metabolism, emphasizing pathways in 
liver. 
 
Lipid metabolism 
The first connection between PPARα and fatty acid catabolism was made in 1992 when it 
was shown that the peroxisomal acyl-coenzyme A (CoA) oxidase gene was a direct target 
gene of PPARα (42, 74). This enzyme carries out the first step of the oxidation of very long 
chain polyunsaturated fatty acids in peroxisomes. Since then, numerous genes involved in 
mitochondrial and peroxisomal fatty acid oxidation have been shown to be under control of 
PPARα, especially in the fasted state. 
 
During fasting, free fatty acids (FFA) are released from adipose tissue storage and are 
transported to the liver. The liver, being a central player in maintaining metabolic 
homeostasis, responds by increasing the rate of fatty acid beta-oxidation and, after 
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prolonged fasting, ketogenesis. Fasting PPARα null mice exhibit a severe impairment in 
hepatic mitochondrial beta-oxidation leading to hypoketonemia, hepatic steatosis, 
myocardial lipid accumulation and hypoglycemia (70-72). It is now evident that PPARα 
not merely governs expression of a few key genes such as Cpt1, Mcad, and Hmgcs2 (21, 
75-77), but actually regulates entire pathways involved in different aspects of hepatic fatty 
acid metabolism, including fatty acid uptake across cell membranes (Cd36, Fatp) (78-81), 
intracellular fatty acid binding and transport (Fabp) (82-84), fatty acid activation (Acsl), 
microsomal fatty acid oxidation (Cyp4a), peroxisomal fatty acid oxidation (Acaa, Acot, 
Ehhadh, Decr2, Acox1), mitochondrial fatty acid oxidation (Acad, Cpt, Hadh, Acot), and 
ketogenesis (Hmgcs2, Hmgcl) (85). Furthermore, PPARα upregulates expression of several 
lipases (Mgll, Lipg, Pnpla2), as well as many genes involved in fatty acid 
synthesis/elongation/desaturation (Fads, Agpat, Scd1, Dgat1). Thus, PPARα can be 
considered a master regulator of hepatic lipid metabolism. Interestingly, although fasting 
increases delivery of free fatty acids to the liver, recent studies suggest that free fatty acids 
are unable to ligand-activate hepatic PPARα, in contrast to lipoprotein-derived fatty acids 
(86, 87). 
 
PPARα has a similar, though less comprehensive role in regulation of lipid metabolism in 
cardiac and skeletal muscle (88-90). Moreover, recent studies also reveal a major role for 
PPARα in the small intestine (91) (Figure 2). 
 
Glucose metabolism 
A role of PPARα in glucose metabolism is supported by the severe hypoglycemia in fasted 
PPARα null mice (71, 72, 92-94). While it is tempting to relate the reduced plasma glucose 
to defective fatty acid oxidation, which in many fatty acid oxidation disorders gives rise to 
hypoglycemia, there is compelling evidence for direct regulation of glucose synthesis by 
PPARα. Several genes involved in synthesis of glucose from gluconeogenic precursors 
have been identified as direct PPARα targets, including PCK1, Pcx, and Gpd, although the 
former gene only in human (95). Specifically the conversion of glycerol into gluconeogenic 
intermediates is under direct control of PPARα (95). The effect of PPARα deletion on 
gluconeogenic fluxes reveals a more complex picture (92). It has been reported that PPARα 
null mice exhibit an increased gluconeogenic flux towards glycogen, thereby diminishing 
hepatic glucose output (96). Synthesis of glycogen is also affected in PPARα null mice, 
which is likely mediated via defective regulation of Gys2 (97). 
 
The hypoglycemia witnessed in PPARα null mice may also partially be due to an increased 
rate of glucose utilization (98). Decreased expression of Pdk4, which is a PPARα target 
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gene in liver, heart, kidney and skeletal muscle, may relieve the block on pyruvate 
oxidation and thus glucose utilization (99-103). Furthermore, regulation of glucose 
utilization may occur via PPARα in the brain (98). 
 
Amino acid metabolism 
In addition to lipid and glucose metabolism, PPARα also governs metabolism of amino 
acids (104, 105). The expression of numerous genes involved in the ammonia 
detoxification pathway and urea synthesis including Cps1, Otc, Ass1, and Asl are 
downregulated by PPARα. Consequently, plasma ammonia levels are increased after 
WY14643 treatment, while plasma urea levels are increased in PPARα null mice (105, 
106). Currently, the molecular mechanisms behind this regulation remain elusive and 
require more detailed investigation (107). 
 
Inflammation 
A delayed inflammatory response to topical administration of leukotriene B4 and 
arachidonic acid provided the first evidence for a link between PPARα and inflammation 
(108). Follow-up studies have shown that PPARα is an extremely important regulator of 
inflammation, mainly by inhibiting inflammatory gene expression (Figure 2). 
 
Hepatic inflammation 
Numerous studies have shown a reduction of hepatic cytokine-stimulated inflammation and 
production of acute phase proteins upon PPARα activation. Several molecular mechanisms 
behind the anti-inflammatory effects of PPARα have been suggested. These include 
interference with several proinflammatory transcription factors including signal transducer 
and activator of transcription (STAT), activator protein-1 (AP-1), and NF-kB by PPARα 
(109). Further studies have revealed that PPARα diminishes the activity of the 
proinflammatory transcription factor CAATT/enhancer binding proteins (C/EBP) via 
sequestration of the coactivator glucocorticoid receptor-interacting protein-1/transcriptional 
intermediary factor-2 (GRIP1/TIF2) (110). Finally, PPARα can also inhibit cytokine 
signaling pathways via downregulation of the IL-6 receptor (111, 112) and upregulation of 
sIL-1 receptor antagonist (113), leading to diminished inflammatory responses. Its potent 
anti-inflammatory activity in liver may confer a protective role for PPARα against 
steatohepatitis. Indeed, several studies in mice have shown that activation of PPARα can 
slow down or even reverse progression of steatohepatitis (114-117). Part of the effect of 
PPARα may be linked to preventing upregulation of the Cox2 gene, which has been 
directly linked to the progression of steatosis to steatohepatitis (118). Conversely, PPARα 
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ablation accelerates development of steatohepatitis in mice rendered obese by chronic high-
fat feeding. PPARα may protect against steatohepatitis by a combination of reducing 
hepatic lipid storage and direct suppression of pro-inflammatory gene expression (119). 
 
Inflammation in vascular wall 
Inflammation in the arterial wall is an important contributor to atherogenesis (120). In 
addition to suppressing inflammatory responses in liver, PPARα also modulates 
inflammatory reactions in the arterial wall. As PPARα is expressed in various cell types 
present in atherosclerotic lesions, including smooth muscle cells, endothelial cells, and 
macrophages, the effect of PPARα on lesion development is rather complex. Immune-
modulating effects of specific PPARα activation have been reported in these various cell 
types. However, some controversy still exists about the exact role of PPARα in the vascular 
wall as both pro- and antiatherogenic effects of PPARα have been demonstrated. 
PPARα has been shown to suppress expression of several proinflammatory genes in the 
vascular wall of animals with extensive atherosclerosis, including monocyte chemotactic 
protein-1 (Mcp-1), tumor necrosis factor alpha (Tnfα), vascular cell adhesion molecule-I 
(Vcam I), intercellular adhesion molecule-I (Icam I), and interferon-γ (Ifnγ) (70). Other 
studies have shown that the anti-inflammatory role of PPARα in the vascular wall depends 
on the severity of inflammation or vascular lesion. In the absence of inflammation or in 
early lesions, the effects of PPARα are mainly proatherogenic (71, 72), whereas the 
development of severe lesions accompanied by inflammation is strongly reduced by 
PPARα activation. 
 
Overall, it is clear that PPARα has a major impact on metabolic and inflammatory gene 
expression, especially in the liver and vascular wall. In general, these effects are positive in 
the context of specific metabolic diseases, including dyslipidemia and atherosclerosis. 
 
PPARβ/δ (NR1C2) 
The PPARβ/δ subtype was first identified in Xenopus laevis under the name PPARβ (42). 
Shortly thereafter the receptor was cloned in mouse (37, 121) and human as NUC1 or 
PPARδ (39). Throughout the remainder of this chapter we will refer to the receptor as 
PPARδ, which represents the official gene name. The human PPARδ gene has been 
mapped to chromosome 6, while its mouse counterpart is present on chromosome 17. 
Human and rodent PPARδ protein are highly homologous, sharing ~90% sequence identity 
in the LBD (65). 
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Similar to PPARα, PPARδ is ubiquitously expressed. High levels of mRNA have been 
found in the skin (122-125), heart (126, 127), skeletal muscle (128), adipose tissue (129, 
130), small intestine (38, 47), and brain (38, 47, 131). A recent study indicates that PPARδ 
protein is especially abundant in mouse small intestine, followed by keratinocytes, liver, 
and at much lower levels in heart and skeletal muscle (132). In comparison to PPARα and 
PPARγ, the function of PPARδ is generally less well understood. However, in the past few 
years, using specific PPARδ agonists and/or PPARδ null mice, significant progress in the 
characterization of PPARδ has been made. It is now evident that PPARδ is involved in 
numerous biological processes including lipid metabolism (65, 131, 133-137), wound 
healing (138, 139), inflammation (140), placental development (65, 141-143), brain 
function and development (131, 144) and colon cancer (130, 145-148). Here the focus will 
be on the role of PPARδ in inflammatory and metabolic processes (Figure 2). 
 
PPARδ can bind both endogenous and synthetic agonists. Endogenous PPARδ ligands 
include naturally occurring fatty acids (27, 149) as well as various eicosanoids such as 
prostaglandin A1 (PGA1), prostaglandin D2 (PGD2) and prostaglandin I2 (PGI2) (68, 150, 
151). Recently, evidence was provided that PPARδ also binds retinoic acid, which is 
selectively delivered to PPARδ via FABP5 (152). 
 
Synthetic ligands of PPARδ are currently explored for their potential to improve plasma 
lipoprotein levels and include GW501516 and GW0742 (153). In a primate model for type 
2 diabetes, GW501516 increased serum HDL cholesterol, improved insulin sensitivity and 
reduced adiposity in diet-induced obese mice (136). In addition, GW501516 was shown to 
reverse multiple abnormalities of the metabolic syndrome in mice and humans, causing 
significant reductions in plasma triglycerides, apolipoprotein B, LDL cholesterol, insulin, 
and glucose tolerance (137, 154-156). So far none of the PPARδ agonists have been 
launched onto the market, though GW510516 and MBX-8025 have entered phase 2 clinical 
trails. 
 
Lipid metabolism 
Analogous to PPARα and PPARγ, evidence is accumulating that PPARδ plays a role in the 
regulation of lipid metabolism (Figure 2). Consequently, PPARδ has become an interesting 
target for the treatment of metabolic syndrome. Effects of PPARδ have been demonstrated 
in several tissues, including skeletal muscle, heart, adipose tissue, and liver. 
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Lipid metabolism in skeletal muscle 
Numerous in vitro studies have shown a stimulatory effect of PPARδ overexpression or 
activation on expression of genes involved in fatty acid catabolism, including 
mitochondrial- (Lcad, Hadha, Decr) and peroxisomal fatty acid oxidation (Ech), fatty acid 
transport (Fatp, Lipe, Acsl, Cpt1) and energy uncoupling (Ucp1, -2, -3) (93, 137, 157-159) 
(Figure 2). In line with these data, administration of GW510516 was found to induce fatty 
acid oxidation in skeletal muscle of C57BL/6J mice (137). Similarly, the PPARδ agonist 
GW610742X decreased muscle lipid content and shifted fuel use towards fatty acids, while 
inducing expression of specific genes (Pdk4, Cpt1b, Ucp3). 
 
Besides governing fatty acid oxidation, PPARδ also determines muscle fiber type 
characteristics. Forced overexpression of PPARδ in skeletal muscle is associated with a 
selective increase in type 2a fast-oxidative fibers or, when expressed at supraphysiological 
levels, causes fiber type transformation towards type I fibers concurrent with an increase in 
endurance exercise performance (160, 161). Endurance exercise performance is also 
increased by GW501516, at least when combined with exercise training (162). Conversely, 
selective deletion of PPARδ in skeletal muscle myocytes is associated with a reduced 
muscle oxidative capacity and a switch in muscle fiber-type characteristics toward less 
oxidative fibers (128). Surprisingly, the role of PPARδ in skeletal muscle fatty acid 
oxidation is not supported by studies using whole body PPARδ null mice (163). 
 
Lipid metabolism in heart 
Similar to the situation in skeletal muscle, PPARδ appears to stimulate fatty acid oxidation 
in heart, although the picture is far from clear. Treatment of neonatal rat cardiomyocytes 
with PPARδ ligands L-165041 and GW501516 increases fatty acid oxidation rate and 
expression of selected genes involved in fatty acid catabolism (127). In vivo, the absence of 
PPARδ in heart leads to myocardial lipid accumulation and cardiomyopathy, as well as 
downregulation of several key fatty acid oxidation genes such as carnitine 
palmitoyltransferase 1 (Cpt1) and acyl-coenzyme A oxidase 1 (Acox1) (164). Conversely, 
treatment of rats with the PPARδ specific agonist GW610742X stimulated fatty acid 
oxidation rate. The metabolic changes were associated with increased expression of genes 
involved in lipid catabolism (Cd36, Cpt1, Ucp3) (165). Remarkably, transgenic 
overexpression of PPARδ in heart had little effect on fatty acid oxidation rate and 
expression of lipid catabolism genes, including Fatp and Cd36. Instead, PPARδ may 
stimulate myocardial glucose utilization, possibly via induction of Slc2a4 (Glut4) and 
phosphofructokinase (126). Thus, while the importance of PPARδ in normal heart 
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functioning is evident, its specific impact on cardiac fatty acid catabolism remains 
somewhat ambiguous. 
 
Lipid metabolism in adipose tissue 
A gain of function study shows that PPARδ promotes fatty acid oxidation in adipocytes 
(155). On the other hand, PPARδ seems to have a facilitative, yet important role in lipo- 
and adipogenesis (166). Presently, the role of PPARδ in adipose tissue remains somewhat 
ambiguous. 
 
Lipoprotein metabolism 
Several studies support a role for PPARδ in lipoprotein metabolism. PPARδ agonists were 
shown to increase plasma HDL levels in mice (135, 167), rhesus monkeys (136), and 
human subjects (168). Although the complete mechanism behind this effect is unknown, 
the effect may be mediated by the cholesterol transporter Abca1, which is a target gene of 
PPARδ (136). 
 
Apart from elevated levels of plasma HDL, primates also show a decrease in plasma 
triglycerides upon PPARδ activation (136, 168). Consistent with these data, plasma TG 
levels are increased in PPARδ null mice (169). Due to their beneficial effect on plasma 
lipoproteins, PPARδ agonists are currently explored for the treatment of dyslipidemia. 
 
Wound healing 
PPARδ is the dominant PPAR subtype in the skin and has been shown to be involved in 
different phases of the healing process of epidermal wounds (49, 139, 170) (Figure 2). 
PPARδ becomes induced in keratinocytes at the wound edge of damaged skin and, in 
contrast to PPARα, which is expressed during the early inflammatory phase of the healing, 
PPARδ remains active until the wound healing process has been completed (139). 
Induction of PPARδ expression is mediated by inflammatory cytokines, which via 
induction of stress-associated kinase pathway target a AP-1 site in the PPARδ promoter 
(171). The increase in PPARδ activity promotes keratinocyte differentiation and protects 
against apoptosis, thereby stimulating wound closure. Suppression of apoptosis is mediated 
by PPARδ-dependent upregulation of integrin-linked kinase and 3-phosphoinositide-
dependent kinase-1 (Pdpk1), which phosphorylates protein kinase B-alpha (Akt1) (172). In 
addition, PPARδ stimulates wound healing by altering actin cytoskeleton plasticity and 
integrin function, resulting in increased cell migration (173). At later stages in wound 
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healing, normal PPARδ expression is restored by a TGFβ and SMAD3-mediated 
suppression of c-JUN binding to the PPARδ promoter (174). 
 
Inflammation 
The role of PPARδ in inflammation has primarily been studied in the context of 
atherosclerosis (Figure 2). Treatment with synthetic PPARδ agonist has been repeatedly 
shown to suppress inflammation in atherosclerotic lesions and lipid loaded macrophages, 
possibly by down-regulating expression of the chemoattractant Ccl2 (Mcp-1) (175-178). 
Recent studies suggest that the inflammatory properties of PPARδ extend to other cell 
types present in the vascular wall, including endothelial cells and vascular smooth muscle 
cells (179, 180). Inhibition of inflammation likely accounts for the marked reduction in 
atherosclerotic lesion size upon PPARδ activation as observed in several but not all studies 
(169, 170, 178, 181). Remarkably, macrophage-specific deletion of PPARδ is also 
associated with a significant reduction in atherosclerotic lesion size (175). Together, these 
data suggest a complex role for PPARδ in atherosclerosis via its presence in macrophages 
and other cells that may involve both pro- and anti-inflammatory activities, as well as 
specific effects on plasma lipoproteins (175). Possibly, the effects of PPARδ on these 
pathways are compounded by its ability to promote lipid accumulation in macrophages via 
induction of genes involved in lipid uptake and storage (CD36, MSR1) (182). 
 
The general anti-inflammatory properties of PPARδ are further substantiated by recent data 
showing that PPARδ promotes alternative activation of macrophages resident in liver and 
adipose tissue, which confers a protection against insulin resistance and hepatic steatosis 
(183, 184). 
 
PPARγ (NR1C3) 
PPARγ is clearly the most widely studied PPAR subtype, which is explained by it serving 
as the molecular target for the insulin-sensitizing thiazolidionedione drugs (TZDs). PPARγ 
also plays a key role in adipogenesis and consequently has been extensively studied for its 
involvement in obesity development. 
 
Four distinct transcript variants of PPARγ are known, PPARγ1 through PPARγ4, that yield 
two protein variants differing at their N-terminus by the addition of 28 (human PPARγ2) or 
30 (mouse PPARγ2) amino acids (42, 185-189). Whereas PPARγ2 is expressed selectively 
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in adipose tissue, (42, 185, 190-194), PPARγ1 has a broader expression pattern and is 
found in gut, brain, vascular cells and macrophages (185, 191, 192, 195). 
 
For the human PPARγ gene, both common and rare sequence variants are known. The 
common Pro12Ala variant has been shown to be associated with a lower BMI, improved 
insulin sensitivity and reduced incidence of type 2 diabetes (196-200). Rare sequence 
variants of PPARγ lead to the formation of a dysfunctional protein that via dominant 
negative action interferes with transcriptional activation, possibly by sequestering 
coactivator proteins (201). Afflicted patients suffer from a form of lipodystrophy 
characterized by loss of fat from the gluteal region, dyslipidemia, hepatic steatosis, and 
severe insulin resistance (202). 
 
Similar to other PPARs, PPARγ is able to bind both endogenous and synthetic ligands. The 
endogenous ligands for PPARγ remain poorly characterized. In contrast to PPARα and 
PPARδ, dietary (poly-unsaturated) fatty acids appear to be relatively weak ligands for 
PPARγ (65, 67, 203, 204). Ligand-activation of PPARγ in specific cell types may occur by 
fatty acid nitration products (205), as well as by oxidized fatty acids such as the linoleic 
acid metabolites 9-HODE and 13-HODE (206). It has been shown that prostaglandin 15d-
PGJ2 efficiently binds and activates PPARγ, yet due to its low concentration its relevance 
as a physiological PPARγ agonist can be questioned. As mentioned above PPARγ is 
activated by synthetic ligands belonging to the antidiabetic thiazolidionedione drugs, which 
include troglitazone, rosiglitazone and pioglitazone (207-212). These drugs improve insulin 
sensitivity and are used in the treatment of type 2 diabetes (208-214). In addition, tyrosine 
derivative drugs like glitazars (215), as well as NSAIDs like ibuprofen and fenoprofen 
(216) have been identified as PPARγ ligands. 
 
Metabolism 
PPARγ is best known for its ability to stimulate adipocyte differentiation, fat storage, and 
glucose metabolism (217-222) (Figure 2). Moreover, PPARγ suppresses inflammation. 
Although it is becoming more evident that metabolism and inflammation are intertwined, 
for the sake of simplicity the impact of PPARγ on the two processes will be discussed 
separately. 
 
Adipose tissue 
Studies with PPARγ null mice as well as PPARγ null stem cells have shown that PPARγ is 
absolutely required for adipocyte differentiation (223-226). For detailed coverage of the 
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role of PPARγ in adipogenesis the reader is referred to several excellent reviews (217-222). 
Here the focus will be on the impact of PPARγ on the fully developed adipose tissue. 
 
In the mature adipocyte, PPARγ stimulates the expression of numerous genes involved in 
fatty acid uptake (Cd36, Slc27a1, Slc27a3), fatty acid synthesis (Elovls, Mogat, Acly), 
lipolysis (Lipe, Pnpla2, Mgll, Lpl), lipid droplet proteins (Cidea, Cidec, Adfp, Plin, S3-12), 
glucose metabolism (Pck1, Pdk4, Gys2, Slc2a4), and glycerol metabolism (Aqp7, Aqp3, 
Gpd1, Gyk, Pck1). Additionally, a set of miscellaneous genes is regulated by PPARγ 
(G0s2, Ucp1, Ucp2, Abca1, Rxrg). The overall effect is enhanced extraction of fatty acids 
from circulating triglycerides, enhanced fatty acid uptake, enhanced fatty acid re-
esterification, and enhanced storage as triglycerides. In addition, uptake of glucose as well 
as its conversion to fatty acid and glycerol phosphate is stimulated, contributing to 
increased energy storage. From a physiological perspective, PPARγ is thus particularly 
important in the fed state to drive storage of consumed nutrients in the adipose tissue. 
 
From a clinical perspective, removal of fatty acids and triglycerides from the circulating 
pool towards storage in the adipose tissue improves dyslipidemia and minimizes ectopic fat 
storage. Indirectly, these changes may also promote insulin sensitivity. This is exemplified 
by the phenotype of hypomorphic PPARγ mice (227) and more distinctly adipose tissue 
specific PPARγ null mice, which show inborn and progressive lipodystrophy characterized 
by accumulation of TG in non-adipose tissue such as liver and skeletal muscle, leading to 
insulin resistance (228, 229). The effect of PPARγ on plasma FFA and ectopic fat storage 
may provide a mechanistic basis for the insulin sensitizing effect of TZDs. 
 
In addition to its primary function as an energy storage organ, adipose tissue produces 
various hormones such as leptin, adiponectin, resistin, and TNFα that play an active role in 
the regulation of energy metabolism. The insulin-sensitizing effect of TZDs may be 
partially accounted for by altered production of these hormones. Indeed, adiponectin, 
production of which is elevated by PPARγ, promotes insulin responsiveness and glucose 
uptake. Other so-called adipokines that are under control of PPARγ and that may mediate 
effects of PPARγ activation include RBP4 and ANGPTL4 (230). 
 
In addition to the mechanisms eluded to above, alternative explanations for the insulin 
sensitizing effect of PPARγ agonists include an increase in the number of small, insulin 
sensitive adipocytes (231), as well as a direct effect on macrophages, as will be further 
discussed below. 
 
 
 
 
 
 
 
 
 
 
PPARs: important regulators in metabolism and inflammation 
 
 33 
Non-adipose tissue 
PPARγ has been shown to induce macrophage expression of scavenger receptor CD36, 
which is involved in uptake of oxidized LDL into the macrophage (206, 232). Overall, 
much overlap is observed between the effect of PPARγ on gene expression in macrophages 
and adipocytes. In addition, macrophage PPARγ governs cholesterol esterification and 
intracellular cholesterol distribution, and stimulates cholesterol removal from the 
macrophage via the target genes ABCA1, ABCG1, caveolin and APOE1 (53, 233-237). 
Collectively, these effects of PPARγ beneficially impact macrophage foam cell formation 
(176). 
 
Although PPARγ is only weakly expressed in skeletal muscle and liver, muscle or liver 
specific PPARγ null mice show a major and complex metabolic phenotype. Presently, the 
relative importance of skeletal muscle PPARγ in TZD-induced muscle glucose disposal 
remains undecided (238, 239). In liver, PPARγ expression increases during over- and high 
fat feeding, concurrent with development of hepatic steatosis, which is aggravated in 
PPARα null mice (73, 226, 240). Hepatic PPARγ is also upregulated in models of 
lipoatrophy and leptin deficiency, and studies employing PPARγ overexpression or 
deletion indicate that PPARγ is necessary and sufficient for inducing fatty liver (241-244). 
 
Inflammation 
Inflammation has become a prime area of interest as a candidate process linking obesity to 
many of its comorbidities. Numerous studies suggest that obesity is associated with a state 
of low grade inflammation, which likely originates from white adipose tissue and has been 
suggested to impact insulin sensitivity. In addition, inflammation importantly contributes to 
the process of atherosclerosis. 
 
Atherosclerosis 
Macrophages play an important role in both innate and adaptive immune responses, 
including phagocytosis of pathogens and defective or dying cells. In addition, by taking up 
oxidized LDL and converting into foam cells macrophages are key contributors to 
development of atherosclerosis. 
 
Although PPARγ may stimulate uptake of oxidized LDL into macrophages, which is pro-
atherogenic, the anti-atherogenic effects of PPARγ via suppression of inflammation seem 
to dominate. PPARγ activation reduces arteriosclerotic lesions at least partially by 
inhibiting inflammatory gene expression in macrophages, including MCP-1, VCAM-1, 
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ICAM-1, IFNγ and TNFα (176). Furthermore, reduced amounts of cytokines (245), nitric 
oxide and macrophage-scavenger receptor class A (SRA) (246) have been observed upon 
PPARγ activation. 
 
Anti-inflammatory effects resulting from PPARγ activation has been shown both in human 
and mouse macrophages. Treatment with PPARγ agonist 15d-PGJ2 was shown to have an 
anti-inflammatory effect by decreasing production of inflammatory cytokines such as 
interleukin IL1h, IL6 and TNFα in human peripheral blood mononuclear cells (PBMCs) 
(245). Furthermore, treatment of activated peritoneal macrophages with 15d-PGJ2 reduced 
expression of inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes, 
partially by inhibiting the transcription factors AP-1, STAT and NFΚB (247). PPARγ 
activation was also shown to suppress expression of COX2, mainly via preventing 
activation and translocation of NFκB (248-250). However, because of its limited specificity 
for PPARγ, many experimental outcomes following 15d-PGJ2 treatment may be only 
partially dependent of PPARγ, which complicates interpretation of the data. 
 
Nevertheless, studies with synthetic PPARγ agonists support a general anti-inflammatory 
effect of PPARγ (251-253), which plays a role in the anti-atherogenic effects of PPARγ, as 
assessed by measurement of carotid arterial intimal and medial complex thickness (254-
256). 
 
Several molecular mechanisms have been proposed underlying the anti-inflammatory 
effects of PPARγ. A major mechanism involves transrepression, which describes the DNA-
binding independent protein-protein interaction between PPARγ and other (pro-
inflammatory) transcription factors such as NFκB, STAT and AP-1, causing a change in 
transcriptional activity (247, 257). In addition, PPARγ may compete with pro-inflammatory 
transcription factors for limited amounts of coactivators such as SRC-1, TIF2, AIB-1, CBP, 
p300, TRAP220, and DRIP205 in the cell (258). Another possibility involves binding of 
PPARγ to nuclear receptor corepressor (NCoR)- histone deacetylase-3 (HDAC3) 
complexes, thereby preventing the removal of these corepressor complexes from promoter 
regions of inflammatory genes and causing a suppression of gene transcription (259). 
Binding of PPARγ to NCoR is initiated by ligand-dependent SUMOylation of the PPARγ 
ligand binding domain (260, 261). 
 
Adipose tissue 
Macrophages are abundant in adipose tissue and together with adipocytes contribute to the 
secretion of a variety of pro- and anti-inflammatory cytokines. It is now evident that in 
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obese individuals adipocyte hypertrophy leads to the recruitment of macrophages in 
adipose tissue, thereby altering its secretory profile (262-267). Recent evidence suggests 
that these macrophages are primarily classically activated and mainly secrete pro-
inflammatory cytokines (268). Indeed, compared with lean individuals, obese persons have 
been observed to have a higher expression of tumor necrosis factor alpha, interleukin 6, 
monocyte chemotactic protein 1, inducible nitric oxide synthase and transforming growth 
factor ß1 (269-279). Presently, the trigger leading to the infiltration of macrophages is 
unclear but may involve local hypoxia as well as adipose cell death. 
 
Recent studies support a major role for PPARγ in regulating not only the amount of 
macrophages present in adipose tissue but also their phenotype and secretory profile. 
Treatment of mice with PPARγ agonist stimulated infiltration of alternatively activated 
macrophages into adipose tissue, thereby reducing pro-inflammatory gene expression 
(280). Conversely, macrophage-specific deletion of PPARγ decreased expression of 
markers of alternatively activated macrophages in adipose tissue, and increased 
inflammatory gene expression (281, 282). The increased abundance of classically activated 
macrophages led to worsening of insulin resistance, especially after high fat feeding (281, 
282). These data suggest that macrophage PPARγ plays a major role in determining 
macrophage polarization in adipose tissue, and may mediate the effect of TZDs on insulin 
sensitivity. 
 
Overall, it is evident that PPARγ has a major influence on metabolic and inflammatory 
gene expression, especially in adipocytes and macrophages. In general, these effects are 
positive in the context of specific metabolic diseases, including insulin sensitivity and 
plausibly atherosclerosis. 
 
Concluding remarks 
It is now evident that the primary functions of PPARs are at the level of regulating 
metabolic processes and inflammation. Presently, PPARα and PPARγ serve as therapeutic 
targets for dyslipidemia and insulin resistance, respectively, and synthetic ligands of 
PPARδ are currently being explored for their potential to improve plasma lipoprotein 
levels. As our understanding of the link between inflammation and metabolism advances, 
better insight will be obtained into the mechanism underlying the therapeutic actions of 
PPAR agonists. 
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Abstract 
PPARα is a ligand-activated transcription factor involved in the regulation of nutrient 
metabolism and inflammation. Although much is already known about the function of 
PPARα in hepatic lipid metabolism, many PPARα-dependent pathways and genes have yet 
to be discovered. 
 
In order to obtain an overview of PPARα-regulated genes relevant to lipid metabolism, and 
to probe for novel candidate PPARα target genes, livers from several animal studies in 
which PPARα was activated and/or disabled were analyzed by Affymetrix GeneChips. 
Numerous novel PPARα-regulated genes relevant to lipid metabolism were identified. Out 
of this set of genes, eight genes were singled out for study of PPARα-dependent regulation 
in mouse liver and in mouse, rat, and human primary hepatocytes, including thioredoxin 
interacting protein (Txnip), electron-transferring-flavoprotein β polypeptide (Etfb), 
electron-transferring-flavoprotein dehydrogenase (Etfdh), phosphatidylcholine transfer 
protein (Pctp), endothelial lipase (EL, Lipg), adipose triglyceride lipase (Pnpla2), hormone-
sensitive lipase (HSL, Lipe), and monoglyceride lipase (Mgll). Using an in silico screening 
approach, one or more PPAR response elements (PPREs) were identified in each of these 
genes. Regulation of Pnpla2, Lipe, and Mgll, which are involved in triglyceride hydrolysis, 
was studied under conditions of elevated hepatic lipids. In wildtype mice fed a high fat diet, 
the decrease in hepatic lipids following treatment with the PPARα agonist WY14643 was 
paralleled by significant upregulation of Pnpla2, Lipe, and Mgll, suggesting that induction 
of triglyceride hydrolysis may contribute to the anti-steatotic role of PPARα. 
 
Our study illustrates the power of transcriptional profiling to uncover novel PPARα-
regulated genes and pathways in liver. 
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Introduction 
The peroxisome proliferator-activated receptors (PPARs) play a pivotal role in the 
regulation of nutrient metabolism. PPARs are ligand-activated transcription factors that 
belong to the superfamily of nuclear hormone receptors (24, 63, 283). They share a 
common mode of action that involves formation of heterodimers with the nuclear receptor 
RXR, followed by binding to specific DNA-response elements in the promoter of target 
genes. The genomic sequence recognized by PPARs, referred to as PPAR response element 
or PPRE, consists of a direct repeat of the consensus hexameric motif AGGTCA 
interspaced by a single nucleotide. Binding of ligands to PPARs leads to recruitment of 
coactivators and causes chromatin remodeling, resulting in initiation of DNA transcription 
and upregulation of specific PPAR target genes (284, 285). Ligands for PPARs include 
both endogenous compounds, such as fatty acids and their eicosanoid derivatives, and 
synthetic agonists. Three different PPAR subtypes have been identified: PPARα, PPARβ/δ, 
and PPARγ. The latter isotype, which is most highly expressed in adipose tissue, is known 
to play an important role in adipocyte differentiation and lipid storage (221, 225, 286). It is 
a target for an important class of antidiabetic drugs, the insulin-sensitizing 
thiazolidionediones. Expression of PPARβ/δ is ubiquitous and has been connected to 
wound healing, cholesterol metabolism, and fatty acid oxidation in adipose tissue and 
muscle (135, 155, 161, 172). Finally, PPARα is highly expressed in liver where it 
stimulates fatty acid uptake and activation, mitochondrial β-oxidation, peroxisomal fatty 
acid oxidation, ketogenesis, and fatty acid elongation and desaturation. In addition, it has a 
major role in glucose metabolism (95) and the hepatic acute phase response (111, 112). 
Importantly, PPARα is the molecular target for the hypolipidemic fibrate class of drugs that 
lower plasma triglycerides and elevate plasma HDL (high density lipoprotein) levels. 
 
In recent years, microarray technology has emerged as a powerful technique to study global 
gene expression. In theory, microarray analysis is a terrific tool to map PPARα-dependent 
genes and further characterize PPARα function. In practice, microarray yields a huge 
amount of data, the analysis and interpretation of which can be very difficult. Numerous 
studies have examined the effect of synthetic PPARα agonists on global gene expression 
using microarrays. While these studies uncovered many possible PPARα target genes, the 
manner in which the data were presented often rendered interpretation difficult. Part of the 
complexity is due to the size of the PPARα-dependent transcriptome in liver, which easily 
exceeds one thousand genes. 
 
The aim of the present study was twofold: (1) to generate a comprehensive overview of 
PPARα-regulated genes relevant to hepatic lipid metabolism and (2) to identify possible 
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novel target genes and target pathways of PPARα connected with lipid metabolism. To that 
end, we (1) combined microarray data from several independent animal experiments 
involving PPARα-/- mice (in these experiments, mice were either given WY14643 or 
fasted for 24 hours), (2) focused on upregulation of genes by PPARα in conformity with 
the general paradigm of transcriptional regulation by nuclear hormone receptors, and (3) 
reduced complexity by progressively moving from the complete PPARα-dependent 
transcriptome towards genes relevant to lipid metabolism, and finally to the identification 
of possible PPARα target genes involved in lipid metabolism. 
 
Materials and Methods 
 
Materials. WY14643 was obtained from ChemSyn Laboratories (Lenexa, KS). 
Recombinant human insulin (Actrapid) was from Novo Nordisk (Copenhagen, Denmark). 
SYBR Green was from Eurogentec (Seraing, Belgium). DMEM, fetal calf serum, calf 
serum, and penicillin/streptomycin/fungizone were from Lonza Bioscience (Verviers, 
Belgium). Otherwise, chemicals were from Sigma (Zwijndrecht, the Netherlands). 
 
Animals. Male pure-bred Sv129 and PPARα-/- mice on a Sv129 background were used at 
3-5 months of age (Jackson Laboratories, Bar Harbor, ME). Animals were fed normal 
laboratory chow (RMH-B diet, Arie Blok animal feed, Woerden, the Netherlands). Study 1: 
fed mice were killed at the end of the dark cycle. Fasting was started at the onset of the 
light cycle for 24 hours (n=5 per group). Studies 2 and 4: wildtype and PPARα-/- mice 
were fed with WY14643 for 5 days by mixing it in their food (0.1%, n=5 per group). 
Studies 2 and 4 were carried out independently and 2 years apart. Study 3: wildtype and 
PPARα-/- mice fasted for 4 hours received a single dose of WY14643 (400μl of 10mg/ml 
WY14643 dissolved in 0.5% carboxymethylcellulose) and were killed 6 hours later (n=5 
per group). Study 5: wildtype and PPARα-/- mice at 2-3 months of age were given a high-
fat diet (D12451, Research Diets, New Brunswick, NJ) for 20 weeks (composition 
available at http://www.researchdiets.com/pdf/Data%20Sheets/DIO%20Series.pdf). During 
the last week, half of the mice were given WY14643 for 7 days by mixing it in their food 
(0.1%, n=5 per group). Livers were dissected and immediately frozen in liquid nitrogen. 
 
All animal experiments were approved by the animal experimentation committee of 
Wageningen University and were carried out in conformity with the public health service 
(PHS) policy on humane care and use of laboratory animals. 
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Primary hepatocytes. Rat (Wistar) and mouse (Sv129) hepatocytes were isolated by 
two-step collagenase perfusion as described previously (287). Cells were plated on 
collagen-coated six-well plates. Viability was determined by Trypan Blue exclusion, and 
was at least 75%. Hepatocytes were suspended in William’s E medium (Lonza Bioscience, 
Verviers, Belgium) supplemented with 10% (v/v) foetal calf serum, 20m-units/ml insulin, 
50nM dexamethasone, 100U/ml penicillin, 100μg/ml of streptomycin, 0.25μg/ml 
fungizone, and 50μg/ml gentamycin. The next day, cells were incubated in fresh medium in 
the presence or absence of WY14643 (10μM) dissolved in DMSO for 24 hours, followed 
by RNA isolation. 
 
Human hepatocytes and Hepatocyte Culture Medium Bulletkit were purchased from Lonza 
Bioscience (Verviers, Belgium). Human hepatocytes were isolated from a single donor. 
Cells were plated on collagen-coated six-well plates. Upon arrival of the cells, the medium 
was discarded and was replaced by Hepatocyte Culture Medium. The next day, cells were 
incubated in fresh medium in the presence or absence of WY14643 (50μM) dissolved in 
DMSO for 12 hours, followed by RNA isolation. 
 
Affymetrix microarray. Total RNA was prepared from mouse livers and primary 
hepatocytes using TRIzol reagent (Invitrogen, Breda, the Netherlands). RNA was either 
pooled per group or treatment (studies 1 and 2, primary hepatocytes), or used individually 
(studies 3 and 4), and further purified using RNeasy micro columns (Qiagen, Venlo, the 
Netherlands). RNA integrity was checked on an Agilent 2100 bioanalyzer (Agilent 
Technologies, Amsterdam, the Netherlands) using 6000 Nano Chips according to the 
manufacturer’s instructions. RNA was judged as suitable for array hybridization only if 
samples exhibited intact bands corresponding to the 18S and 28S ribosomal RNA subunits, 
and displayed no chromosomal peaks or RNA degradation products (RNA Integrity 
Number >8.0). Ten micrograms of RNA were used for one cycle cRNA synthesis 
(Affymetrix, Santa Clara, CA). Hybridization, washing, and scanning of Affymetrix 
Genechip MOE430 (studies 1 and 2) or mouse genome 430 2.0 arrays (studies 3 and 4) was 
according to standard Affymetrix protocols. 
 
Scans of the Affymetrix arrays were processed using packages from the Bioconductor 
project (288). Expression levels of probesets were calculated using GCRMA (289), 
followed by identification of differentially expressed probesets using Limma (290). 
Comparison was between fasted wildtype and fasted PPARα-/- mice (study 1) or between 
WY14643-treated wildtype and WY14643-treated PPARα-/- mice (studies 2–4). P-values 
were corrected for multiple testing using a false discovery rate method (291). Probesets that 
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satisfied the criterion of FDR <1% (q-value <0.01) and fold change >1.5 were considered 
to be significantly regulated. Functional clustering of the array data was performed by a 
method based on overrepresentation of Gene Ontology (GO) terms (292). 
 
For the primary hepatocytes, expression levels were calculated applying the multichip-
modified gamma model for oligonucleotide signal (multi-mgMOS) (293) and a remapped 
chip description file (294). 
 
All microarray datasets were deposited to gene expression omnibus (GEO). The GEO 
series accession numbers are as follows: study 1: GSE8290, study 2: GSE8291, study 3: 
GES8292, study 4: GSE8295, primary hepatocytes: GSE8302. 
 
RNA isolation and qRT-PCR. Total RNA was extracted from tissues with TRIzol 
reagent (Invitrogen, Breda, the Netherlands). 1μg of total RNA was reverse-transcribed 
with iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA was PCR-amplified with 
Platinum Taq DNA polymerase (Invitrogen) on a Bio-Rad iCycler orMyIQ PCR machine. 
Primers were designed to generate a PCR amplification product of 100-200 bp and were 
taken from PrimerBank (http://pga.mgh.harvard.edu/primerbank). Specificity of the 
amplification was verified by melt-curve analysis and evaluation of efficiency of PCR 
amplification. The sequence of primers used is available upon request. The mRNA 
expression of all genes reported was normalized to 36B4 or cyclophilin gene expression. 
 
In silico screening of putative PPREs using a PPRE classifier. Genomic 
sequences for mouse genes spanning 20KB centered at the transcriptional start site (TSS) 
were extracted from the Ensembl database (NCBI36) and screened for DR1-type REs with 
predicted binding strength of at least 1%. The binding strength prediction was based on a 
PPRE classifier that uses a database of in vitro binding data for PPARs to assign predicted 
binding strength according to a classification scheme (295). The conservation of the 
putative PPREs between mouse, human, dog, and rat were evaluated using the Vertebrate 
Multiz Alignment and Conservation track available from UCSC genome browser (NCBI 
releases for human and mouse genomes, hg18 and mm8, February 2006). 
 
Histological examination of liver. 5μ sections were cut from frozen liver pieces. For 
oil red O staining, sections were air dried for 30 minutes, followed by fixation in formal 
calcium (4% formaldehyde, 1% CaCl2). Oil red O stock solution was prepared by 
dissolving 0.5g oil red O in 500ml isopropanol. An oil red O working solution was 
prepared by mixing 30ml oil red O stock with 20ml dH2O. Sections were immersed on 
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working solution for 10 minutes followed by extensive washes in H2O. Haematoxylin and 
eosin staining of frozen liver sections was carried out as described 
(http://www.ihcworld.com/histology.htm). 
 
Results 
 
Global analysis of PPARα-dependent gene regulation 
We analyzed the data from four independent microarray studies to obtain a comprehensive 
picture of PPARα-dependent upregulation of gene expression in mouse liver. In the first 
study, mRNA was compared between livers of 24 hour fasted wildtype and PPARα-/- mice. 
In the second study, mRNA was compared between liver of wildtype mice and PPARα-/- 
mice fed the PPARα agonist WY14643 for 5 days. In these two studies, RNA was pooled 
from 4-5 mice and hybridized to Affymetrix MOE430A GeneChip arrays. Since no 
biological replicates were analyzed, only a fold change threshold criteria could be applied. 
Using a cutoff of 1.5-fold, expression of a total of 1847 probesets was lower in 24 hour 
fasted PPARα-/- mice compared with 24 hour fasted wildtype mice (Figure 1A) 
(http://nutrigene.4t.com/microarray/ppar2007). Using the same cutoff, 2234 probesets were 
at least 1.5-fold lower in the livers of PPARα-/- mice fed WY14643 compared to wildtype 
mice fed WY14643 (http://nutrigene.4t.com/microarray/ppar2007). The number of 
probesets that overlapped between the two groups was 569. A large proportion of these 
genes, which are thus under control of PPARα under pharmacological and physiological 
conditions, may represent target genes of PPARα. 
 
In the third study, mRNA was compared between livers of wildtype mice and PPARα-/- 
mice treated with WY14643 for 6 hours, while in the fourth study mRNA was compared 
between livers of wildtype mice and PPARα-/- mice fed WY14643 for 5 days. Study 4 was 
carried out independently of study 2 in a different set of mice. For these two studies, 
biological replicates (4-5 mice per group) were run using Affymetrix mouse genome 430 
2.0 GeneChip arrays, enabling statistical analysis of the data which was not possible for 
studies 1 and 2. Applying a false discovery rate of 0.01 and a 1.5-fold cutoff, 1679 
probesets were lower in the livers of PPARα-/- mice compared to wildtype mice 6 hours 
after treatment with WY14643, and 2207 probesets after 5 days of feeding WY14643 
(Figure 1B) (http://nutrigene.4t.com/microarray/ppar2007). While the majority of genes 
regulated by PPARα after 6 hours of WY14643 treatment were also, and generally more 
significantly, regulated after 5 days of WY14643 treatment (overlap of 1001 probesets), 
many genes were specifically or more significantly regulated after 6 hours, including the 
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direct PPAR target G0s2 and the EL gene, respectively. The complete set of data from 
studies 2 and 4, which includes up- and downregulated genes, has been submitted to the 
Peroxisome Proliferators compendium assembled by Dr. J.C. Corton (US EPA, Research 
Triangle Park, USA). They will be analyzed in conjunction with numerous other 
microarray experiments involving peroxisome proliferators to obtain the “peroxisome 
proliferator transcriptome.” In addition, the datasets have been submitted to GEO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Microarray analysis of PPARα-dependent gene regulation in mouse liver. (A) 
Venn diagram showing the number of differentially expressed probesets between livers of 24-hour 
fasted wildtype and PPARα-/- mice, and between wildtype and PPARα-/- mice treated with the 
PPARα agonist WY14643 for 5 days. Pooled RNA was hybridized to Affymetrix MOE430A Arrays. 
A fold change of >1.5 was used as cutoff. (B) Venn diagram showing the number of differentially 
expressed probesets between livers of wildtype and PPARα-/- mice treated with the PPARα agonist 
WY14643 for 6 hours, and between wildtype and PPARα-/- mice treated with WY14643 for 5 days. 
RNA from individual mice was hybridized to Affymetrix Mouse 430 2.0 Arrays. Probesets that 
satisfied the criteria of fold change >1.5 and FDR <0.01 were considered to be significantly 
regulated. 
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Pathway analysis of PPARα-dependent gene regulation 
Functional clustering analysis of the microarray data by Gene Ontology classification 
indicated that numerous Gene Ontology classes were overrepresented among the genes that 
were >1.5-fold upregulated in 24 hour fasted wildtype compared to 24 hour fasted PPARα-
/- mice. The same was true for the comparison between wildtype and PPARα-/- mice 
treated with WY14643 for 5 days. Among the overrepresented Gene Ontology classes, we 
found many classes that are known to be governed by PPARα, including fatty acid β-
oxidation, acyl-CoA metabolism, leukotriene metabolism, and peroxisome organization 
and biogenesis (http://nutrigene.4t.com/microarray/ ppar2007). Interestingly, we also 
noticed that numerous Gene Ontology classes were specifically upregulated by PPARα 
under fasting conditions or by WY14643 feeding. The data suggest, for example, that 
pyruvate metabolism and posttranslational protein targeting to membrane are specifically 
regulated in a PPARα-dependent manner by WY14643 but not by fasting. Indeed, it is clear 
that some genes (e.g., Acot2 and Cd36) are PPARα-dependently regulated by WY14643 
and much less so by fasting, whereas others (e.g., Gpam, Hmgcs2) are PPARα-dependently 
regulated by fasting and much less so by WY14643. However, it is important to emphasize 
that the ErmineJ Gene Ontology classification, as any functional clustering analysis, needs 
to be interpreted carefully. 
 
The Gene Ontology classification analysis of the comparison wildtype versus PPARα-/- 
mice treated with WY14643 for 6 hours (study 3) was almost identical to the analysis for 
mice treated with WY14643 for 5 days (study 4), suggesting that most of the gene 
expression changes elicited by WY14643 treatment are fast transcriptional responses in 
correspondence with direct regulation of gene expression by PPARα. One notable 
exception was the class representing the acute phase response, which was regulated by 5 
day but not 6 hour treatment with WY14643. 
 
Comprehensive list of PPARα targets involved in lipid metabolism 
Using these lists of genes that are upregulated by PPARα in mouse liver, we were able to 
create a comprehensive picture of PPARα-regulated genes connected with lipid 
metabolism. Genes in bold are PPARα-dependently regulated by WY14643 and during 
fasting, representing a conservative list of PPARα targets (Figure 2). Genes in normal font 
are PPARα-dependently regulated in any of the four studies included. From this picture, it 
is evident that rather than merely regulating the rate limiting enzyme in fatty acid 
oxidation, PPARα appears to regulate virtually every single step in the peroxisomal and 
mitochondrial fatty acid oxidation pathway. Furthermore, many genes involved in fatty 
acid binding and activation, lipid transport, and glycerol metabolism were controlled by 
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PPARα. What is remarkable is that PPARα also governs the expression of numerous genes 
involved in the synthesis of fats, which runs counter to the idea that PPARα mainly 
regulates fat catabolism. Several genes belonging to the lipogenic pathway have previously 
been recognized as PPARα targets, including Mod1 and Scd1, yet the extent of regulation 
by PPARα is unexpected (21). Regulation of lipogenesis by PPARα was mainly observed 
after WY14643 treatment, and to a much lesser extent after fasting. 
 
 
 
 
 
 
Figure 2. Overview of PPARα-regulated genes involved in hepatic lipid metabolism. 
Genes in bold are PPARα-dependently regulated during fasting and by WY14643, representing a 
conservative list of PPARα targets. Genes in normal font are PPARα-dependently regulated in any of 
the four studies included. Functional classification is based on a self-made functional annotation 
system of genes involved in lipid metabolism (http://nutrigene.4t.com/microarray/ppar2007). 
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Figure 3. PPARα-dependent regulation in mouse liver of selected genes involved in 
lipid metabolism as shown by heat map. The (GCRMA normalized) expression data were 
derived from four separate microarray studies. Expression levels are shown as fold change according 
to color scale compared to wildtype mice without treatment (set at 1). (A) Expression data derived 
from studies 1 and 2. (B) Expression data derived from studies 3 and 4. Genes in bold were selected 
for expression analysis by qRT-PCR and in silico screening for putative PPREs. 
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Novel putative targets of PPARα involved in lipid metabolism 
In addition to providing an overview of PPARα-dependent gene regulation, we were 
interested in identifying novel PPARα-regulated genes that are implicated in lipid 
metabolism. To that end, we went through the array data from studies 1 and 2 on the one 
hand, and studies 3 and 4 on the other hand, and selected a number of genes to generate a 
heat map showing their PPARα-dependent upregulation by fasting and/or WY14643 
(Figure 3). To our knowledge, none of the genes shown, all of which are involved in 
hepatic lipid metabolism, has yet been reported to be regulated by PPARα. This includes 
phosphatidylcholine transfer protein (lipoprotein metabolism), glycerol-3-phosphate 
acyltransferase (triglyceride synthesis), very low-density lipoprotein receptor, choline 
phosphotransferase (phosphatidylcholine synthesis), and leptin receptor. Since all of these 
genes, except Abcg5, Abcg8, and Lipe, were upregulated 6 hours after WY14643 treatment, 
they possibly represent novel direct target genes of PPARα in liver, although PPREs have 
yet to be identified in their respective gene promoters. 
 
Eight genes (shown in bold, Figure 3) were selected for more detailed investigation of 
PPARα-dependent gene regulation. Three of these genes are expected to be involved in the 
breakdown of hepatic triglycerides towards fatty acids: adipose triglyceride lipase 
(Pnpla2), hormone sensitive lipase (Lipe), and monoglyceride lipase (Mgll). Recent studies 
suggest that this threesome of genes is responsible for adipose tissue lipolysis (296-298). In 
addition, we selected endothelial lipase (EL, Lipg), a recently identified member of 
triglyceride lipase gene family that is a major determinant of plasma HDL cholesterol (299-
301), and electron transferring flavoprotein dehydrogenase (Etfdh) and electron transferring 
flavoprotein β polypeptide (Etfb), which are components of the electron transport chain and 
accept electrons from at least nine mitochondrial matrix flavoprotein dehydrogenases (302, 
303). Finally, we selected phosphatidylcholine transfer protein (Pctp), which is involved in 
lipoprotein metabolism, and thioredoxin interacting protein (Txnip), which was recently 
identified as a major regulator of the hepatic response to fasting, similar to PPARα. The 
selection of these genes was based entirely on perceived novelty and potential functional 
importance of the observed regulation. Using real-time quantitative PCR (qRT-PCR), we 
confirmed that the expression of all eight genes in liver was increased by WY14643 
feeding in a PPARα-dependent manner (Figure 4A). In addition, we measured regulation of 
expression of this set of genes by PPARα during the course of fasting (Figure 4B). 
Expression of all eight genes went up during fasting which, except for Pnpla2, was 
PPARα-dependent. However, the pattern of expression was remarkably different between 
the various genes, suggesting for each gene a complex and unique interplay between 
several fasting-dependent transcription factors, including PPARα. 
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Figure 4. PPARα governs expression of selected genes in mouse liver. (A) Regulation 
of expression of selected genes by WY14643 feeding (5 days) in liver of wildtype (+/+) and PPARα-
/- mice (-/-), as determined by qRT-PCR. Error bars represent SEM. Differences were evaluated 
statistically using two-way ANOVA. Significance (P-value) of effect of genotype (G), treatment (T) 
and interaction (I) between genotype and treatment is indicated in each figure. (B) Regulation of 
expression of selected genes by fasting in liver of wildtype (black boxes) and PPARα-/- mice (purple 
boxes), as determined by qRT-PCR. Error bars represent SEM. Differences in expression between 
wildtype and PPARα-/- mice at each time point were evaluated by student’s t-test. *P < 0.05; **P < 
0.01; ***P < 0.001. 
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Figure 5. Regulation of selected genes involved in lipid metabolism in primary 
hepatocytes by WY14643. (A) Microarray-based heatmap showing relative expression levels of 
genes calculated using a multichip modified gamma model for oligonucleotide signal (multi-
mgMOS) and a remapped chip description file. Expression levels in the absence of ligand were set at 
1. (B) Relative induction of expression of selected genes in primary hepatocytes by WY14643, as 
determined by qRT-PCR. The primary hepatocytes used for qRT-PCR and microarray analysis were 
from independent experiments. Genes were not included when expression was extremely low (Ct > 
30). Error bars represent SD. The effect of WY14643 on gene expression was evaluated by student’s 
t-test. *P < 0.05; **P < 0.01. 
 
 
 
 
Figure 6 (next page). In silico screening for putative PPREs for the selected eight 
genes. 10KB up- and downstream of the transcriptional start site were examined for the presence of 
putative PPREs. For each putative PPRE identified, the predicted PPAR subtype specific binding 
strength was determined, as reflected by the height of the bar. The sequence conservation of the 
PPRE among various species is indicated. 
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PPARα-dependent regulation in primary hepatocytes 
To examine whether the PPARα-dependent regulation of the set of genes shown in Figure 3 
was not an indirect consequence of metabolic perturbations elicited by the experimental 
challenge, we studied the effect of PPARα activation in primary mouse, rat, and human 
hepatocytes. Gene expression was first analyzed by microarray (Figure 5A), followed by 
targeted analysis of the selected eight genes by qRT-PCR (Figure 5B). Expression levels 
were calculated by applying a multichip modified gamma model for oligonucleotide signal 
(multi-mgMOS) (293) and a remapped chip description file (294) to allow for parallel 
analysis of the same gene within different species. Expression of almost every gene studied 
was highly upregulated by WY14643 in mouse and rat hepatocytes, compared to a more 
modest or no induction in human hepatocytes. For reasons that are not completely clear, in 
human hepatocytes, data from qRT-PCR and microarray did not always perfectly align. 
Overall, the data indicate that the PPARα-dependent regulation observed in vivo can be 
reproduced in primary hepatocytes. Furthermore, the data suggest that expression of six 
genes is governed by PPARα in human as well. 
 
In silico screening of putative PPREs 
To evaluate whether the selected eight genes represent possible direct PPAR target genes, 
the (mouse) genes were analyzed for the presence of putative PPREs using an in silico 
screening method (Figure 6). Ten KB up- and downstream of the TSS were examined. For 
each putative PPRE identified, the predicted PPAR subtype specific binding strength was 
determined. For each gene, at least one PPRE was identified that was conserved among rat, 
dog, and human. The Etfdh and Txnip genes were characterized by the presence of two very 
strong putative PPREs that were conserved in human. Up to six putative PPREs were 
identified in the Mgll gene, only one of which was conserved in human. A similar picture 
was found for Pnpla2. The putative PPREs located in the EL gene were weak and generally 
not conserved. Interestingly, a strong putative PPRE was identified in the Pctp gene, which 
however was not conserved in human. Conversely, the human PCTP gene contained 
several putative PPREs that were not conserved in mouse (data not shown). 
 
PPARα activation prevents hepatic lipid storage after fasting 
Our data extend the role of PPARα in hepatic lipid metabolism and suggest that PPARα 
may govern triglyceride hydrolysis. To find out whether activation of the triglyceride 
hydrolysis pathway by PPARα is associated with a decrease in hepatic triglyceride stores, 
we compared wildtype and PPARα-/- mice fed a high fat diet (HFD) for 20 weeks, 
followed by treatment for one week with WY14643. Numerous studies, including ours 
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(72), have shown that chronic HFD increases hepatic triglyceride stores. In wildtype mice 
fed the HFD, treatment with WY14643 markedly decreased hepatic lipids (Figures 7A and 
7B), as shown by smaller lipid droplets, which was paralleled by significant induction of 
expression of Pnpla2, Lipe, and Mgll (Figure 7C). These data suggest that induction of the 
triglyceride hydrolysis pathway may contribute to the overall reduction in liver 
triglycerides elicited by PPARα activation. 
 
 
 
 
Figure 7. Induction of the triglyceride hydrolysis pathway by WY14643 is paralleled by 
a decrease in hepatic lipid stores. Hematoxilin and eosin staining (A) and oil red O staining (B) 
of representative liver sections of wildtype and PPARα-/- mice treated or not with WY14643 for 7 
days (magnification 200X). All mice were given a high fat diet for 20 weeks prior to WY14643 
treatment. (C) Hepatic expression of Mgll, Lipe, and Pnpla2 in the four experimental groups as 
determined by qRT-PCR. Error bars represent SEM. Differences were evaluated statistically using 
two-way ANOVA. Significance (P-value) of effect of genotype (G), treatment (T), and interaction (I) 
between genotype and treatment is indicated in each figure. 
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Discussion 
The aim of our study was twofold: (1) to generate a comprehensive overview of PPARα-
regulated genes relevant to hepatic lipid metabolism, and (2) to identify possible novel 
target genes and target pathways of PPARα connected with lipid metabolism. 
 
It can be argued that to identify possible novel PPARα targets, the proper comparison 
should have been between wildtype and wildtype treated with WY14643, as opposed to 
wildtype treated with WY14643 and PPARα-/- treated with WY14643, in order to avoid 
inclusion of genes that are differentially expressed between wildtype and PPARα-/- mice 
under basal conditions (and could represent genes indirectly regulated by PPARα). The 
rationale behind our decision was that we wanted to be open-minded about the PPARα-
dependent transcriptome and not exclude genes that are solely regulated by PPARα under 
basal conditions. For example, opting for the comparison wildtype versus wildtype treated 
with WY14643 would have led to the exclusion of Etfdh, which according to our data 
represents a prime candidate PPARα target gene in mouse and human. Furthermore, to 
enable comparison between the effects of fasting and WY14643, it was essential to include 
the PPARα dependency, since the majority of genes regulated by fasting are regulated in a 
PPARα-independent manner. 
 
Gene Ontology classification analysis showed that numerous pathways and biological 
processes beyond lipid metabolism were regulated by PPARα. We observed that the 
expression of almost 1700 probesets was significantly increased 6 hours after a single oral 
dose of WY14643. Although not all genes regulated may represent direct PPARα targets, 
and even though the functional consequences of the observed regulation still needs to be 
demonstrated, these data at least suggest a major role for PPARα in hepatic gene expression 
and overall liver homeostasis. 
 
In agreement with the first aim, we created a comprehensive overview of hepatic PPARα-
regulated genes connected to lipid metabolism (Figure 2). A functional PPRE has been 
found in the promoter of several of these genes, classifying them as direct PPARα target 
genes, and many more genes have been shown to be upregulated by PPARα without a 
functional PPRE having been identified (21). It can be presumed that the far majority of 
genes presented in Figure 2 (as well as the other genes that were shown to be regulated by 
PPARα) are actually direct target genes of PPARα, but it is beyond the scope and capacity 
of the present study to address this issue in more detail. Our hope is that by combination of 
expression arrays with global analysis of promoter occupancy by PPARα using chromatin 
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immunoprecipitation and tiling or promoter arrays (so-called ChIP-on-chip analysis), the 
complete picture of direct PPARα target genes will be available in the future. 
 
The second aim of our study was to identify possible novel target genes of PPARα 
representing specific steps in lipid metabolism unknown to be governed by PPARα. As part 
of this effort, we identified several genes for which a link with PPARα has not yet been 
reported, including VLDL receptor, leptin receptor, and choline phosphotransferase. We 
focused our energy on eight genes for which regulation by PPARα was deemed most novel 
and functionally interesting. All eight genes, except for Lipe, were significantly upregulated 
6 hours after treatment with WY14643. 
 
Using an in silico method to screen for PPREs, for each gene several putative PPREs could 
be located within 10KB of the transcriptional start site. Within this region, at least one 
PPRE was identified that was conserved among rat, dog, and human. The presence of 
multiple strong putative PPREs within the mouse Mgll gene is in correspondence with the 
marked regulation of Mgll expression in mouse liver and isolated hepatocytes. To a lesser 
extent, this is also true for the Pnpla2 and Pctp genes. Furthermore, the predicted presence 
of two strong, well-conserved putative PPREs in the Etfdh and Txnip genes is in agreement 
with the highest fold-induction of these genes by WY14643 in primary human hepatocytes. 
Although in silico screening may not be able to substitute for analysis of direct promoter 
binding by ChIP, the predictive power of the method explored has been shown to be 
remarkably robust (295). Our results also substantiate the developing notion that PPAR-
dependent gene regulation is generally mediated by multiple PPREs, rather than a single 
PPRE. 
 
One remarkable outcome of the global analysis of gene regulation by PPARα is that 
PPARα appears to play a major role in governing lipogenesis. While several genes 
involved in lipogenesis were already known as PPARα targets, including Δ5 and Δ5 
desaturase (Fads), stearoyl-CoA desaturase (Scd), microsomal triglyceride transfer protein 
(Mttp), and malic enzyme (Mod1) (21), the extent of regulation of lipogenesis is somewhat 
surprising, especially since PPARα is generally considered to stimulate fat catabolism 
rather than fat synthesis. It can be speculated that upregulation of fatty acid desaturation 
and elongation enzymes by PPARα might serve to stimulate production of PPARα ligands, 
and is part of a feed forward action of PPARα that also includes auto regulation of gene 
expression. 
 
Although the triglyceride hydrolysis pathway in liver still has to be fully elucidated, it may 
very well be similar to the pathway operating in adipose tissue (296). Adipose tissue 
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triglycerides are likely hydrolyzed in a three-step process catalyzed by adipose triglyceride 
lipase (Pnpla2), hormone sensitive lipase (Lipe), and monoglyceride lipase (Mgll) (296-
298, 304). Remarkably, deletion of the Pnpla2 gene in mice not only results in more 
adipose mass but also causes a marked increase in lipid storage in a variety of organs, 
including liver and heart, suggesting that the triglyceride hydrolysis pathway is conserved 
between various organs (296). Disabling the PPARα gene is known to increase hepatic 
triglyceride accumulation, especially under conditions of fasting (71, 72, 305). Conversely, 
treatment with PPARα agonists lowers hepatic triglyceride levels in various models of 
hepatic steatosis (306-309). The antisteatotic effect of PPARα has generally been ascribed 
to stimulation of fatty acid oxidation, which, by decreasing intracellular fatty acid levels, 
will act as a drain on intracellular triglyceride stores. However, our data suggest that 
PPARα may directly govern the triglyceride hydrolysis pathway in liver via upregulation of 
lipases Pnpla2, Lipe, Mgll, and possibly Ces1 and Ces3 (Figure 2). Although it is 
impossible to provide definite experimental proof that induction of the triglyceride 
hydrolysis pathway by PPARα, or induction of fatty acid oxidation for that matter, is 
necessary and sufficient for its hepatic triglyceride-lowering effect, it likely contributes to 
the overall reduction in liver triglycerides elicited by PPARα agonists. 
 
Our data suggest that expression of EL is under control of PPARα. EL, synthesized in 
endothelial cells, plays an important role in governing plasma lipoprotein concentrations 
and is a major determinant of plasma HDL cholesterol and apoAI concentrations. Indeed, 
overexpression of EL in the liver results in a significant decrease in HDL cholesterol and 
apoAI (299-301). EL has been shown to have some triglyceride lipase but mainly 
phospolipase activity (310). Although in silico screening failed to detect a strong PPRE in 
this gene, in our study EL expression was highly increased by 6 hours WY14643 treatment 
and by fasting in a PPARα-dependent manner, suggesting that EL may be a direct PPARα 
target gene. As EL expression was minimal in primary hepatocytes, EL transcripts likely 
originated from liver epithelial cells rather than liver parenchymal cells. Although further 
work is necessary, we suspect that EL may be a direct PPARα target in endothelial cells. 
Considering that, in contrast to EL, PPARα agonists raise plasma HDL, the functional 
importance of regulation of EL by PPARα needs to be further validated. 
 
Another novel PPARα-regulated gene of relevance to lipoprotein metabolism is Pctp. Pctp 
is a steroidogenic acute regulatory-related transfer domain protein that binds 
phosphatidylcholines with high specificity. Studies with Pctp-null mice suggest that it may 
modulate HDL particle size and rates of hepatic clearance (311). According to our data, 
expression of Pctp increases during fasting, which is abolished in PPARα-/- mice. 
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WY14643 markedly upregulated Pctp mRNA in mouse liver as well as in mouse, rat, and 
human hepatocytes, suggesting it may represent a novel PPARα target gene. 
 
Etfdh and Etfb are essential components of the oxidative phosphorylation pathway. They 
are responsible for the electron transfer from at least nine mitochondrial flavin-containing 
dehydrogenases to the main respiratory chain (302, 303). According to our data, expression 
of Etfdh and Etfb is governed by PPARα, suggesting that besides the β-oxidation pathway, 
PPARα also regulates components of the respiratory chain involved in the transfer of 
electrons from fatty acids and other molecules. 
 
The last gene that we studied in more detail was Txnip, which is also known as Hyplip1. A 
spontaneous mutation within the Txnip gene gives rise to a complex phenotype that 
resembles familial-combined hyperlipidemia, including hypercholesterolemia and 
hypertriglyceridemia (312). Recent studies suggest that Txnip plays an important metabolic 
role in the fasting-feeding transition by altering the redox status of the cell, which results in 
stimulation of the tricarboxylic acid cycle at the expense of ketone body or fatty acid 
synthesis (313). Indeed, Txnip-deficient mice show elevated plasma ketones, elevated free 
fatty acids, hypercholesterolemia, and hypertriglyceridemia, yet decreased glucose levels 
(312, 314). The phenotype is very similar to that of PPARα-/- mice with the exception of 
the elevated plasma ketones. Since hepatic expression of Txnip is decreased in PPARα-/- 
mice, it can be hypothesized that part of the effect of PPARα deletion on lipid and glucose 
metabolism is mediated by downregulation of Txnip in liver, which subsequently might 
affect redox status. It is unclear to what extent Txnip expression is affected by PPARα 
deletion in tissues other than liver. 
 
In conclusion, our data indicate that the role of PPARα in hepatic lipid metabolism is much 
more extensive than previously envisioned. By generating a schematic overview of 
PPARα-dependent gene regulation in mouse liver, and, for a selected set of genes, by 
providing evidence for direct regulation by PPARα in rodents and human, we have 
extended the role of PPARα in the control of hepatic lipid metabolism. 
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Abstract 
The effect of dietary fats on human health and disease are likely mediated by changes in 
gene expression. Several transcription factors have been shown to respond to fatty acids, 
including SREBP-1c, NF-ΚB, RXRs, LXRs, FXR, HNF4α, and PPARs. However, it is 
unclear to what extent these transcription factors play a role in gene regulation by dietary 
fatty acids in vivo. 
 
Here, we take advantage of a unique experimental design using synthetic triglycerides 
composed of one single fatty acid in combination with gene expression profiling to 
examine the effects of various individual dietary fatty acids on hepatic gene expression in 
mice. We observed that the number of significantly changed genes and the fold-induction 
of genes increased with increasing fatty acid chain length and degree of unsaturation. 
Importantly, almost every single gene regulated by dietary unsaturated fatty acids remained 
unaltered in mice lacking PPARα. In addition, the majority of genes regulated by 
unsaturated fatty acids, especially docosahexaenoic acid, were also regulated by the 
specific PPARα agonist WY14643. Excellent agreement was found between the effects of 
unsaturated fatty acids on mouse liver versus cultured rat hepatoma cells. Interestingly, 
using Nuclear Receptor PamChip® Arrays, fatty acid- and WY14643-induced interactions 
between PPARα and coregulators were found to be highly similar, although several 
PPARα-coactivator interactions specific for WY14643 were identified. 
 
We conclude that the effects of dietary unsaturated fatty acids on hepatic gene expression 
are almost entirely mediated by PPARα and mimic those of synthetic PPARα agonists in 
terms of regulation of target genes and molecular mechanism. Use of synthetic dietary 
triglycerides may provide a novel paradigm for nutrigenomics research. 
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Introduction 
Dietary fatty acids have multiple functions in the human body. They are an important 
energy source, form an essential part of the phospholipid bilayer of membranes, and 
function as precursors to several signaling molecules, such as the eicosanoids. A huge body 
of literature collected in the past few decades provides compelling evidence that changes in 
the dietary fatty acid composition can profoundly influence health and disease. For 
example, it is well established that replacing dietary saturated fatty acids with n-6 mono- 
and polyunsaturated leads to a decrease in plasma concentration of low density lipoprotein, 
which is a well-known risk factor for atherosclerosis (315). Likewise, increased 
consumption of n-3 fatty acids, especially eicosapentaenoic acid and docosahexaenoic acid 
present in fish oil, is associated with decreased plasma triglyceride (TG) concentrations 
(316), may prevent against cardiac arrhythmias (317), and improves visual acuity in 
preterm infants (318). Numerous molecular mechanisms may underlie the effects of dietary 
fatty acids on parameters of health. While historically the main focus was on changes in 
plasma membrane fluidity as a result of changes in phospholipid composition, the 
discovery of nuclear receptors has progressively shifted the emphasis to regulation of gene 
expression. 
 
The superfamily of nuclear receptors encompasses a related but diverse set of transcription 
factors that share a number of structural and functional features (319). They consist of a 
central DNA-binding domain that directs the receptor to specific DNA sequences within a 
gene promoter, and a ligand-binding domain, which can accommodate a variety of different 
compounds. Roughly, nuclear receptors can be divided into three main groups: the 
endocrine receptors that bind steroid hormones, the adopted orphan receptors that bind 
dietary lipids, and the orphan receptors, for which no ligand exists or still has to be 
identified (320). The adopted orphan receptors share a common mode of action that 
involves heterodimerization with the nuclear retinoid X receptor (RXR). Binding of ligands 
to the receptor leads to recruitment of coactivators and dissociation of corepressors, 
resulting in chromatin remodeling followed by initiation of DNA transcription. Adopted 
orphan receptors mainly function as lipid sensors by altering the rate of transcription of 
specific genes in response to changes in lipid concentration (320). These lipids include 
oxysterols, bile acids, and fat soluble vitamins. In addition, many adopted orphan receptors 
have been shown to bind fatty acids and alter transcription in response to changes in fatty 
acid concentration and/or composition, including RXR, peroxisome-proliferator activated 
receptors (PPARα, β/δ and γ), hepatic nuclear factor 4α (HNF-4α), liver X receptor (LXR) 
α and β, and farnesoid X receptor (321, 322). Other receptors that mediate the effects of 
dietary fatty acids on gene expression include the sterol regulatory element binding protein 
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1, and the nuclear factor kappaB (321). However, the relative contribution of all these 
receptors to fatty acid-dependent gene regulation in vivo remains completely unclear. 
 
Here, we take advantage of a unique experimental design using synthetic triglycerides 
composed of one single fatty acid in combination with gene expression profiling to 
examine the effects of individual dietary fatty acids on hepatic gene expression in mice. By 
conducting these experiments in wildtype and PPARα-/- mice, we were able to explore the 
specific contribution of PPARα. We conclude that the effects of dietary unsaturated fatty 
acids on hepatic gene expression are almost exclusively mediated by PPARα and mimic 
those of synthetic PPARα agonists in terms of target genes regulation and molecular 
mechanism. 
 
Materials and Methods 
 
Materials. WY14643 was purchased from ChemSyn Laboratories (Lenexa, KS, USA). 
Triolein was from Fluka (Zwijndrecht, the Netherlands). Trilinolein, trilinolenin, 
tridocosahexaenoin and trieicosapentaenoin were from Nu-Chek-Prep, Inc. (Elysian, MN, 
USA). Fetal bovine serum and penicillin/streptomycin were from Cambrex Bioscience 
(Seraing, Belgium). SYBR Green was purchased from Eurogentec (Seraing, Belgium). All 
other chemicals were from Sigma (Zwijndrecht, the Netherlands). 
 
Animals. Male pure-bred Sv129 and PPARα-/- mice (2-6 months of age) on a Sv129 
background were used. Two weeks before start of the experiment, the animals were 
switched to a run-in diet consisting of a modified AIN76A diet (corn oil was replaced by 
olive oil) (Research Diet Services, Wijk bij Duurstede, the Netherlands). Starting at 5 a.m. 
the animals were fasted for 4 hours followed by an intragastric gavage of 400µl synthetic 
triglyceride (triolein, trilinolein, trilinolenin, trieicosapentaenoin or tridocosahexaenoin) 
(Figure 1). WY14643 and fenofibrate were given as 10mg/ml suspension in 0.5% 
carboxymethyl cellulose, which also served as control treatment (400µl). Four to five mice 
per group were used, adding up to 78 mice in total. 6 hours after gavage, mice were 
anaesthetized with a mixture of isofluorane (1.5%), nitrous oxide (70%) and oxygen (30%). 
Blood was collected by orbital puncture, after which the mice were sacrificed by cervical 
dislocation. Livers were removed, snap-frozen in liquid nitrogen and stored at -80°C until 
further analysis. For RNA analyses, tissue from the same part of the liver lobe was used. 
The animal studies were approved by the Local Committee for Care and Use of Laboratory 
Animals at Wageningen University. 
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Figure 1. Schematic representation of dietary intervention. Wildtype and PPARα-/- mice 
fasted for four hours were given a single oral dose of different synthetic triglycerides composed of 
one single unsaturated fatty acid (400μl), or one of the PPARα agonists WY14643 or fenofibrate 
(4mg). After six hours, the livers were used for gene expression profiling using Affymetrix Mouse 
Genome 430 2.0 Microarrays (~45000 probesets) on biological replicates. CMC = carboxymethyl 
cellulose. 
 
 
 
 
 
 
Lipid absorption and tissue distribution. Measurement of intestinal lipid absorption 
was carried out exactly as previously described (323). For the lipid loading test wildtype 
mice were fasted for 4 hours followed by administration of 400µl olive oil via intragastric 
gavage. Blood was collected by tail bleeding every 2 hours for plasma TG measurement. 
Tissue uptake of [3H]-labeled TG packaged into VLDL-like emulsion particles was 
measured as previously described (324). The data shown reflect percentage of bolus 
radioactivity taken up after 30 minutes by a specific tissue expressed per gram tissue. 
 
Triglycerides. Plasma and liver triglycerides were measured with a commercially 
available kit from Instruchemie (Delfzijl, the Netherlands). Livers were weighed and 
homogenized in a buffer (pH 7.5) containing 250mM sucrose, 1mM EDTA and 10mM 
Tris, with a final tissue concentration of 5%. 2µl of plasma or liver homogenate was used 
to determine TG. 
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RNA isolation and qRT-PCR. Total liver RNA was isolated with TRIzol reagent 
(Invitrogen, Breda, the Netherlands) according to manufacturer’s instructions. A NanoDrop 
ND-1000 spectrophotometer (Isogen, Maarssen, the Netherlands) was used to determine 
RNA concentrations. 1µg of total RNA was reverse transcribed using iScript (Bio-Rad, 
Veenendaal, the Netherlands). cDNA was amplified on a Bio-Rad MyIQ or iCycler PCR 
machine using Platinum Taq DNA polymerase (Invitrogen, Breda, the Netherlands). PCR 
primer sequences were taken from the PrimerBank (325) and ordered from Eurogentec 
(Seraing, Belgium). Sequences of the primers used are available upon request. 
 
Affymetrix microarray. Total RNA from mouse liver was extracted with TRIzol 
reagent, and purified and DNAse treated using the SV Total RNA Isolation System 
(Promega, Leiden, the Netherlands). RNA quality was assessed on an Agilent 2100 
bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands) with 6000 Nano Chips 
using the Eukaryote Total RNA Nano assay. RNA was judged as suitable for array 
hybridization only if samples showed intact bands corresponding to the 18S and 28S rRNA 
subunits, displayed no chromosomal peaks or RNA degradation products, and had a RIN 
(RNA integrity number) above 8.0. Five micrograms of RNA were used for one cycle 
cRNA synthesis (Affymetrix, Santa Clara, CA). Hybridization, washing and scanning of 
Affymetrix Mouse Genome 430 2.0 Arrays was carried out according to standard 
Affymetrix protocols. 
 
Packages from the Bioconductor project were used for analyzing the scanned Affymetrix 
arrays (288). Arrays were normalized using quartile normalization, and expression 
estimates were compiled using GC-RMA applying the empirical Bayes approach (289). A 
non-specific filtering step was applied to remove probesets with low variation, as they 
provide no discriminating power (326). Only those probesets were included that had an 
inter-quartile range (IQR) across the samples of at least 0.25 on the log2-scale. 
Differentially expressed probesets were identified using linear models, applying moderated 
t-statistics that implement empirical Bayes regularization of standard errors (327). 
 
Comparisons were made between wildtype treated and untreated (control) and also between 
PPARα-/- treated and untreated animals. Probesets that presented a P-value <0.01 were 
considered to be significantly changed by treatment. If a probeset was significantly 
changed in the wildtype but not the PPARα-/- mouse, it was considered to be PPARα-
dependent (also probesets that were significantly changed in the PPARα-/- mouse, but had 
a fold change <1.5 of the fold change in the wildtype mouse were included in this 
category). 
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Functional analysis of the array data was performed by a method based on 
overrepresentation of Gene Ontology (GO) terms, where the functional class score (FCS) 
method was used (292, 328, 329). 
 
Cell culture. Rat hepatoma FAO cells were grown in DMEM containing 10% (vol/vol) 
fetal bovine serum, 100U/ml penicillin and 100µg/ml streptomycin. Cells were incubated 
with albumin-bound fatty acids (100µM) dissolved in ethanol or synthetic PPARα ligands 
dissolved in DMSO (5µM WY14643, 50µM fenofibrate). Incubation continued for 24 
hours and was followed by RNA isolation and qRT-PCR. 
 
Cofactor recruitment assay. Nuclear Receptor PamChip® Arrays (PamGene, 
s’Hertogenbosch, the Netherlands) were used according to the manufacturer’s instructions. 
Upon binding a ligand, PPARα undergoes a conformational change which promotes the 
formation of a cofactor binding pocket, subsequently allowing interaction with the so-
called LxxLL motif within some coregulators. The PamChip® arrays consist of 48 peptides 
encompassing the LxxLL motifs of 19 different coregulator proteins ((330), Koppen et al. 
2007. Micro Array assay for Real-time analysis of Coregulator-Nuclear receptor 
Interaction. Manuscript submitted.) Briefly, the arrays were incubated with glutathione-S-
transferase (GST)-tagged PPARα-LBD (Invitrogen, Breda, the Netherlands) in the presence 
or absence of ligand. Quantification of interaction between PPARα and coregulators was 
made using Alexa488-conjugated anti-GST rabbit polyclonal antibody (Invitrogen). As 
ligands, either a negative control (EtOH), the synthetic PPARα agonist WY14643 or one of 
the fatty acids C18:1, C18:2, C18:3, C20:5 or C22:6 were used. 
 
Results 
Mice that were fasted for 4 hours were given a single oral dose (400l) of synthetic 
triglycerides (TGs) consisting of one single fatty acid, followed by collection of tissues 6 
hours thereafter (Figure 1). A parallel treatment in mice lacking PPARα was performed to 
enable estimation of the importance of PPARα in gene regulation by dietary fatty acids. 
The fatty acids studied were oleic acid (C18:1), linoleic acid (C18:2), linolenic acid 
(C18:3), eicosapentaenoic acid (C20:5), and docosahexaenoic acid (C22:6). No saturated 
fatty acids were included because triglycerides composed of common dietary saturated 
fatty acids are solid at room temperature and could not be administered orally. The 6 hour 
time point was chosen because in an independent oral fat load experiment, plasma 
triglyceride levels peaked 2 hours after the fat load and almost returned back to baseline 
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after 6 hours (Figure 2A), indicating that at that point most of the fat bolus has been cleared 
from the blood and taken up by the tissues. Indeed, we observed that 6 hours after oral 
dosing plasma TG levels had almost returned to baseline (Figure 2B), and were similar in 
wildtype and PPARα-/- mice, suggesting no major differences in plasma TG kinetics 
between the various fatty acids and between wildtype and PPARα-/-. Also, no major 
differences in the rate of intestinal TG absorption were observed between wildtype and 
PPARα-/- mice (Figure 2C). Finally, while as expected liver TG levels were higher in the 
PPARα-/- mice compared to wildtype mice, in the wildtype mice liver TG levels were 
similar between the various fatty acids (Figure 2D). These data argue against major 
differences in metabolic processing of dietary fat between wildtype and PPARα-/- mice and 
between different dietary fatty acids. 
 
The focus of the present study is on liver since we observed that, when expressed per gram 
organ weight, the liver and heart take up most of the fatty acids present in TG-rich 
lipoproteins (Figure 2E). A future publication will address the effect of dietary fatty acids 
on gene expression and the involvement of PPARs in heart. 
 
PPARα-dependent gene regulation by dietary unsaturated fatty acids 
Expression profiling was carried out on individual mouse livers. Use of Affymetrix Mouse 
Genome 430 2.0 Arrays (whole mouse genome array), which contain more than 45000 
probesets corresponding to over 34000 genes, allows for a genome-wide analysis of the 
number of significantly changed genes in the various treatment groups. After inter-quartile 
range (IQR) filtering, 11463 probesets (equivalent to 7231 genes) were left for analysis. A 
regularized t-test was performed to analyze changes in gene expression between the control 
and oral triglyceride group. The regularized t-test statistic has the same interpretation as an 
ordinary t-test statistic, except that the standard errors have been moderated across genes, 
i.e. shrunk to a common value, using a Bayesian model (327). A probeset was found to be 
significantly changed after treatment if P<0.01. All microarray results have been deposited 
into the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/) and can be 
accessed online under series number GSE8396. Quantitative real-time PCR was carried out 
on ~30 genes in order to confirm the results from the microarray, and the results were 
found to be in close agreement with the microarray data (Figure 3). 
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Figure 2. Metabolic processing of dietary triglycerides. (A) Wildtype mice were given an 
oral fat load of 400µl olive oil via intragastric gavage. TG levels were measured in plasma collected 
via the tail vein at the indicated time points. Errors bars represent SEM (n=11). (B) Plasma TG of 
wildtype and PPARα-/- mice sacrificed 6 hours after intragastric gavage with synthetic triglycerides, 
WY14643, or fenofibrate. Error bars represent SD (n=4-5 per group). (C) Intestinal triglyceride 
absorption rate was determined in 5h fasted wildtype (black boxes) and PPARα-/- (purple boxes) 
mice by measuring the appearance of [3H] in plasma after intragastric gavage with 7uCi glycerol-
tri[3H]oleate mixed with olive oil (200µl). Immediately before the gavage, mice received an 
intraorbital injection of tyloxapol (Triton WR1339) dissolved in saline at 500mg/kg bodyweight. 
Blood was sampled via the tail vein at the indicated time points for measurement of 3H-activity. Error 
bars represent SEM. (D) Liver TG of wildtype and PPARα-/- mice sacrificed 6 hours after 
intragastric gavage with synthetic triglycerides, WY14643, or fenofibrate. Error bars represent SD 
(n=4-5 per group). (D) Tissue uptake of radiolabeled VLDL-like emulsion particles. VLDL-like 
particles labeled with glycerol tri[3H]oleate were injected into anesthetized mice. After 30 minutes, 
mice were euthanized and tissues collected for measurement of 3H-activity. Error bars represent SEM 
(n=4). 
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Figure 3. Close agreement between microarray and qRT-PCR data. mRNA expression of 
several genes was measured by quantitative real-time PCR to confirm the results from microarray. 
Results are shown as fold change compared to wildtype control. Error bars represent SD. 
 
 
 
 
 
 
The highest number of statistically significantly changed genes was found after treatment 
with C22:6 (519, P<0.01), followed by, in turn, C18:3 (400), C18:2 (287), C20:5 (280) and 
C18:1 (114) (Figure 4 and Table 1). These numbers are relatively low in comparison with 
the synthetic PPARα agonists WY14643 (1674) and fenofibrate (1005). The data indicate 
that of all fatty acids studied, C22:6 is the most potent activator of gene expression. 
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Regulation of gene expression by dietary fatty acids or synthetic agonists was defined as 
PPARα-dependent when expression was statistically significantly up- or downregulated in 
wildtype but not PPARα-/- mice. As expected, gene regulation by WY14643 and 
fenofibrate in wildtype mice was almost completely abolished in PPARα-/- mice. 
Surprisingly, a similar though slightly less extreme picture was observed for dietary 
unsaturated fatty acids. Indeed, the far majority of genes regulated by dietary unsaturated 
fatty acids in wildtype mice did not show regulation in PPARα-/- mice, indicating PPARα-
dependent regulation. This was highest for C20:5 (94.6%), followed by C22:6 (93.1%), 
C18:1 (88.6%), C18:2 (87.1%) and C18:3 (84.0%) (Figure 4 and Table 1). Similar numbers 
were obtained for up- and downregulation of gene expression. The few genes that were up- 
or downregulated by dietary unsaturated fatty acids independently of PPARα included 
Lpin2 and Srebp-1, respectively. Together, these data suggest that the (short term) effects 
of dietary unsaturated fatty acids on hepatic gene expression are almost exclusively 
mediated by PPARα. 
 
 
 
 
 
Figure 4. PPARα-dependent regulation of gene expression by dietary unsaturated 
fatty acids. Bars show number of up- (A) and downregulated (B) probesets in the different 
treatment groups. The number of probesets regulated by unsaturated fatty acids in a PPARα-
dependent manner (purple bars, not changed in the PPARα-/- mouse), or PPARα-independent manner 
(black bars, changed in wildtype and PPARα-/- mice) are shown, with percentage PPARα 
dependence indicated. Probesets were considered statistically significantly regulated if P<0.01. 
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Table 1. Total number as well as PPARα-dependent up- and downregulated probesets and 
corresponding genes for each treatment group (P<0.01). 
    
 Probesets Genes  
 Total 
number 
PPARα-
dep % dep 
Total 
number 
PPARα-
dep % dep 
 
WY14643 1180 1165 98.7% 797 789 99.0% 
fenofibrate 800 794 99.3% 549 544 99.1% 
C18:1 51 47 92.2% 47 44 93.6% 
C18:2 260 221 85.0% 212 186 87.7% 
C18:3 349 285 81.7% 283 237 83.7% 
C20:5 249 238 95.6% 201 194 96.5% 
C22:6 425 393 92.5% 313 296 94.6% 
U
pregulated 
WY14643 1092 1081 99.0% 877 867 98.9% 
fenofibrate 540 537 99.4% 456 454 99.6% 
C18:1 69 60 87.0% 67 57 85.1% 
C18:2 77 65 84.4% 75 64 85.3% 
C18:3 133 112 84.2% 117 99 84.6% 
C20:5 84 76 90.5% 79 71 89.9% 
C22:6 221 201 91.0% 206 187 90.8% 
D
ow
nregulated 
WY14643 2272 2246 98.9% 1674 1656 98.9% 
fenofibrate 1340 1331 99.3% 1005 998 99.3% 
C18:1 120 107 89.2% 114 101 88.6% 
C18:2 337 286 84.9% 287 250 87.1% 
C18:3 482 397 82.4% 400 336 84.0% 
C20:5 333 314 94.3% 280 265 94.6% 
C22:6 646 594 92.0% 519 483 93.1% 
U
p- and 
dow
nregulated 
 
 
 
 
 
 
Overlap in gene regulation between dietary unsaturated fatty acids and 
WY14643 
To further explore the role of PPARα in regulation of gene expression by dietary 
unsaturated fatty acids, the overlap in gene regulation between fatty acids and WY14643, 
which specifically targets PPARα, was studied. Remarkably, C22:6 showed a huge overlap 
in gene regulation with WY14643 (Figure 5A). Quantitatively, 84% of genes upregulated 
and 76% of genes downregulated by C22:6 (P<0.01) were also regulated by WY14643 
(average 80.5%), suggesting that C22:6 impacts mainly PPARα target genes. Much less 
overlap was observed between C18:1 and WY14643 (average 32.4%), suggesting that gene 
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regulation by C18:1 may be less dependent on PPARα, or alternatively the existence of 
PPARα target genes specifically regulated by C18:1 (Figure 5A). An intermediate degree 
of overlap was observed between WY14643 and the other fatty acids studied (Table 2). 
 
To further compare the effects of WY14643 and C22:6 on gene expression, for all 
probesets left after IQR-filtering the fold changes in expression in response to WY14643 
and C22:6 were plotted against each other, with each probeset represented by a single dot 
(Figure 5B). The vast majority of probesets ended up in the lower left or upper right 
compartments, indicating that genes up- or downregulated by WY14643 were also up- or 
downregulated by C22:6, respectively, thus confirming the overlap in gene regulation 
between C22:6 and WY14643. Additionally, the positioning of the dots around a straight 
line with slope <1 shows that the relative magnitude of gene induction by C22:6 related to 
WY14643 was remarkably constant across all probesets. Thus, compared to WY14643, 
C22:6 behaves as an almost equally specific, yet less potent PPARα agonist. Nevertheless, 
several genes could be identified that were upregulated disproportionally strongly by 
WY14643 including Cd36, Fabp4 (aP2), and Cpt1b, or by C22:6 including Prlr and Txnip 
(Figure 5B). A much more scattered picture was observed for the comparison between 
WY14643 and C18:1, indicating that these compounds have much less in common in terms 
of gene regulation. Again, the other fatty acids gave an intermediate picture (data not 
shown). 
 
 
 
 
 
 
 
Table 2. Overlap in gene regulation between dietary unsaturated fatty acids and WY14643. Genes 
were considered statistically significantly regulated if P<0.01. 
    
Treatment Number of changed genes 
Number of changed 
genes overlapping 
with WY14643 
% changed genes 
overlapping with 
WY14643 
WY14643 1674   
fenofibrate 1005 875 87.1% 
C18:1 114 37 32.4% 
C18:2 287 142 49.5% 
C18:3 400 244 61.0% 
C20:5 280 220 78.6% 
C22:6 519 418 80.5% 
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Figure 5. Similarities between two dietary unsaturated fatty acids and the synthetic 
PPARα agonist WY14643. (A) Venn diagrams showing the overlap in up- (left panel) and 
downregulated (right panel) genes after treatment with WY14643, C22:6 and C18:1. Genes were 
considered statistically significantly regulated if P<0.01. (B) Scatter plots demonstrating similarities 
in gene regulation between C22:6 and WY14643. Graphs show fold change in gene expression after 
treatment with WY14643 compared to C22:6 and C18:1. Genes that are upregulated disproportionally 
strongly by WY14643 (Cd36, Fabp4 (aP2), and Cpt1b), or by C22:6 (Prlr and Txnip) are marked. In 
constructing the scatter plots, all probesets left after IQR-filtering were used. (C) Overlap in 
overrepresented Gene Ontology classes between C22:6, C18:1, and WY14643, based on a functional 
class score (FCS) method. The GO class unique to C22:6 and C18:1 is GO:0016070 (RNA 
metabolism), whereas the GO classes unique to C18:1 are GO:0007409 (axonogenesis) and 
GO:0016072 (rRNA metabolism). 
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Table 3. Overlap in overrepresented Gene Ontology classes between dietary unsaturated fatty acids 
and fenofibrate and WY14643 based on analysis with Functional Class Score method, FDR <0.0001. 
Treatment 
No. over-
represented 
GO classes 
No. GO 
classes 
overlapping 
with WY14643 
% GO classes 
overlapping 
with WY14643 
GO classes not in WY14643 
WY14643 62    
fenofibrate 48 40 83.3% 
GO:0006084 - acetyl-CoA metabolism; 
GO:0006519 - amino acid and derivative 
metabolism; 
GO:0006695 - cholesterol biosynthesis; 
GO:0006816 - calcium ion transport; 
GO:0009308 - amine metabolism; 
GO:0009725 - response to hormone 
stimulus; 
GO:0016126 - sterol biosynthesis; 
GO:0043283 - biopolymer metabolism 
C18:1 8 5 62.5% 
GO:0007409 - axonogenesis; 
GO:0016070 - RNA metabolism; 
GO:0016072 - rRNA metabolism 
C18:2 11 9 81.8% 
GO:0007167 - enzyme linked receptor 
protein signaling pathway; 
GO:0009725 - response to hormone 
stimulus 
C18:3 13 11 84.6% 
GO:0006445 - regulation of translation; 
GO:0006928 - cell motility 
C20:5 13 13 100% - 
C22:6 19 18 94.7% GO:0016070 - RNA metabolism 
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An alternative approach to study similarities in gene regulation is via determining the 
overlap in Gene Ontology (GO) classes overrepresented in the respective treatment groups 
(Table S1). P-values derived from t-test for all ~45000 probesets on the microarray were 
used for the GO-based functional clustering. The comparisons were made between the 
control group and each treatment group in wildtype mice. Out of a total of 19 GO classes 
overrepresented after C22:6 treatment, only one class (GO:0016070, RNA metabolism) 
was not shared between C22:6 and WY14643 (Figure 5C). Interestingly, this GO class was 
shared between C22:6 and C18:1 suggesting it may be specifically regulated by dietary 
unsaturated fatty acids and not WY14643. The remainder of fatty acids studied, except for 
perhaps C18:1, similarly showed a high degree of overlap with WY14643 (Table 3), 
thereby corroborating the very large resemblance in gene regulation between WY14643 
and the dietary fatty acids studied. Overall, these data support the dominant role of PPARα 
in gene regulation by dietary unsaturated fat. 
 
Hierarchy between dietary unsaturated fatty acids 
Of all fatty acids studied, the number of significantly changed genes was highest for C22:6, 
followed by C18:3. The number was about equal for C20:5 and C18:2, while much fewer 
genes were changed after C18:1 treatment. Since the dietary fatty acids regulated gene 
expression principally via PPARα, the data are indicative of a hierarchy in in vivo PPARα-
activating potency between dietary unsaturated fatty acids. Direct evidence for this notion 
came from comparison of fold changes in expression of PPARα target genes between the 
various fatty acid treatments. Genes involved in two major PPARα-regulated pathways 
were examined: mitochondrial fatty acid oxidation and peroxisomal fatty acid oxidation 
(Figure 6). These functional classes were created in house for various pathways within lipid 
metabolism and were specifically designed for Affymetrix GeneChip analysis (available at 
http://nutrigene.4t.com/microarray/ppar2007). By visualizing the changes in gene 
expression in the form of a heatmap, a clear hierarchy in PPARα-activating potency can be 
observed between the various treatments, which can be expressed as 
WY14643>fenofibrate>C22:6>C20:5=C18:3>C18:2>C18:1. 
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Figure 6. Differential induction of genes involved in fatty acid oxidation between 
various dietary fatty acids. (A) Genes involved in mitochondrial fatty acid oxidation. (B) Genes 
involved in peroxisomal fatty acid oxidation. The heatmaps were generated directly from the 
microarray data, using for each probeset the mean signal from 4-5 biological replicates. The scale 
represents fold-induction relative to wildtype control, which was set at 1. Only probesets showing 
significant (P<0.01) upregulation by WY14643 were included in the analysis. A list of probesets 
belonging to the functional class of mitochondrial fatty acid oxidation can be found at 
http://nutrigene.4t.com/microarray/ppar2007. 
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Since a direct comparison between synthetic agonists and dietary fatty acids is complicated 
by differences in dosage (4mg vs. 400μl), further comparisons were made between fatty 
acids only. For all probesets shown in the heatmaps as well as probesets belonging to the 
lipogenesis pathway we estimated the relative induction by each fatty acid expressed as a 
percentage of induction by C22:6. The median for all probesets within a functional class 
was calculated for each treatment group (Figure 7, bar). These data indicate that C22:6 is 
the most potent activator of PPARα-dependent gene regulation in mouse liver, while C18:1 
is the least active. 
 
 
 
 
 
 
 
 
Figure 7. Differential induction of genes involved in lipid metabolism between dietary 
unsaturated fatty acids. For each probeset, the induction of expression by each fatty acid was 
expressed as a percentage relative to C22:6 (100%), using the mean signal from 4-5 biological 
replicates. Each dot represents one probeset. The horizontal bars represent the median percentage of 
induction relative to C22:6 calculated separately for each pathway and fatty acid. Only probesets 
showing significant (P<0.01) upregulation by WY14643 were included in the analysis. A list of 
probesets belonging to the three functional classes can be found at 
http://nutrigene.4t.com/microarray/ppar2007. 
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To examine whether the difference in in vivo PPARα-activating potency between the 
dietary fatty acids could be reproduced in vitro, cultured rat FAO hepatoma cells were 
treated with various unsaturated fatty acids. It was observed that the pattern of regulation of 
PPARα targets Pdk4, Ehhadh and Cyp4A14 by unsaturated fatty acids was highly similar 
between the FAO cells and intact mouse liver (Figure 8). These data provide additional 
evidence that differences in metabolic processing of fatty acids are unlikely to explain 
differential fold-induction of genes between dietary fatty acids observed in vivo. Rather, 
they indicate an intrinsic difference in PPARα-activating potency between dietary 
unsaturated fatty acids, which is supported by published in vitro data. 
 
 
 
 
 
 
 
Figure 8. Close agreement between fatty acid-dependent gene regulation in vivo and 
in vitro. mRNA expression of three genes (Pdk4, Ehhadh and Cyp4A14) was determined in mouse 
liver and in rat hepatoma FAO cells using quantitative real-time PCR. Results are shown as fold 
change compared to control group. Error bars represent SD. 
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While in terms of target gene regulation dietary unsaturated fatty acids thus generally 
mimic the effect of the synthetic PPARα agonist WY14643 except for being less potent, it 
is unclear whether these different compounds activate PPARα and stimulate transcription 
of target genes via the exact same mechanism. To explore this issue we used Nuclear 
Receptor PamChip® Arrays to identify differences in coregulator recruitment between 
WY14643 and C22:6. In this system the interaction between nuclear receptors and 
immobilized peptides corresponding to specific coregulator-nuclear receptor binding 
regions is studied. Both C22:6 and WY14643 promoted the interaction between PPARα 
and numerous coregulator peptides. Interestingly, no PPARα-coregulator interactions 
unique to C22:6 could be identified. However, at least four interactions, representing the 
coregulator proteins TRIP3, TRIP8, RIP140, and the nuclear receptor SHP1, seemed to be 
elicited specifically by WY14643 (Figure 9). No differences in PPARα-coregulator 
interaction patterns could be observed between the various fatty acids studied (data not 
shown). 
 
 
 
 
 
Figure 9. Cofactor recruitment assay with WY14643 and C22:6. The Nuclear Receptor 
PamChip® assay was used to measure the interaction between PPARα and immobilized peptides 
corresponding to specific coregulator-nuclear receptor binding regions. Measurements were 
performed in the presence of control (EtOH), WY14643 (5μM) or C22:6 (100μM). Arrows point to 
those coactivators selectively recruited by WY14643 but not C22:6. All images were taken after 100 
msec exposure time. 
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Discussion 
Dietary fats have numerous effects on human health. Current dietary guidelines strongly 
discourage consumption of saturated and trans fatty acids, whereas consumption of 
unsaturated fatty acids, especially n-3 fatty acids present in fish oil, is promoted (331-333). 
It is believed that dietary fatty acids mainly influence biological processes by altering DNA 
transcription. In the present paper, using a unique dietary intervention protocol consisting 
of a single dose of synthetic triglycerides composed of a single fatty acid, we show that in 
mouse liver PPARα dominates gene regulation by dietary unsaturated fat. Furthermore, we 
demonstrate that dietary polyunsaturated fatty acids (PUFAs), especially docosahexaenoic 
acid, are the most potent activators of PPARα in vivo. These latter data align well with in 
vitro experiments showing that in general PUFAs are more potent PPARα ligands 
compared to mono- and saturated fatty acids, although the results may depend somewhat on 
the method used (27, 41, 67, 68, 204, 334, 335). 
 
It can be argued that our data and conclusions may be biased due to possible differential 
absorption and metabolic processing between the various fatty acids and between wildtype 
and PPARα-/- mice. Unfortunately, the unavailability of radioactive TG besides triolein 
makes it impossible to get complete and comparative information on the kinetic behavior of 
the various fatty acids used. However, several lines of evidence argue against major 
differences in kinetic behavior between the fatty acids: 1) it has been previously 
demonstrated that hepatic uptake of fatty acids from chylomicron remnants is unaffected by 
the fatty acid composition (336); 2) at the moment of sacrifice, plasma TG levels were 
highly similar for the various fatty acid groups; 3) fatty acid treatment in vivo and in vitro 
revealed a similar hierarchy in PPARα-activating potency between the fatty acids and in 
both analyses C22:6 emerged as the most potent PPARα agonist. 
 
In addition, no major differences in the kinetics of dietary fat metabolism are expected 
between wildtype and PPARα-/- mice as: 1) wildtype and PPARα-/- mice show similar 
rates of intestinal TG absorption; 2) at the moment of sacrifice, plasma TG levels were 
highly similar between wildtype and PPARα-/- mice; 3) while synthetic PPARα agonists 
are known to stimulate plasma TG clearance (337), no evidence is available that points to 
differences in plasma TG clearance and tissue fatty acid uptake between wildtype and 
PPARα-/- mice; 4) genes that are upregulated by fatty acids in a PPARα-independent 
manner were induced to the same extent in wildtype and PPARα-/- mice (data not shown), 
suggesting that the dietary fatty acids were taken up at the same rate in liver of wildtype 
and PPARα-/- mice. 
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While PPARα activity is known to respond to changes in dietary fat content and 
composition (73, 338, 339), the large dominance of PPARα in fatty acid-dependent gene 
regulation in liver is surprising given that the activity of numerous transcription factors can 
be modulated by fatty acids, including SREBP-1, HNF4α, LXRs, FXR, RXRs, NF-ΚB, as 
well as PPARβ/δ and PPARγ (340-352). For several of these proteins, including RXRs and 
HNF4α, physical binding by fatty acids or fatty acyl-CoAs has been demonstrated (345-
347, 353-357). RXR forms a permissive heterodimer with PPARα and accordingly it may 
be theorized that transcriptional activation of PPAR target genes by fatty acids may occur 
via their binding to either the PPARα and/or RXR moiety. The loss of fatty acid-dependent 
gene regulation in PPARα-/- mice, the very large overlap in gene regulation between 
unsaturated fatty acids and WY14643, and the less potent binding of fatty acids to RXR 
relative to PPARα strongly suggest a dominant role for PPARα in gene regulation by 
unsaturated fatty acids (343, 346, 358, 359). However, an additional role for RXR is hard to 
exclude as the effects of RXR activation seem to occur primarily via PPARα (360). It 
remains to be investigated to what extent the dominant role of PPARα in gene regulation by 
unsaturated fatty acids extends to tissues other than liver. Likely, the relative role of other 
transcription factors is related to their relative expression in a particular tissue. 
 
Although it is clear that gene regulation by unsaturated fatty acids is highly dependent on 
PPARα, genes that are regulated in a PPARα-dependent manner do not necessarily 
represent direct PPARα targets. Some regulation is also expected to occur indirectly via 
activation of other transcription factors that are under direct control of PPARα. Analysis of 
the microarray data showed very little changes in the expression of other nuclear receptors 
in response to the intervention with the exception of CAR, which was upregulated, and 
RXRα and AhR, which were downregulated, although not necessarily in all treatments. The 
nuclear receptor CAR was recently identified as a PPARα target (361), suggesting that 
some genes may be regulated by PPARα and fatty acids via CAR. Secondary gene 
regulation was likely kept to a minimum by harvesting the livers only six hours after the 
oral gavage. It should also be noted that none of the putative fatty acid responsive 
transcription factors were significantly decreased in PPARα-/- mice, suggesting that their 
transcriptional regulatory function is not intrinsically suppressed in PPARα-/- mice. 
 
Our study shows a clear hierarchy between unsaturated dietary fatty acids in terms of 
number of significantly changed genes and fold-induction of genes, with especially C22:6 
behaving as a highly potent inducer of PPARα-dependent gene expression. The difference 
in in vivo PPARα-activating potency between the dietary fatty acids was reproduced in 
vitro and thus suggest an intrinsic difference in PPARα-activating potency between dietary 
unsaturated fatty acids, which is supported by in vitro receptor binding and transactivation 
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studies and thus likely reflects differences in binding affinity for PPARα (27, 340-344). 
Even though C18:2 was not the most potent inducer of gene expression, one could 
speculate that it likely represents the quantitatively most important dietary activator of 
PPARα, as the average intake of C18:2 is much higher than that of C18:3, C20:5 and 
C22:6. 
 
In recent years, the concept of Selective PPAR Modulators (SPPARM) has emerged by 
analogy to Selective Estrogen Receptor Modulators (SERM). According to this concept, 
different PPAR agonists would induce differential gene expression based on selective 
receptor-coregulator interactions. While recent evidence supports the concept of selective 
PPARγ modulation (362-364), only limited data are available on PPARα (365). The design 
of our study allowed us to explore the concept of SPPARM in the comparison between 
unsaturated fatty acids and synthetic agonists. We hypothesized that fatty acids and 
synthetic PPARα agonists, while both activating PPARα, may induce differential gene 
expression patterns possibly via selective receptor-coregulator interactions. 
 
In our analysis we found that almost every gene significantly up- or downregulated by 
C22:6 was also significantly up- or downregulated by WY14643, respectively. Clearly, the 
reverse was not true, illustrating that WY14643 is a more potent PPARα agonist than 
C22:6. Importantly, the scatter plot indicated that across all probesets the relative induction 
of gene expression by C22:6 when related to WY14643 was remarkably constant, 
suggesting that C22:6 behaves as a less potent, yet almost equally specific PPARα agonist. 
Nevertheless, several genes could be identified that were upregulated disproportionally 
strongly by WY14643 including Cd36, Fabp4 (aP2), and Cpt1b, or by C22:6 including 
Prlr and Txnip (Figure 5B). Thus, differences in gene regulation between C22:6 and 
WY14643 could not entirely be accounted for by the lesser potency of C22:6. Interestingly, 
using the Nuclear Receptor PamChip® assay, at least four interactions, representing the 
coregulator proteins TRIP3, TRIP8, RIP140, and the nuclear receptor SHP1, seemed to be 
stimulated specifically by WY14643. However, no PPARα-coregulator interactions could 
be identified that were stimulated specifically by C22:6 and not WY14643. 
 
Overall, similar observations were made for the other fatty acids studied, although 
compared to C22:6 they were less potent and/or less specific activators of PPARα, 
especially C18:1. The data indicate that in general dietary PUFAs mimic the effect of 
WY14643 on hepatic gene expression in terms of regulation of target genes and molecular 
mechanism, including coregulator interactions. In addition to being a more potent PPARα 
agonist in comparison with unsaturated fatty acids, WY14643 disproportionally induces 
expression of specific genes, which may be mediated via interactions with specific 
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coactivator proteins including RIP140. Thus, our data underscore the concept of selective 
PPARα modulation when comparing WY14643 with endogenous PPARα agonists, e.g. 
PUFAs. 
 
Currently, one major drawback when performing microarray analyses on data derived from 
dietary intervention studies is the lack of proper statistical tools. The statistical methods 
developed to cope with the huge amount of data derived from microarray analyses work 
sufficiently well for stronger interventions, such as drug studies. When dealing with 
nutrition, however, changes in gene expression are often weak although no less important. 
Multiple testing methods normally used in microarray analyses to correct for false positives 
include FDR (false discovery rate) and Q-value (366-368). These methods are usually too 
restrictive for nutritional intervention, however, and will result in a loss of important 
results, as became apparent in the present study. Use of Q-value instead of P-value resulted 
in loss of a considerable amount of important information (data not shown). Numerous 
quantitative real-time PCR reactions have been carried out on the livers from this study 
supporting the use of the P-value. 
 
In conclusion, dietary unsaturated fatty acids, especially docosahexaenoic acid and other 
PUFAs, acutely influence gene expression in mouse liver which, despite the presence of 
numerous other putative fatty acid-dependent transcription factors, is almost entirely 
mediated by PPARα. Consequently, dietary PUFAs largely mimic the effect of synthetic 
PPARα agonists on hepatic gene expression, both in terms of regulation of specific target 
genes and molecular mechanism including coregulator interactions, although compared to 
WY14643 and fenofibrate they are clearly less potent PPARα agonists. Our analysis 
underscores the power of a (nutri)genomics approach to investigate the potential molecular 
mechanisms underlying the effect of specific dietary components on (biomarkers of) health. 
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Table S1. Overrepresented GO classes in each treatment group based on analysis with Functional 
Class Score method, FDR <0.0001. 
         
 GO ID GO Class Probes in class 
Genes 
in class 
Raw 
score FDR 
 
1 GO:0006637 acyl-CoA metabolism 24 14 4.56 3.16E-11 
2 GO:0001676 long-chain fatty acid metabolism 11 9 3.60 8.87E-05 
3 GO:0007031 peroxisome organization and biogenesis 31 16 3.08 2.89E-11 
4 GO:0006732 coenzyme metabolism 63 35 2.87 2.41E-11 
5 GO:0006635 fatty acid beta-oxidation 21 14 2.79 8.15E-05 
6 GO:0019395 fatty acid oxidation 38 21 2.53 2.73E-11 
7 GO:0006090 pyruvate metabolism 42 20 2.46 3.26E-11 
8 GO:0019752 carboxylic acid metabolism 215 115 2.36 4.40E-11 
9 GO:0019319 hexose biosynthesis 43 21 2.27 4.04E-11 
10 GO:0008654 phospholipid biosynthesis 92 34 2.19 3.37E-11 
11 GO:0006469 negative regulation of protein kinase activity 70 26 2.12 7.22E-11 
12 GO:0009408 response to heat 51 25 1.94 2.53E-10 
13 GO:0046467 membrane lipid biosynthesis 92 34 1.86 9.19E-11 
14 GO:0006869 lipid transport 118 60 1.85 2.25E-11 
15 GO:0009266 response to temperature stimulus 68 38 1.77 5.95E-11 
16 GO:0006725 aromatic compound metabolism 60 34 1.71 2.35E-11 
17 GO:0006644 phospholipid metabolism 116 45 1.68 4.21E-11 
18 GO:0008203 cholesterol metabolism 122 55 1.64 5.62E-11 
19 GO:0006986 response to unfolded protein 138 64 1.63 1.12E-10 
20 GO:0006333 chromatin assembly or disassembly 110 37 1.59 8.72E-05 
21 GO:0051789 response to protein stimulus 123 56 1.57 1.01E-09 
22 GO:0045859 regulation of protein kinase activity 83 33 1.57 8.29E-05 
23 GO:0009607 response to biotic stimulus 145 73 1.57 2.53E-11 
24 GO:0007050 cell cycle arrest 122 49 1.55 2.11E-11 
25 GO:0012502 induction of programmed cell death 182 81 1.53 2.66E-11 
26 GO:0008202 steroid metabolism 210 104 1.53 2.06E-11 
27 GO:0008610 lipid biosynthesis 230 108 1.52 1.44E-10 
28 GO:0016125 sterol metabolism 114 52 1.51 1.94E-11 
29 GO:0006694 steroid biosynthesis 119 56 1.45 5.32E-11 
30 GO:0043065 positive regulation of apoptosis 283 117 1.44 2.47E-11 
31 GO:0043067 regulation of programmed cell death 238 107 1.43 8.43E-11 
32 GO:0045786 negative regulation of progression through cell cycle 273 108 1.41 2.15E-11 
33 GO:0035023 regulation of Rho protein signal transduction 145 63 1.41 3.06E-11 
34 GO:0045087 innate immune response 83 56 1.39 1.26E-10 
35 GO:0006260 DNA replication 282 108 1.39 2.97E-11 
36 GO:0006917 induction of apoptosis 241 106 1.38 6.32E-11 
37 GO:0006006 glucose metabolism 86 47 1.38 8.43E-05 
38 GO:0007507 heart development 255 102 1.36 5.06E-11 
39 GO:0001525 angiogenesis 209 92 1.30 1.91E-11 
W
Y14643 
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 GO ID GO Class Probes in class 
Genes 
in class 
Raw 
score FDR 
 
35 GO:0006260 DNA replication 282 108 1.39 2.97E-11 
36 GO:0006917 induction of apoptosis 241 106 1.38 6.32E-11 
37 GO:0006006 glucose metabolism 86 47 1.38 8.43E-05 
38 GO:0007507 heart development 255 102 1.36 5.06E-11 
39 GO:0001525 angiogenesis 209 92 1.30 1.91E-11 
40 GO:0007243 protein kinase cascade 278 109 1.30 3.49E-11 
41 GO:0008284 positive regulation of cell proliferation 209 94 1.29 3.61E-11 
42 GO:0007266 Rho protein signal transduction 207 87 1.29 1.84E-11 
43 GO:0006916 anti-apoptosis 189 75 1.28 5.06E-10 
44 GO:0016568 chromatin modification 284 107 1.27 1.01E-10 
45 GO:0043066 negative regulation of apoptosis 284 115 1.26 3.74E-11 
46 GO:0042060 wound healing 106 62 1.26 8.57E-05 
47 GO:0045934 
negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism 
179 70 1.26 2.30E-11 
48 GO:0016481 negative regulation of transcription 274 109 1.25 1.87E-11 
49 GO:0006814 sodium ion transport 198 105 1.24 2.02E-11 
50 GO:0000165 MAPKKK cascade 214 85 1.23 1.98E-11 
51 GO:0007067 mitosis 268 114 1.21 6.74E-11 
52 GO:0048514 blood vessel morphogenesis 236 98 1.19 4.81E-11 
53 GO:0051242 positive regulation of cellular physiological process 201 91 1.18 4.60E-11 
54 GO:0040008 regulation of growth 215 89 1.18 2.81E-11 
55 GO:0019538 protein metabolism 215 101 1.17 1.81E-11 
56 GO:0030036 actin cytoskeleton organization and biogenesis 299 112 1.17 1.69E-10 
57 GO:0001558 regulation of cell growth 228 94 1.16 2.20E-11 
58 GO:0051056 regulation of small GTPase mediated signal transduction 195 86 1.16 2.02E-10 
59 GO:0006325 establishment and/or maintenance of chromatin architecture 299 112 1.15 7.78E-11 
60 GO:0000087 M phase of mitotic cell cycle 239 104 1.15 3.89E-11 
61 GO:0006092 main pathways of carbohydrate metabolism 206 99 1.15 3.37E-10 
62 GO:0045045 secretory pathway 288 115 1.10 2.59E-11 
W
Y14643 
1 GO:0006637 acyl-CoA metabolism 24 14 4.66 4.04E-11 
2 GO:0001676 long-chain fatty acid metabolism 11 9 2.87 1.26E-10 
3 GO:0006732 coenzyme metabolism 63 35 2.78 3.06E-11 
4 GO:0006084 acetyl-CoA metabolism 28 9 2.58 9.54E-05 
5 GO:0007031 peroxisome organization and biogenesis 31 16 2.46 3.61E-11 
6 GO:0006635 fatty acid beta-oxidation 21 14 2.31 2.30E-11 
7 GO:0009725 response to hormone stimulus 35 13 2.20 3.37E-10 
8 GO:0006090 pyruvate metabolism 42 20 2.12 4.21E-11 
9 GO:0019395 fatty acid oxidation 38 21 1.98 3.49E-11 
10 GO:0019752 carboxylic acid metabolism 215 115 1.90 6.74E-11 
11 GO:0019319 hexose biosynthesis 43 21 1.85 5.95E-11 
12 GO:0006519 amino acid and derivative metabolism 57 27 1.76 3.89E-11 
13 GO:0006695 cholesterol biosynthesis 50 22 1.72 5.06E-10 
14 GO:0008654 phospholipid biosynthesis 92 34 1.68 4.60E-11 
15 GO:0016126 sterol biosynthesis 59 25 1.66 1.12E-10 
16 GO:0009308 amine metabolism 65 30 1.65 2.81E-11 
17 GO:0008203 cholesterol metabolism 122 55 1.45 8.43E-11 
18 GO:0046467 membrane lipid biosynthesis 92 34 1.39 1.69E-10 
19 GO:0006725 aromatic compound metabolism 60 34 1.37 2.97E-11 
fenofibrate 
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 GO ID GO Class Probes in class 
Genes 
in class 
Raw 
score FDR 
 
20 GO:0006869 lipid transport 118 60 1.27 2.89E-11 
21 GO:0007050 cell cycle arrest 122 49 1.27 2.66E-11 
22 GO:0016125 sterol metabolism 114 52 1.26 2.47E-11 
23 GO:0043283 biopolymer metabolism 88 39 1.26 9.72E-05 
24 GO:0008610 lipid biosynthesis 230 108 1.26 2.53E-10 
25 GO:0006644 phospholipid metabolism 116 45 1.25 6.32E-11 
26 GO:0006694 steroid biosynthesis 119 56 1.19 7.78E-11 
27 GO:0006986 response to unfolded protein 138 64 1.17 2.02E-10 
28 GO:0007243 protein kinase cascade 278 109 1.15 4.81E-11 
29 GO:0043067 regulation of programmed cell death 238 107 1.15 1.44E-10 
30 GO:0045786 negative regulation of progression through cell cycle 273 108 1.14 2.73E-11 
31 GO:0008202 steroid metabolism 210 104 1.12 2.59E-11 
32 GO:0012502 induction of programmed cell death 182 81 1.06 3.37E-11 
33 GO:0007507 heart development 255 102 1.06 7.22E-11 
34 GO:0006092 main pathways of carbohydrate metabolism 206 99 1.06 1.01E-09 
35 GO:0006260 DNA replication 282 108 1.05 3.74E-11 
36 GO:0043065 positive regulation of apoptosis 283 117 1.04 3.16E-11 
37 GO:0007266 Rho protein signal transduction 207 87 1.03 2.35E-11 
38 GO:0043066 negative regulation of apoptosis 284 115 1.03 5.32E-11 
39 GO:0006816 calcium ion transport 208 86 1.02 4.40E-11 
40 GO:0007067 mitosis 268 114 1.02 1.01E-10 
41 GO:0006917 induction of apoptosis 241 106 1.01 9.19E-11 
42 GO:0045934 
negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism 
179 70 1.00 9.91E-05 
43 GO:0008284 positive regulation of cell proliferation 209 94 1.00 5.06E-11 
44 GO:0016481 negative regulation of transcription 274 109 0.99 2.41E-11 
45 GO:0000087 M phase of mitotic cell cycle 239 104 0.98 5.62E-11 
46 GO:0000165 MAPKKK cascade 214 85 0.97 9.36E-05 
47 GO:0006814 sodium ion transport 198 105 0.97 2.53E-11 
48 GO:0045045 secretory pathway 288 115 0.96 3.26E-11 
fenofibrate 
1 GO:0016072 rRNA metabolism 149 75 0.83 5.06E-10 
2 GO:0016070 RNA metabolism 187 75 0.81 1.44E-10 
3 GO:0007266 Rho protein signal transduction 207 87 0.81 1.26E-10 
4 GO:0000087 M phase of mitotic cell cycle 239 104 0.79 2.53E-10 
5 GO:0007067 mitosis 268 114 0.78 3.37E-10 
6 GO:0007409 axonogenesis 275 112 0.77 1.01E-09 
7 GO:0043066 negative regulation of apoptosis 284 115 0.75 2.02E-10 
8 GO:0007243 protein kinase cascade 278 109 0.73 1.69E-10 
C
18:1 
1 GO:0009725 response to hormone stimulus 35 13 1.81 5.06E-10 
2 GO:0006637 acyl-CoA metabolism 24 14 1.78 1.69E-10 
3 GO:0006333 chromatin assembly or disassembly 110 37 1.16 1.12E-10 
4 GO:0035023 regulation of Rho protein signal transduction 145 63 0.96 1.44E-10 
5 GO:0007266 Rho protein signal transduction 207 87 0.94 9.19E-11 
6 GO:0008284 positive regulation of cell proliferation 209 94 0.93 2.02E-10 
7 GO:0051056 regulation of small GTPase mediated signal transduction 195 86 0.91 1.01E-09 
8 GO:0019752 carboxylic acid metabolism 215 115 0.91 2.53E-10 
9 GO:0001558 regulation of cell growth 228 94 0.85 1.01E-10 
C
18:2 
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 GO ID GO Class Probes in class 
Genes 
in class 
Raw 
score FDR 
 
10 GO:0043067 regulation of programmed cell death 238 107 0.82 3.37E-10 
11 GO:0007167 enzyme linked receptor protein signaling pathway 305 115 0.82 1.26E-10 
C
18:2 
1 GO:0006637 acyl-CoA metabolism 24 14 2.48 1.26E-10 
2 GO:0006732 coenzyme metabolism 63 35 1.45 8.43E-11 
3 GO:0019752 carboxylic acid metabolism 215 115 1.11 2.02E-10 
4 GO:0008203 cholesterol metabolism 122 55 1.02 3.37E-10 
5 GO:0006445 regulation of translation 133 48 0.99 1.12E-10 
6 GO:0006986 response to unfolded protein 138 64 0.94 1.01E-09 
7 GO:0006260 DNA replication 282 108 0.89 1.01E-10 
8 GO:0006928 cell motility 225 84 0.88 7.78E-11 
9 GO:0051242 positive regulation of cellular physiological process 201 91 0.83 2.53E-10 
10 GO:0043066 negative regulation of apoptosis 284 115 0.82 1.69E-10 
11 GO:0043065 positive regulation of apoptosis 283 117 0.81 9.19E-11 
12 GO:0006917 induction of apoptosis 241 106 0.79 5.06E-10 
13 GO:0007243 protein kinase cascade 278 109 0.78 1.44E-10 
C
18:3 
1 GO:0006637 acyl-CoA metabolism 24 14 2.20 1.01E-10 
2 GO:0006732 coenzyme metabolism 63 35 1.33 8.43E-11 
3 GO:0019752 carboxylic acid metabolism 215 115 0.90 1.44E-10 
4 GO:0006986 response to unfolded protein 138 64 0.86 5.06E-10 
5 GO:0048514 blood vessel morphogenesis 236 98 0.83 1.69E-10 
6 GO:0009607 response to biotic stimulus 145 73 0.82 9.19E-11 
7 GO:0007243 protein kinase cascade 278 109 0.82 1.12E-10 
8 GO:0007067 mitosis 268 114 0.81 2.02E-10 
9 GO:0001525 angiogenesis 209 92 0.81 7.78E-11 
10 GO:0016568 chromatin modification 284 107 0.80 3.37E-10 
11 GO:0000087 M phase of mitotic cell cycle 239 104 0.78 1.26E-10 
12 GO:0030036 actin cytoskeleton organization and biogenesis 299 112 0.77 1.01E-09 
13 GO:0006325 establishment and/or maintenance of chromatin architecture 299 112 0.76 2.53E-10 
C
20:5 
1 GO:0006637 acyl-CoA metabolism 24 14 2.77 9.19E-11 
2 GO:0006732 coenzyme metabolism 63 35 1.74 5.32E-11 
3 GO:0009408 response to heat 51 25 1.50 5.06E-10 
4 GO:0019395 fatty acid oxidation 38 21 1.50 7.22E-11 
5 GO:0019752 carboxylic acid metabolism 215 115 1.25 1.26E-10 
6 GO:0006986 response to unfolded protein 138 64 1.23 2.02E-10 
7 GO:0051789 response to protein stimulus 123 56 1.21 1.01E-09 
8 GO:0009266 response to temperature stimulus 68 38 1.16 1.44E-10 
9 GO:0009607 response to biotic stimulus 145 73 1.15 5.95E-11 
10 GO:0016070 RNA metabolism 187 75 0.97 7.78E-11 
11 GO:0012502 induction of programmed cell death 182 81 0.95 6.74E-11 
12 GO:0045045 secretory pathway 288 115 0.94 6.32E-11 
13 GO:0043066 negative regulation of apoptosis 284 115 0.93 1.12E-10 
14 GO:0008610 lipid biosynthesis 230 108 0.93 2.53E-10 
15 GO:0030036 actin cytoskeleton organization and biogenesis 299 112 0.91 3.37E-10 
16 GO:0007243 protein kinase cascade 278 109 0.91 1.01E-10 
17 GO:0043065 positive regulation of apoptosis 283 117 0.90 5.62E-11 
18 GO:0007067 mitosis 268 114 0.88 1.69E-10 
19 GO:0006260 DNA replication 282 108 0.87 8.43E-11 
C
22:6 
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Abstract 
PPARα is an important transcription factor in liver that can be activated physiologically by 
fasting or pharmacologically using high-affinity synthetic agonists. Here we initially set out 
to elucidate the similarities in gene induction between WY14643 and fasting. 
 
Numerous genes were commonly regulated in liver between the two treatments, including 
many classical PPARα target genes such as Aldh3a2 and Cpt2. Remarkably, several genes 
induced by WY14643 were upregulated by fasting independently of PPARα, including 
Lpin2 and St3gal5, suggesting involvement of another transcription factor. Using chromatin 
immunoprecipitation, Lpin2 and St3gal5 were shown to be direct targets of PPARβ/δ 
during fasting, whereas Aldh3a2 and Cpt2 were exclusive targets of PPARα. Binding of 
PPARβ/δ to the Lpin2 and St3gal5 genes followed the plasma FFA concentration, 
consistent with activation of PPARβ/δ by plasma FFAs. Subsequent experiments using 
transgenic and knockout mice for Angptl4, a potent stimulant of adipose tissue lipolysis, 
confirmed the stimulatory effect of plasma FFAs on Lpin2 and St3gal5 expression via 
PPARβ/δ. In contrast, the data did not support activation of PPARα by plasma FFA. 
 
The results identify Lpin2 and St3gal5 as novel PPARβ/δ target genes and show that 
upregulation of gene expression by PPARβ/δ is sensitive to plasma FFA levels. In contrast, 
this is not the case for PPARα, revealing a novel mechanism for functional differentiation 
between PPARs. 
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Introduction 
Hepatic lipid metabolism is governed by a complex interplay between hormones, 
transcription factors, and energy substrates, allowing for rapid adaptations to changes in 
metabolic needs (369). According to the traditional view, energy substrates such as fatty 
acids influence lipid metabolism by promoting flux through a particular pathway via mass 
action. However, it has become clear that energy substrates can also directly govern the 
transcription of enzymes involved in lipid metabolism via mechanisms analogous to that of 
many hormones. Indeed, it is now evident that glucose and fatty acids play a major 
regulatory role in hepatic lipid metabolism via direct activation or inhibition of specific 
transcription factors, including ChREBP (370, 371), SREBP1 (348-350, 372, 373), and 
PPARα (21). 
 
Although numerous transcription factors have been shown to be activated by fatty acids in 
vitro, recent data suggest that PPARα is dominant in mediating the effects of dietary fatty 
acids on gene expression in liver (69). PPARα is a member of the superfamily of nuclear 
receptors and closely related to the other PPAR isoforms β/δ and γ (374) . Similar to 
several other nuclear receptors, PPARs function as heterodimers with the retinoid X 
receptor (RXR) and bind to specific sequences on the DNA referred to as PPAR-response 
elements (PPREs) (24, 63, 283). Numerous studies have shown that fatty acids can directly 
bind to PPARs and activate DNA transcription (39, 41, 67, 68, 204, 335). Binding of fatty 
acids changes the conformation of the PPAR protein (27, 149, 375, 376), and leads to 
recruitment of coactivator proteins (69, 204). Besides fatty acids and their derivatives, 
PPARs bind synthetic agonists including the thiazolidionediones, which serves as agonist 
for PPARα, and the fibrates, which are PPARα agonists (377). 
 
Most of the information about the function of PPARα in liver and its impact on target genes 
is based on studies that have used high-affinity synthetic PPARα agonists. These 
pharmacological studies have shown that PPARα regulates a remarkably large number of 
genes, many of which are involved in hepatic lipid metabolism, thereby explaining the 
positive effect of synthetic PPARα agonists on plasma lipid parameters (21, 337). 
However, PPARα did not evolve as a receptor for fibrates but rather as a fatty acid sensor. 
Accordingly, the question arises to what extent results from pharmacological studies reflect 
the physiological function of PPARα. 
 
Physiological experiments using PPARα-/- mice have shown that PPARα is especially 
important for the adaptive response to fasting. During fasting, the absence of PPARα elicits 
a complex phenotype characterized by fatty liver, hypoketonemia, hypoglycemia, 
 
 
 
 
 
 
 
 
Chapter 5 
 
 92 
hypothermia, and elevated plasma FFA levels (70-72, 96). Furthermore, the hepatic 
induction of numerous metabolic genes during fasting is abolished in PPARα-/- mice. 
While both pharmacological and physiological studies thus support a major role for PPARα 
in hepatic lipid metabolism, evidence is suggesting that there is only partial overlap 
between genes upregulated by PPARα during fasting and genes upregulated by synthetic 
PPARα agonists (85). One possible explanation is that PPARα responds differently to 
pharmacological compared to physiological activation. Additionally, there may be a role 
for other PPAR subtypes. Besides PPARα, PPARβ/δ has been shown to be well expressed 
in hepatocytes (44, 47). However, the functional role of PPARβ/δ in hepatocytes and its 
physiological mechanisms of activation remain unknown. 
 
Here we initially set out to elucidate the similarities and discrepancies in gene regulation in 
liver between pharmacological PPARα activation by WY14643 and physiological PPARα 
activation by fasting. While our data reveal major overlap between the effects of WY14643 
and fasting, the data also indicate that a number of pharmacological PPARα target genes 
are induced by fasting independently of PPARα. Subsequent analysis uncovered a role for 
PPARβ/δ in hepatic gene regulation and revealed different mechanisms of activation of 
PPARα versus PPARβ/δ in mouse liver. Specifically, we find that upregulation of gene 
expression by PPARβ/δ is sensitive to plasma FFAs while this is not the case for PPARα. 
 
Materials and Methods 
 
Materials. Tridocosahexaenoin were from Nu-Chek-Prep, Inc. (Elysian, MN, USA). 
SYBR Green was purchased from Eurogentec (Seraing, Belgium). Protease inhibitor 
cocktail was purchased from Roche Diagnostics (Almere, the Netherlands), sonicated 
salmon sperm DNA was from Invitrogen (Breda, the Netherlands) and Proteinase K was 
from Fermentas (St.Leon–Rot, Germany). All other chemicals were from Sigma 
(Zwijndrecht, the Netherlands). 
 
Animals. Pure-bred Sv129 PPARα-/- mice (129S4/SvJae) and corresponding wildtype 
mice (129S1/SvImJ) were purchased from Jackson Laboratory (Bar Harbor, Maine, USA). 
The PPARβ/δ-/- mice were on a mixed background (Sv129/C57Bl/6) and have been 
previously described (378). The Angptl4-/-, +/-, and transgenic mice were on a C57Bl/6 
background and have been previously described (324, 379, 380). Angptl4-transgenic mice 
overexpress Angptl4 in numerous tissues including adipose tissue (324, 379), while the 
Angptl4-/- lack Angptl4 expression in all tissues (380). Only male mice were used at 4-10 
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mice per group. For the fasting experiment, food was withdrawn for 24 hours starting at the 
onset of the light cycle. 
 
PPARα ligand: Wildtype and PPARα-/- mice were fasted for 4h, and thereafter given an 
intragastric gavage of 400µl WY14643 (10 mg/ml in 0.5% carboxymethyl cellulose). 
Control treatment was 400µl 0.5% carboxymethyl cellulose. Livers were collected after 6h. 
Oral lipid load: Wildtype and PPARα-/- mice were given an intragastric gavage of 400µl 
synthetic triglyceride (tridocosahexaenoin) after a four hour fast. Control treatment was 
0.5% carboxymethyl cellulose (400µl). Livers were collected 6h after gavage. PPARβ/δ 
ligand: Wildtype mice were given a single oral gavage of 150µg GW501516. Alternatively, 
PPARα-/- mice were fed 0.025% (wt/wt) L165041 mixed in food for 5 days. 
 
Mice were anaesthetized with a mixture of isofluorane (1.5%), nitrous oxide (70%) and 
oxygen (30%). Blood was collected by orbital puncture, after which the mice were 
sacrificed by cervical dislocation. Livers were dissected and directly frozen in liquid 
nitrogen. For RNA analyses, tissue from the same part of the liver lobe was used. 
 
The animal studies were approved by the Local Committee for Care and Use of Laboratory 
Animals at Wageningen University, the Netherlands and the University of Lausanne, 
Switzerland. 
 
Affymetrix microarray. Total RNA from mouse liver was extracted with TRIzol 
reagent, and purified and DNAse treated using the SV Total RNA Isolation System 
(Promega, Leiden, the Netherlands). RNA quality measurements were performed on an 
Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands) using 6000 
Nano Chips in combination with the Eukaryote Total RNA Nano assay. RNA was judged 
as suitable for array hybridization only if samples showed intact bands corresponding to the 
18S and 28S rRNA subunits, displayed no chromosomal peaks or RNA degradation 
products, and had a RIN (RNA integrity number) above 8.0. Five micrograms of RNA 
were used for one cycle cRNA synthesis (Affymetrix, Santa Clara, CA, USA). 
Hybridization, washing and scanning of Affymetrix Mouse Genome 430 2.0 arrays / 
Affymetrix NuGO mouse arrays was carried out according to standard Affymetrix 
protocols. 
 
Packages from the Bioconductor project were used for analyzing the scanned arrays (381). 
Arrays were normalized using quantile normalization, and expression estimates were 
compiled using GC-RMA applying the empirical Bayes approach (382). A non-specific 
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filtering step was applied to remove genes with low variation, and included only those 
genes that had an inter-quartile range (IQR) across the samples of at least 0.25 on the log2-
scale (326). 
 
Gene set enrichment analysis (GSEA) was used to relate changes in gene expression to 
functional changes between mice treated with the PPARα agonist WY14643 for 6h and 
mice fasted for 24h. GSEA takes into account a broad context of physically interacting 
networks in which gene products function, including biochemical, metabolic and signal 
transduction routes (383). Gene sets with a FDR P-value <0.1 were considered significantly 
overrepresented. 
 
Plasma metabolites. Plasma was obtained from blood by centrifugation for 10 minutes 
at 10000g. Plasma triglycerides and glycerol concentration in cell culture medium were 
determined using kits from Instruchemie (Delfzijl, the Netherlands). Plasma free fatty acids 
were determined using a kit from WAKO Chemicals (Instruchemie, Delfzijl, the 
Netherlands). 
 
Fat explants. Epididymal adipose tissue was excised and cut into 0.2 – 0.3 cm3 pieces. 
The explants were subsequently incubated for 15 min at 37ºC in DMEM containing 1% 
lipid-free BSA and 1 mg/ml collagenase type 1. Fat cells were liberated by gentle stirring 
followed by centrifugation of the cell suspension for 1 min at 400g. Fat cells were isolated 
from the surface and washed once in PBS. Subsequently, fat cells were incubated in 
DMEM containing 1% lipid-free BSA and 1µM isoproterenol at 37ºC with 5% CO2. 
Medium was collected at various time points and frozen for measurement of free fatty acids 
and glycerol (kits from Instruchemie, Delfzijl, the Netherlands). 
 
RNA isolation and qRT-PCR. Total liver RNA was isolated with TRIzol reagent 
(Invitrogen) according to manufacturer’s instructions. A NanoDrop ND-1000 
spectrophotometer (Isogen Life Science, IJsselstein, the Netherlands) was used to 
determine RNA concentrations. 1µg of total RNA was reverse transcribed using iScript 
(Bio-Rad, Veenendaal, the Netherlands). cDNA was amplified on a Bio-Rad MyIQ or 
iCycler PCR machine using Platinum Taq DNA polymerase (Invitrogen). PCR primer 
sequences were taken from the PrimerBank (384) and ordered from Eurogentec. Sequences 
of the primers used are available upon request. 
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Transactivation assay. Conserved PPREs were identified at 1291 or 23333 nucleotides 
downstream of the TSS of the mouse Lpin2 or St3gal5 gene, respectively, using a published 
algorithm (295). A 201-nucleotide and 183-nucleotide fragment surrounding the putative 
PPRE within the Lpin2 and St3gal5 genes, respectively, was PCR amplified from mouse 
genomic DNA (strain C57Bl/6) and subcloned into the KpnI and BglII sites of the pGL3 
promoter vector (Promega, Leiden, the Netherlands). The reporter vector (PPRE)3-TK-
luciferase was included as a positive control. Reporter vectors were transfected into human 
hepatoma HepG2 cells together with an expression vector (pSG5) for mPPARβ/δ, in the 
presence or absence of GW501516 (1μM). A β-galactosidase reporter vector was co-
transfected to normalize for differences in transfection efficiency. Transfections were 
carried out using Nanojuice (Novagen, Nottingham, UK). Luciferase activity was measured 
24h post-transfection using the Promega luciferase assay kit (Promega) on a Fluoroskan 
Ascent FL apparatus (Thermo labsystems, Breda, the Netherlands). β-galactosidase activity 
was measured in the cell lysate by a standard assay using 2-nitrophenyl- β D-
galactopyranoside as a substrate. 
 
Chromatin Immunoprecipitation (ChIP) assay. It is becoming increasingly apparent 
that most nuclear receptor binding sites, including PPREs, are not found in proximity of the 
annotated transcriptional start site (TSS) of a gene but are often located quite distant (385-
387). Nuclear receptors bound to such distal sites likely contact the basal transcription 
machinery via DNA looping. Binding of PPAR to distant PPREs can thus be demonstrated 
by showing cross-linking of PPAR to the TSS (388, 389). 
 
Wildtype and PPARα-/- on a Sv129 background were fed or fasted for 24 hours (n = 3). 
Transgenic mice overexpressing Angptl4 (Angptl4-Tg), wildtype (Angptl4+/+) and 
homozygous knockout (Angptl4-/-) mice (n=3) were fasted for 24h. At the end of the 
fasting period, mice were killed by cervical dislocation and livers were extracted. Livers 
were cut in smaller pieces and directly put in PBS containing 1% formaldehyde. Cross-
linking was stopped after 15 minutes by adding glycine to a final concentration of 0.125M 
for 5 minutes at room temperature. After a short centrifugation to collect the liver pieces, 
two washing steps with ice-cold PBS were carried out. Livers were homogenized and 
thereafter centrifuged. After supernatant was removed, liver homogenate was resuspended 
in lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl pH 8.1, protease inhibitors) and 
the lysates were sonicated with a Bioruptor™ (Diagenode, Liège, Belgium) to achieve a 
DNA length of 300 – 1000 bp. After removal of cellular debris by centrifugation, 
supernatants were diluted 1:10 in ChIP dilution buffer (150mM NaCl, 1% Triton X-100, 
2mM EDTA, 20mM Tris-HCl pH 7.5, protease inhibitors). Chromatin was incubated 
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overnight at 4ºC with 2µg antibody, 25µl BSA (10mg/ml) and 2.4µl sonicated salmon 
sperm (10mg/ml). Antibodies used were anti-PPARα (sc-9000), anti-PPARGC1α (sc-
13067) and anti-PPARβ/δ (sc-7197), all of which were obtained from Santa Cruz 
Biotechnologies (Heidelberg, Germany). Immunocomplexes were collected with 25µl 
MagaCell® Protein A Magnetic beads (Isogen Life Science) for 1 hour at room 
temperature, and subsequently washed sequentially with 700µl of the following buffers: 
ChIP wash buffer 1 (150mM NaCl, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH8, 
protease inhibitors) two times, ChIP wash buffer 2 (500mM NaCl, 1% Triton X-100, 2mM 
EDTA, 0.1% SDS, 20mM Tris-HCl pH8, protease inhibitors), ChIP wash buffer 3 (250mM 
LiCl, 1% NP40, 1% Deoxycholate, 1mM EDTA, 10mM Tris-HCl pH8), and two times TE 
buffer (1mM EDTA, 10mM Tris-HCl pH8). Elution of immunocomplexes were carried out 
in 250µl elution buffer (10mM EDTA, 0.5% SDS, 25mM Tris-HCl pH7.5) at 64ºC for 30 
minutes. After collection of supernatant, elution was repeated with 250µl elution buffer at 
room temperature for 2 minutes. After combining the supernatants, cross-linking was 
reversed at 64°C overnight with 2.5µl Proteinase K (20mg/ml) for digestion of any 
remaining proteins. Genomic DNA fragments were recovered by phenol-chloroform 
extraction with phase lock gel (Eppendorf, Wesseling-Berzdorf, Germany), followed by 
salt-ethanol precipitation. Samples were diluted in sterile H2O, and analyzed with 
quantitative PCR. 
 
Primers were from Eurogentec and designed to cover the transcription start sites (TSS) of 
the following genes: Aldh3a2 (F: 5’-CAGGTGAGGGAGCACAGTAC-3’, R: 5’-
CGCTTGGCTCTTTTCTGAAG-3’); Cpt2 (F: 5’-GCCAGTCACGCAACAGCAG-3’, R: 
5’-TAGTTTAGAGACCGCTTCCG-3’); Lpin2 (F: 5’-CCGTCTTGTGATTGGGCAGG-
3’, R: 5’-GAAGGAAACTCACCAGAATCC-3’); St3gal5 (F: 5’- 
GCCTTCCACTATCTAATCACG-3’, R: 5’- GTGTCCGCTCTGCCGACTG-3’) and 
Rplp0 (F: 5’- CGAGGACCGCCTGGTTCTC-3’, R: 5’- GTCACTGGGGAGAGAGAGG-
3’). 
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Results 
 
Overlap in gene regulation between pharmacological and physiological 
PPARα activation 
PPARα in liver can be activated pharmacologically using synthetic agonists such as 
WY14643 or physiologically by fasting. To assess the similarities and discrepancies in 
gene regulation between these two stimuli, we compared microarray data from livers of 
mice treated with the synthetic PPARα agonist WY14643 for 6h and mice subjected to 24h 
fasting. Gene set enrichment analysis (GSEA) showed great similarity and overlap in top-
regulated pathways between fasting and WY14643 treatment, almost all of which 
corresponded to pathways of lipid metabolism (Figure 1A). Much less overlap was 
observed at the individual gene level (Figure 1B). Nevertheless, a substantial number of 
genes upregulated by WY14643 were also induced by fasting. Many of these genes 
represent classical PPARα target genes involved in fatty acid catabolism such as Acox1, 
Cpt2, Aldh3a2, Acot8, Ehhadh and Hmgcs2. Consistent with an important role of PPARα, 
induction of classical PPARα target genes by fasting was abolished in PPARα-/- mice 
(Figure 1C, red dots; Figure 1D, upper panel). In contrast, a number of WY14643-
responsive genes could be identified that were more significantly upregulated by fasting in 
PPARα-/- mice compared to wildtype mice, suggesting PPARα-independent regulation 
during fasting (Figure 1C, blue dots; Figure 1D, lower panel). Overall, these data indicate 
that targets of pharmacological PPARα activation exhibit diverse responses following 
physiological PPARα activation by fasting, being either up- or downregulated and showing 
a variable dependence on PPARα. 
 
To explore the possible mechanism underlying the more significant induction by fasting of 
a number of pharmacological PPARα targets in PPARα-/- mice compared to wildtype 
mice, two representative genes were investigated in more detail: Lpin2 and St3gal5. 
Remarkably, in contrast to classical PPARα targets Cpt2 and Aldh3a2 (Figure 2A and 
Figure 2C), induction of Lpin2 and St3gal5 by fasting and dietary fatty acids was largely 
maintained in PPARα-/- mice (Figure 2B and Figure 2D). These results imply that the 
effects of fasting and dietary fatty acids on hepatic expression of Lpin2 and St3gal5 may be 
partially mediated by a transcription factor other than PPARα. On the contrary, effects of 
fasting and dietary fatty acids on Cpt2 and Aldh3a2 are entirely mediated by PPARα. It 
should be mentioned that the expression profiles of Cpt2 and Aldh3a2 are representative of 
a large set of classical PPARα targets (see Figure 1D). 
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Figure 1. Hepatic genes activated by WY14643 and fasting show a variable 
dependence on PPARα. Livers from wildtype and PPARα-/- mice treated with the PPARα 
agonist WY14643 for 6h or fasted for 24h were used for gene expression profiling (n=4-5 mice per 
group). A) Overlap in top-regulated pathways between WY14643 treatment and fasting according to 
Gene Set Enrichment Analysis. Genesets with an FDR P-value <0.1 were considered significant. B) 
Overlap of upregulated genes between WY14643 treatment and fasting (criteria for inclusion: P < 
0.01 and fold change > 1.5). C) Scatter plot showing the effect of fasting in genes significantly 
upregulated by WY14643. The Y-axis and X-axis show the effect of fasting in wildtype and PPARα-
/- mice, respectively. Red dots represent classical PPARα target genes, while blue dots are 
WY14643-responsive genes that are more significantly upregulated by fasting in the PPARα-/- mouse 
compared to wildtype. D) Heatmap showing fold changes of genes compared to wildtype control / fed 
state. Upper panel: classical PPARα target genes, showing a PPARα-dependent increase in gene 
expression upon WY14643 treatment as well as fasting. The lower panel of genes exhibit a PPARα-
dependent induction upon WY14643 treatment, but are induced independently of PPARα upon 
fasting. 
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Figure 2. Lpin2 and St3gal5 are induced during fasting independently of PPARα. 
Livers from wildtype and PPARα-/- mice fasted for 24h or treated with tridocosahexaenoin (DHA) 
for 6h were used for gene expression profiling (n=4-5 mice per group). Gene expression of classical 
PPARα targets Aldh3a2 and Cpt2 (A) and Lpin2 and St3gal5 (B) in fed and fasted wildtype and 
PPARα-/- mice. Gene expression of Aldh3a2 and Cpt2 (C) and Lpin2 and St3gal5 (D) after treatment 
with the dietary fatty acid DHA. Error bars represent SEM. * = significantly different according to 
student’s t-test (P<0.05). 
 
 
 
 
 
PPARβ/δ as an alternative transcription factor to PPARα in mouse liver 
during fasting 
One obvious candidate alternative transcription factor is PPARβ/δ, which is well expressed 
in liver (47, 132). Supporting regulation of Lpin2 and St3gal5 by PPARβ/δ, the PPARβ/δ 
agonists GW501516 and L165041 significantly induced Lpin2 and St3gal5 mRNA (Figure 
3A). To establish whether Lpin2 and St3gal5 are direct PPAR target genes, we identified a 
conserved PPRE within the Lpin2 and St3gal5 genes (Figure 3B) and cloned a genomic 
region encompassing the PPRE in front of a luciferase reporter to perform transactivation 
assays. GW501516 significantly increased reporter activity for the Lpin2 and St3gal5 
genomic regions, which was further enhanced by co-transfection with PPARβ/δ (Figure 
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3C). In subsequent chromatin immunoprecipitation (ChIP) experiments, PPARβ/δ as well 
as PPARα could be cross-linked to the transcriptional start site (TSS) of the Lpin2 and 
St3gal5 genes, at least in the fasted state, which provides evidence for the presence of a 
distant functional PPRE (Figure 3D). These data suggest that Lpin2 and St3gal5 genes 
represent direct PPAR target genes. Interestingly, while fasting increased binding of both 
PPARα and PPARβ/δ to the Lpin2 and St3gal5 genes, fasting increased binding of only 
PPARα to the Aldh3a2 and Cpt2 genes (Figure 3D). No binding of PPARα and PPARβ/δ to 
the negative control gene Rplp0 was observed. All together these data suggest that Lpin2 
and St3gal5 are dual targets of PPARα and PPARβ/δ, whereas Aldh3a2 and Cpt2 are 
exclusive targets of PPARα. In agreement with this notion, induction of Lpin2 and St3gal5 
by fasting was partially abolished in PPARβ/δ-/- mice (Figure 3E). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 (next page). PPARβ/δ as alternative transcription factor to PPARα in mouse 
liver. A) Lpin2 and St3gal5 expression in liver of wildtype mice (n=5) treated with the PPARβ/δ 
agonist GW501516 for 6 hours or PPARα-/- mice (n=5) treated with the PPARβ/δ agonist L165041 
for 5 days. Error bars represent SEM. B) PPREs conserved between mouse and human were 
identified 1291 bp and 23333 bp downstream of the TSS of the Lpin2 and St3gal5 genes. C) HepG2 
cells were transfected with a PPARβ/δ expression vector and a SV40 reporter vector containing a 
201-nucleotide and 183-nucleotide fragment containing the putative PPRE within the Lpin2 and 
St3gal5 genes, respectively. The reporter vector (PPRE)3-TK-luciferase served as positive control. 
Luciferase and β-galactosidase activities were determined 24 hours after exposure of the cells to 1µM 
GW501516. Error bars represent SEM. D) Chromatin was extracted from livers of fed and 24 hour 
fasted wildtype and PPARα-/- mice (n=3 per group). ChIP was performed with antibodies against 
PPARα and PPARβ/δ on the TSS of Lpin2, St3gal5, Aldh3a2, Cpt2 and Rplp0. Rabbit IgGs was used 
as a specificity control. Grey bars = fed state; black bars = 24h fasted state. Error bars represent SD. 
E) Expression of Lpin2 and St3gal5 in livers of fed and 24 hour fasted wildtype and PPARβ/δ-/- mice 
(n=4-5 per group). Relative induction by fasting is indicated. Error bars represent SEM. Plasma FFA 
levels in wildtype and PPARα-/- mice (F) or wildtype and PPARβ/δ-/- mice (G) sacrificed in fed or 
24 hour fasted state. Error bars represent SEM. * = significantly different according to student’s t-test 
(P<0.05). 
 
 
 
 
 
 
 
 
PPARβ/δ but not PPARα serves as plasma free fatty acid sensor in liver 
 
 101 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 102
Given the more pronounced induction of Lpin2 and St3gal5 by fasting in PPARα-/- vs. 
wildtype mice, we speculated that either expression of PPARβ/δ may be upregulated in 
PPARα-/- mice as a compensatory mechanism, or that ligand-activation of PPARβ/δ is 
enhanced in PPARα-/- mice. While we could not detect a change in PPARβ/δ mRNA in 
PPARα-/- mice (data not shown), consistent with the second scenario plasma FFA levels 
were markedly elevated in fasted PPARα-/- mice (Figure 3F), which was associated with 
marked induction of PPARβ/δ binding to the Lpin2 and St3gal5 promoter (Figure 3D). 
These data suggest that in the absence of PPARα plasma FFAs can induce Lpin2 and 
St3gal5 expression via PPARβ/δ. It should be noted that induction of plasma FFAs by 
fasting is unaltered in PPARβ/δ-/- mice (Figure 3G). 
 
Circulating FFAs activate PPARβ/δ but not PPARα in mouse liver 
Importantly, recent evidence suggests that PPARα in liver cannot be (ligand)-activated by 
plasma FFA, while it can be activated by fatty acids synthesized de novo (86). To study the 
activation of PPARα and PPARβ/δ by plasma FFA, we modulated fasting plasma FFA 
levels by taking advantage of a unique transgenic model system based on whole body 
overexpression or inactivation of the mouse Angptl4 gene, which encodes a pro-lipolytic 
factor involved in lipid metabolism (379, 390). Previously, intravenous injection of 
Angptl4 was shown to cause an immediate increase in plasma FFA (391). In support, 
Angptl4 increased release of glycerol from 3T3-L1 adipocytes (Figure 4A). 
 
Consistent with a pro-lipolytic effect of Angptl4, Angptl4 overexpression in mice was 
associated with a significant increase in release of fatty acids and glycerol from adipose 
tissue, whereas the opposite was observed in Angptl4-/- mice (Figure 4B). In agreement 
with these data, fasting plasma FFA levels were increased or decreased upon Angptl4 
overexpression or inactivation, respectively (Figure 4C). In fact, the fasting-induced 
increase in plasma FFA was entirely blunted in Angptl4-/- mice. Plasma TG levels were 
increased or decreased upon Angptl4 overexpression or inactivation (Figure 4D), 
respectively, reflecting the well-documented inhibitory effect of Angptl4 on LPL activity 
(392). Finally, the defective lipolysis in Angptl4+/- and -/- mice was supported by the 
absence of changes in adipocyte cell size upon fasting, in contrast to Angptl4-Tg and 
wildtype mice (Figure 4E). These results corroborate the stimulatory effect of Angptl4 on 
adipose tissue lipolysis, which we exploited to study the effect of plasma FFAs on hepatic 
gene expression. 
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Figure 4. Angptl4 stimulates adipose tissue lipolysis. A) Glycerol concentration in medium 
of 3T3-L1 cells treated for 30 minutes with isoproterenol or with concentrated conditioned medium 
of HEK293 cells transfected with mAngptl4. Control cells were treated with condition medium of 
non-transfected HEK293 cells. Error bars represent SEM. * = significantly different according to 
student’s t-test (P<0.05). B) Increase in fatty acid and glycerol concentration in medium of adipose 
tissue explants from transgenic mice overexpressing Angptl4 (Tg), wildtype (+/+) and homozygous 
knockout (-/-) mice. Values are corrected for weight of explants. Plasma FFAs (C) and triglycerides 
(D) in transgenic mice overexpressing Angptl4 (Angptl4-Tg), wildtype (Angptl4+/+), heterozygous 
(Angptl4+/-) and homozygous (Angptl4-/-) mice in fed or 24 hour fasted state (n=5). Grey bars = fed 
state; black bars = 24 hour fasted state. Error bars represent SEM. Different letters indicate 
statistically significant difference (student’s t-test, P<0.05). E) Eosin and hematoxylin staining of 
epididymal adipose tissue. 
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Figure 5. Plasma FFAs do not activate hepatic PPARα. Transgenic mice overexpressing 
Angptl4 (Angptl4-Tg), wildtype (Angptl4+/+), heterozygous (Angptl4+/-) and homozygous knockout 
(Angptl4-/-) mice were sacrificed in fed state or after a 24 hour fast (n=5). Hepatic gene expression of 
classical PPARα targets Aldh3a2 and Cpt2 (A), Pparα (B) and Pparβ/δ (C). Grey bars = fed state; 
black bars = 24 hour fasted state. Error bars represent SEM. * = P<0.05. C). D) Chromatin was 
extracted from livers of 24 hour fasted transgenic mice overexpressing Angptl4 (Tg), wildtype (+/+) 
and homozygous Angptl4 knockout (-/-) mice (n=3 per group). ChIP was performed with antibodies 
against PPARα and PPARβ/δ on the TSS of Lpin2, St3gal5, or Rplp0. Rabbit IgGs was used as a 
specificity control. Error bars represent SD. Different letters indicate statistically significant 
difference (student’s t-test, P<0.05). E) Hepatic gene expression of Lpin2 and St3gal5. Grey bars = 
fed state; black bars = 24 hour fasted state. Error bars represent SEM. Different letters indicate 
statistically significant difference (student’s t-test, P<0.05). 
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Figure 6. Classical PPARα target genes do not follow plasma FFAs. Transgenic mice 
overexpressing Angptl4 (Angptl4-Tg), wildtype (Angptl4+/+), heterozygous (Angptl4+/-) and 
homozygous knockout (Angptl4-/-) mice were sacrificed in fed state or after a 24h fast (n=5). A) 
Gene expression of a representative set of classical PPARα target genes. Grey bars = fed state; black 
bars = 24h fasted state. Error bars represent SEM. B) Gene expression of a representative set of other 
WY14643-induced genes whose expression followed plasma FFA concentration independent of 
PPARα. Grey bars = fed state; black bars = 24h fasted state. Error bars represent SEM. 
 
 
 
 
 
If hepatic PPARα is activated by plasma FFAs, expression of classical PPARα target genes 
during fasting would be expected to be proportional to the plasma FFA level throughout the 
various Angptl4 mouse models. Remarkably, rather than going down, gene expression of 
classical PPARα targets Aldh3a2, Cpt2 and others was stable or went up as plasma FFAs 
decline (Figure 5A, Figure 6A). Expression of Pparα itself, which is auto-regulated, 
followed a very similar pattern (Figure 5B), suggesting that regulation of classical PPARα 
targets is determined by PPARα expression level. Supporting the use of the Angptl4 mouse 
models to study hepatic gene regulation by FFA, hepatic expression of Srebp1, which is 
known to be suppressed by fatty acids, negatively correlated with plasma FFA 
concentration (data not shown). In combination with previously published data (86), these 
data strongly suggest that PPARα is not activated by plasma FFA in mouse liver. 
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While plasma FFAs seemingly do not activate hepatic PPARα, data presented above 
suggested that FFAs induce Lpin2 and St3gal5 expression by activating PPARβ/δ, at least 
in PPARα-/- mice. To assess activation of PPARβ/δ by FFA in the presence of PPARα, we 
determined binding of PPARβ/δ to the Lpin2 and St3gal5 genes in the Angptl4 mouse 
models using ChIP. Importantly, independent of PPARβ/δ gene expression levels, which 
remained constant (Figure 5C), binding of PPARβ/δ to the Lpin2 and St3gal5 genes was 
proportional to the plasma FFA concentration and mimicked fasting Lpin2 and St3gal5 
expression levels (Figure 5D and Figure 5E). In contrast, binding of PPARα to the Lpin2 
and St3gal5 genes was minimal and did not follow the plasma FFA concentration (Figure 
5D). Again, no binding of PPARα and PPARβ/δ to negative control gene Rplp0 was 
observed. These data suggest that PPARβ/δ can be activated by plasma FFA. Other 
WY14643-induced genes whose expression followed plasma FFA concentration 
independent of PPARα included lipid droplet proteins 2310076L09Rik (MLDP) and S3-12, 
as well as Slc16a5 and Gadd45b, suggesting they might represent targets of PPARβ/δ as 
well (Figure 6B). 
 
PPARα target genes may be upregulated during fasting via induction of 
PGC1α 
If elevated plasma FFAs can not account for the induction of classical PPARα activation 
during fasting, the question arise what other mechanism may be responsible. One 
possibility is increased coactivator expression. The coactivator PGC1α plays a major role in 
the liver during fasting by upregulating genes involved in gluconeogenesis and fatty acid 
oxidation/ketogenesis, mediating activation by several transcription factors including 
PPARα (34-36). In agreement with previous data (35), expression of Pgc1a went up 
significantly during fasting (Figure 7A). Importantly, fasting markedly enhanced binding of 
PGC1α to the TSS of the PPARα target genes Aldh3a2 and Cpt2, which was abolished in 
PPARα-/- mice (Figure 7B). No binding of PGC1α to Rplp0 was observed. These data 
suggest that upregulation of Pgc1α mRNA may contribute to induction of classical PPARα 
target genes during fasting via increased PPARα-dependent binding of PGC1α to gene 
promoters. 
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Figure 7. PPARα activation during fasting may be mediated by PGC1α upregulation. 
A) Expression of Pgc1a in livers of fed or fasted wildtype mice (n=5). Fasting statistically 
significantly induced gene expression of Pgc1α (P<0.05). Error bars represent SEM. B) Chromatin 
was extracted from livers of fed and 24 hour fasted wildtype and PPARα-/- mice (n=3 per group). 
ChIP was performed with antibodies against PGC1α on the TSS of Aldh3a2 and Cpt2, and negative 
control gene Rplp0. Rabbit IgGs was used as a specificity control. Purple bars = fed state; black bars 
= 24 hour fasted state. Error bars represent SD. Fasting significantly induced binding of PGC1α in 
wildtype but not PPARα-/- mice (P<0.05). 
 
 
 
Discussion 
It has been clearly established that PPARα governs the fasting-induced upregulation of 
numerous genes involved in hepatic fatty acid oxidation, many of which are direct PPARα 
target genes (70-72). However, it has remained unclear whether elevated plasma FFAs 
themselves are responsible for the induction of hepatic fatty acid catabolism via enhanced 
ligand-activation of PPARα (70-72). Recently, using mice with liver-specific inactivation 
of the Fasn gene, Chakravarthy et al. showed that unlike dietary fatty acids and de novo 
synthesized fatty acids, circulating FFAs fail to activate hepatic PPARα (86). In the present 
study, using mice differentially expressing Angptl4 we arrive at essentially the same 
conclusion. 
 
Importantly, our data also suggest that in contrast to PPARα, hepatic PPARβ/δ can be 
activated by plasma FFA, which accounts for the plasma FFA- and fasting-dependent 
upregulation of several genes in wildtype and PPARα-/- mice, including Lpin2 and St3gal5. 
Indeed, we demonstrate that Lpin2 and St3gal5 expression and binding of PPARβ/δ to the 
Lpin2 and St3gal5 promoter closely mirror plasma FFA levels. The role of PPARβ/δ in 
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gene regulation by plasma FFA during fasting was substantiated by the observation that 
induction of Lpin2 and St3gal5 by fasting is reduced in PPARβ/δ-/- mice. 
 
In contrast to plasma FFAs, evidence abounds indicating that dietary fatty acids are able to 
activate PPARα (73, 338, 339). Recently, it was shown that the effects of dietary fatty acids 
on hepatic gene expression are quantitatively almost entirely mediated by PPARα (69). 
Additionally, the present data suggest that dietary fatty acids can also activate PPARβ/δ as 
induction of Lpin2 and St3gal5 by dietary fat was entirely or partially maintained in 
PPARα-/- mice. 
 
It may be argued that the lack of effect of declining plasma FFAs on hepatic PPARα 
activation may be because PPARα, in contrast to PPARβ/δ, is already saturated with fatty 
acids at low plasma FFA levels, thus allowing no further activation. Previously, it has been 
shown that fatty acids bind to PPARβ/δ with an about 5 to10-fold lower affinity compared 
to PPARα (27). However, as treatment with synthetic agonists clearly results in more 
pronounced PPARα activation compared to fasting (73), the argument of PPARα saturation 
is only tenable if we assume fatty acids to act as partial agonists that do not elicit full 
PPARα activity compared to synthetic agonists. Saturation of PPARα is also not supported 
by Chakravarthy (86). 
 
Alternatively, it is conceivable that fatty acids are present in hepatocytes in distinct pools, 
which have different activity towards PPARα and PPARβ/δ. In this context, it should be 
realized that dietary fatty acids present in chylomicron remnants are internalized differently 
compared to plasma FFAs. Whereas the former are liberated after endosomal and 
lysosomal degradation of cholesteryl-esters and triglycerides, plasma FFA are likely 
internalized via diffusion as well as via specific fatty acid transport proteins, including 
CD36 and FATPs. The third contributor to the hepatic fatty acid pool is de novo 
lipogenesis, a process which occurs in the cytosol. It is presently unclear to what extent 
these three sources of fatty acids undergo similar metabolic fates. Recent studies support 
the existence of distinct hepatic fatty acid pools that are differentially shuttled into various 
metabolic pathways, including oxidation and incorporation into VLDL-triglycerides (393). 
For example, there is evidence that fatty acids generated by de novo lipogenesis only 
marginally contribute to VLDL-triglycerides, in contrast to plasma FFAs (394). Our 
present and previous data suggest that in terms of gene regulation, a similar type of 
segregation occurs between the three sources of fatty acids (86). The mechanism 
underlying the differential activity of fatty acids from distinct pools towards PPARα and 
PPARβ/δ remains unknown. One could hypothesize a role for fatty acid binding proteins 
(FABPs). It can be speculated that FABP1, which has been shown to interact with PPARα 
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(82), picks up lipoprotein-derived fatty acids and shuttles them to PPARα, whereas another 
FABP expressed in liver such as FABP2 may selectively bind free fatty acids coming from 
plasma and shuttle them to PPARβ/δ. 
 
An important lingering question is that if plasma FFAs do not activate hepatic PPARα 
during fasting, what mechanism accounts for activation of PPARα-dependent gene 
regulation during fasting? Previously, a role for PGC1α in fasting-dependent upregulation 
of hepatic mitochondrial fatty acid oxidation and ketogenesis was shown (34, 36). Our 
ChIP analysis indicates enhanced recruitment of PGC1α, which itself is upregulated by 
fasting, to classical PPARα target genes during fasting. Accordingly, activation of PPARα 
by fasting may be driven by the increase in PGC1α expression, although an important role 
of other coactivators cannot be excluded. Recently, it was shown that PGC1α cooperates 
with BAF60a (SMARCD1) to activate transcription of PPARα target genes involved in 
peroxisomal and mitochondrial fatty acid oxidation genes (395). 
 
While our data suggest that PPARβ/δ mediates the effect of plasma FFAs on a small set of 
genes in liver, the overall importance of PPARβ/δ in hepatic gene regulation by FFAs 
remains unclear. The same is true for the actual functional role of PPARβ/δ in liver. 
Presently, combined transcriptomics and metabolomics analyses of livers of PPARα-/- and 
PPARβ/δ-/- mice are underway to gain more understanding about the role of PPARβ/δ in 
liver and to determine the extent to which PPARα and PPARβ/δ regulate distinct sets of 
genes and govern distinct metabolic pathways, especially under physiological 
circumstances. 
 
In this study we have used variable expression of the Angptl4 gene to create variations in 
fasting plasma FFA levels in mice. Angptl4 is a potent inhibitor of lipoprotein lipase and 
hepatic lipase and decreases uptake of lipoprotein remnants by the liver, thereby decreasing 
hepatic uptake of dietary fatty acids (324). In addition, it stimulates adipose tissue lipolysis, 
as shown by the acute increase in plasma FFA upon injection of recombinant Angptl4 
(391), and by elevated plasma FFAs and glycerol levels in mice overexpressing Angptl4 
(379). The pro-lipolytic effect of Angptl4 is supported by recent data in humans (390). In 
the present paper, Angptl4 markedly induced glycerol release from 3T3-L1 adipocytes. 
Activation of lipolysis by Angptl4 was further substantiated by the altered release of fatty 
acids and glycerol from adipose tissue explants from Angptl4-Tg and Angptl4-/- mice, as 
well as by the lack of an increase in FFA during fasting in Angptl4-/- mice. As a 
consequence, hepatic VLDL production is reduced in Angptl4-/- mice (396). By inhibiting 
LPL and stimulating adipose tissue lipolysis, Angptl4 promotes switching of hepatic fatty 
acid uptake from remnant-derived fatty acids towards plasma FFAs (379). Importantly, the 
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variations in plasma FFAs in the Angptl4 mouse models are specifically elicited by fasting, 
permitting study of the impact of differential plasma FFAs on hepatic gene expression 
during fasting. 
 
While in vivo and in vitro studies using synthetic PPARα agonists are extremely relevant to 
assess the toxicological and pharmacological impact and significance of PPARα, it is 
unclear to what extent they report on the physiological role of PPARα in liver. Our results 
reveal that several genes upregulated following pharmacological PPARα activation are not 
induced by PPARα under physiological conditions such as fasting, or are induced by 
fasting independently of PPARα but dependently of PPARβ/δ. It is well known that in 
reporter assays PPARα and PPARβ/δ (and PPARγ) can activate the same genes, suggesting 
that all PPARs share an intrinsic ability to transactivate any given PPAR target gene. The 
present data on Lpin2 and St3gal5 are consistent with the notion that in vivo the dominant 
receptor in the regulation of a particular PPAR target is context dependent and importantly 
may differ between pharmacological and physiological stimuli. Genes other than Lpin2 and 
St3gal5 that have been shown to be activated by both PPARα and PPARβ/δ include Adfp 
(397), G0s2 (398) and Pdk4 (388). Overall, the data imply that studies using high-affinity 
synthetic PPAR agonists are not perfectly suited to assess the functions of PPARs during 
normal physiology. 
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Abstract 
The nuclear hormone receptors PPARα and PPARγ are major drug targets for treatment of 
metabolic disorders. However, much less is known about PPARβ/δ. Here we set out to 
better characterize the role of PPARβ/δ in liver by comparing the effect of PPARα and 
PPARβ/δ deletion on liver function. In fed state, PPARα and PPARβ/δ were expressed in 
mouse liver at about equal levels, while in fasted state PPARα expression was markedly 
higher. Consistent with these data, the number of genes altered by PPARα and PPARβ/δ 
deletion was similar in fed state, whereas in fasted state the effect of PPARα deletion was 
much more pronounced. Minor overlap was found between PPARα- and PPARβ/δ-
dependent gene regulation in liver. According to Gene Set Enrichment Analysis (GSEA), 
pathways upregulated by PPARβ/δ deletion were connected to innate immunity. Pathways 
specifically downregulated by PPARβ/δ deletion included lipoprotein metabolism and 
various pathways related to glucose utilization, which correlated with elevated plasma 
glucose and triglyceride levels and reduced plasma cholesterol levels in PPARβ/δ-/- mice. 
Downregulated genes that likely underlie these metabolic alterations include Pklr, Fbp1, 
Apoa4, Vldlr, Lipg, and Pcsk9, which may represent novel PPARβ/δ target genes. In 
contrast to PPARα-/- mice, no changes in plasma FFA, plasma β-hydroxybutyrate, liver 
triglycerides and liver glycogen were observed in PPARβ/δ-/- mice. Overall, the results 
reveal that unlike PPARα, PPARβ/δ does not mediate an adaptive response to fasting. Our 
data point to a role for PPARβ/δ in hepatic glucose utilization and lipoprotein metabolism, 
as well as innate immunity. 
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Introduction 
Disturbances in lipid metabolism are at the basis of many chronic disorders, including 
obesity, diabetes, non-alcoholic fatty liver disease and atherosclerosis. Regulation of lipid 
metabolism is mainly coordinated by the liver, which therefore is a key target organ for the 
pharmacological treatment of the abovementioned diseases. Lipid metabolism is governed 
via a complex interplay between hormones, transcription factors, and energy substrates, 
allowing for rapid adaptations to changes in metabolic requirements (369). An important 
class of ligand-activated transcription factors involved in regulation of hepatic lipid 
metabolism are the nuclear hormone receptors, more specifically the farnesoid X receptor 
(FXR), the liver X receptors (LXR), and the peroxisome proliferator activated receptors 
(PPAR) (63, 399). Specific biological processes under control of FXR, LXRs and PPARs 
in liver include bile acid synthesis and metabolism, lipogenesis, lipoprotein metabolism, 
and fatty acid degradation. Additionally, FXR, LXRs and PPARs have been implicated in 
glucose metabolism, although the mechanisms and specific target genes involved remain 
poorly defined. FXR, LXRs and PPARs activate gene transcription by forming a complex 
with the retinoid X receptor, RXR, followed by binding of the heterodimeric complex to 
response elements in the DNA (24). Binding of ligand to the nuclear receptors results in the 
recruitment of coactivators and dissociation of corepressors, leading to chromatin 
remodeling and subsequent initiation of DNA transcription. 
 
The PPAR group of nuclear receptors can be further separated into three subtypes: PPARα, 
PPARβ/δ and PPARγ (20, 21). All three PPARs are activated by fatty acids and by a 
variety of fatty acid-derived compounds including eicosanoids, oxidized fatty acids, and 
fatty acid amides. PPARα has been shown to be a key regulator of hepatic fatty acid 
metabolism, a role which is especially prominent during fasting. Indeed, lack of PPARα in 
fasted mice is associated with pronounced hepatic steatosis, a lack of increase in plasma 
ketone bodies, decreased plasma glucose, hypothermia, and elevated plasma free fatty acid 
(FFA) levels (42, 70-72, 74). These severe metabolic disturbances are the result of 
decreased expression of a large number of genes involved in hepatic lipid metabolism, 
many of which have been identified as direct PPARα target genes (78, 79, 81, 82, 85). 
Despite the relatively low expression level of PPARγ in liver, evidence suggests that 
PPARγ is critical for development of hepatic steatosis (73, 241, 243). Surprisingly, very 
limited information is available on the function of PPARβ/δ in liver, even though PPARβ/δ 
is well expressed in liver (47, 132). PPARβ/δ expression has been shown to be highest in 
the endothelial cells and hepatocytes, followed by liver resident macrophages (Kupffer 
cells) (44). Recent studies indicate that PPARβ/δ may influence the inflammatory 
properties of Kupffer cells (184). Other studies have linked PPARβ/δ to proliferation of 
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stellate cells and vitamin A metabolism (400, 401). Finally, activation of PPARβ/δ was 
shown to impact plasma lipoprotein levels (135, 136, 167). However, the overall role of 
PPARβ/δ in hepatic gene regulation remains poorly defined. 
 
Here we set out to better elucidate the role of PPARβ/δ in hepatic function. The results 
reveal that unlike PPARα, PPARβ/δ does not mediate an adaptive response to fasting. Our 
data point to a role for PPARβ/δ in hepatic glucose utilization and lipoprotein metabolism. 
 
Materials and Methods 
 
Animals. A breeding colony of pure-bred Sv129 PPARα-/- mice (129S4/SvJae) and 
corresponding wildtype mice (129S1/SvImJ) was purchased from Jackson Laboratory (Bar 
Harbor, Maine, USA) and further expanded in our local animal facility. The PPARβ/δ-/- 
mice were on a mixed background (Sv129/C57Bl/6) and have been previously described 
(378). 
 
Male mice (n=4-5 per group) were either fed or fasted for 24 hours. At the end of the 
experiment, mice were anaesthetized with a mixture of isofluorane (1.5%), nitrous oxide 
(70%) and oxygen (30%). Blood was collected by orbital puncture, after which the mice 
were sacrificed by cervical dislocation. Livers were dissected, snap frozen in liquid 
nitrogen and kept at -80ºC until further analysis. For RNA analyses, tissue from the same 
part of the liver lobe was used. 
 
The animal studies were approved by the Local Committee for Care and Use of Laboratory 
Animals at Wageningen University, the Netherlands and the University of Lausanne, 
Switzerland. 
 
RNA isolation and qRT-PCR. Total liver RNA was isolated with TRIzol reagent 
(Invitrogen, Breda, the Netherlands) according to manufacturer’s instructions. RNA 
concentrations were measured on a NanoDrop ND-1000 spectrophotometer (Isogen Life 
Science, IJsselstein, the Netherlands). 1µg of total RNA was reverse transcribed using 
iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA was amplified on a Bio-Rad MyIQ 
or iCycler PCR machine using Platinum Taq DNA polymerase (Invitrogen). PCR primer 
sequences were taken from the PrimerBank (325) and ordered from Eurogentec (Seraing, 
Belgium). Primer sequences are available upon request. 
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Affymetrix microarray. Total RNA from mouse liver was extracted with TRIzol reagent 
(Invitrogen), and subsequently purified and DNAse treated using the SV Total RNA 
Isolation System (Promega, Leiden, the Netherlands). RNA quality was measured on an 
Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands) using 6000 
Nano Chips according to manufacturer’s instructions. RNA was judged as suitable for array 
hybridization only if samples showed intact bands corresponding to the 18S and 28S rRNA 
subunits, displayed no chromosomal peaks or RNA degradation products, and had a RIN 
(RNA integrity number) above 8.0. Five micrograms of RNA were used for one cycle 
cRNA synthesis (Affymetrix, Santa Clara, CA, USA). Hybridization, washing and 
scanning of Affymetrix NuGO Mouse Arrays (wildtype and PPARα-/- mice) and 
Affymetrix GeneChip® Mouse Exon 1.0 ST Arrays (wildtype and PPARβ/δ-/- mice) was 
carried out according to standard Affymetrix protocols. 
 
Scans of the Affymetrix arrays were processed using packages from the Bioconductor 
project (288). Arrays were normalized with quantile normalization, and expression levels 
of probesets were calculated using the Robust Multichip Average (RMA) method (402, 
403). Differentially expressed probesets were identified using Limma, and genes were 
considered to be significantly changed when raw P<0.01 (327). The dendrograms were 
created with the hclust command in R (stats library) utilizing the Ward clustering algorithm 
and the Pearson correlation measure (404). Functional analysis of the array data was 
performed using Gene Set Enrichment Analysis (383). 
 
Microarray data were analyzed through the use of Ingenuity Pathway Analysis (Ingenuity® 
Systems, www.ingenuity.com). Canonical pathway analysis identified the pathways from 
the Ingenuity Pathways Analysis library that were differentially expressed between 
knockout and wildtype mice. Genes from the data set that met the cut-off of p < 0.01 and 
were associated with a canonical pathway in the Ingenuity Pathways Knowledge Base were 
considered for the analysis. Fisher’s exact-test was used to calculate a P-value for each 
pathway. Pathways were considered to be differentially expressed between genotypes when 
the Fischer’s exact P-value < 0.05. 
 
Plasma metabolites. Plasma was obtained from blood by centrifugation for 10 minutes 
at 10000g. Plasma free fatty acids were measured with a commercially available kit from 
WAKO Chemicals (Sopachem, Wageningen, the Netherlands). Plasma glucose 
concentration was determined using a kit from Elitech (Sopachem, Wageningen, the 
Netherlands). Plasma and liver triglycerides, plasma β-hydroxybutyrate and plasma 
cholesterol were determined using kits from Instruchemie (Delfzijl, the Netherlands). 
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For measurement of liver glycogen, liver pieces were dissolved in 10 volumes of 1M 
NaOH and incubated at 55ºC. After 1-2 hours an equal volume of 1M HCl was added, 
followed by centrifugation for 5 min at 3000 rpm. Subsequently, 5μl of supernatant was 
added to 50μl of amyloglucosidase (1000U/ml in 0.2M sodium acetate buffer pH 4.8) and 
incubated for 2 hours with shaking (700 rpm) at 42ºC. After short centrifugation, glucose 
was measured using standard glucose assay (Glucose PAP SL, Elitech). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Basal gene expression of PPARα and PPARβ/δ and whole genome 
expression profiling from wildtype, PPARα-/- and PPARβ/δ-/- mouse liver. (A) Relative 
expression of PPARα and PPARβ/δ vs. the housekeeping gene 36b4 was measured with qRT-PCR. 
Error bars represent SEM. * = significantly different from fed mice according to student’s t-test 
(P<0.05). (B) Number of upregulated genes between knockout and wildtype mice. (C) Number of 
downregulated genes between knockout and wildtype mice. Grey bars are fed mice (n=5), black bars 
are fasted mice (n=5). 
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Results 
We first determined basal gene expression of PPARα and PPARβ/δ in mouse liver using 
qRT-PCR. Hepatic expression of PPARα and PPARβ/δ was similar in fed state. As 
previously shown (47, 72), PPARα expression increased during fasting whereas the 
opposite was true for PPARβ/δ (Figure 1A). As a consequence, PPARα mRNA clearly 
exceeded PPARβ/δ mRNA in fasted state. 
 
In order to compare the role of PPARα and PPARβ/δ in gene regulation in liver, we 
performed whole genome expression profiling experiments on livers of fed and fasted 
wildtype and PPARα-/- or PPARβ/δ-/- mice. Since two different types of Affymetrix arrays 
were used, only genes present on both arrays (15004 genes in total) were included in the 
analysis. As expected, the number of genes differentially expressed between PPARα-/- 
mice vs. wildtype mice was much higher in the fasted state than in the fed state (Figure 1B 
and 1C). Interestingly, the number of genes differentially expressed between PPARβ/δ-/- 
mice vs. wildtype mice was about equal in fasted and fed state. Dendrogram of hierarchical 
clustering of the various groups showed that fasted PPARα-/- mice formed a highly distinct 
group, illustrating the dramatic impact of PPARα deletion specifically in fasted mice 
(Figure 2). In contrast to the situation for PPARα-/- mice, differences between wildtype and 
PPARβ/δ-/- were more pronounced in fed state compared to fasted state. Together, these 
data demonstrate that PPARα becomes much more important during fasting, whereas the 
opposite appears to be true for PPARβ/δ. 
 
 
 
Figure 2. Hierarchical clustering of fed and fasted wildtype, PPARα-/- and PPARβ/δ-/- 
mice. Dendrograms showing PPARα (A) or PPARβ/δ (B). n = 5 per group. 
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Figure 3. Overlap in genes altered upon PPARα and PPARβ/δ deletion and top 50 of 
genes most significantly downregulated in PPARβ/δ mice. Venn diagrams showing overlap 
in changed genes between PPARα and PPARβ/δ in the fed (A) and fasted (B) state. Heatmaps 
showing downregulated genes in fasted (C) and fed (D) state. Gene regulation is shown as fold 
change compared to wildtype fed mice according to color scale. Genes were included in analysis if P 
< 0.01 (C: PPARβ/δ-/- fasted vs. wildtype fasted; D: PPARβ/δ-/- fed vs. wildtype fed). n = 5 per 
group. 
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Figure 4. Top 50 of genes most significantly downregulated in PPARα mice. Heatmaps 
showing downregulated genes in fasted (A) and fed (B) state. Gene regulation is shown as fold 
change compared to wildtype fed mice according to color scale. Genes were included in analysis if P 
< 0.01 (A: PPARα -/- fasted vs. wildtype fasted; B: PPARα -/- fed vs. wildtype fed), n = 5 per group. 
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To examine to what extent PPARα and PPARβ/δ govern the same genes, we created Venn 
diagrams showing the overlap in genes altered upon PPARα and PPARβ/δ deletion. In the 
fed state, little overlap is observed between PPARα and PPARβ/δ deletion (Figure 3A). In 
the fasted state, however, a relatively large proportion of the genes altered upon PPARβ/δ 
deletion were also altered upon PPARα deletion, suggesting common regulation (Figure 
3B). This finding is further illustrated by examining the top 50 of genes most significantly 
downregulated in PPARβ/δ-/- mice in fasted state. Indeed, several genes in the list were 
also reduced upon PPARα deletion, including Lgals4, Serinc2, and Tlr5. In contrast, few 
genes within the top 50 of downregulated genes in PPARα-/- mice in fasted state were also 
affected by PPARβ/δ deletion (Figure 3C, 3D and Figure 4). The expression of a number of 
individual genes representing specific profiles of regulation is illustrated in Figure 5. 
Aldh3a2, representing the group of classical PPARα target genes, was upregulated during 
fasting in a PPARα-dependent and PPARβ/δ-independent manner. An opposite pattern was 
observed for Apoa4. Interestingly, the fasting-induced expression of a number of genes, 
including Lgals4 and Lipg, was dependent on both PPARα and PPARβ/δ. Overall, the data 
suggest limited functional overlap between the two PPARs in liver in fed state, whereas 
more significant overlap was observed in fasted state. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Gene expression of four genes representing specific profiles of regulation. 
Gene expression is shown as fold change vs. wildtype fed mice. Grey bars = fed state; black bars = 
fasted state. Error bars represent SEM. n = 5 per group. * = significantly different from corresponding 
wildtype mice according to student’s t-test (P<0.05). 
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Figure 6. Selected pathways identified by Gene Set Enrichment Analysis. Only 
pathways are shown that had a false discovery rate Q-value of < 0.15. The normalized enrichment 
score reflects the degree to which a gene set is overrepresented at the top (upregulated) or bottom 
(downregulated) of the ranked gene list and is corrected for gene set size. Data are for the fed state. 
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Figure 7. Signaling pathways that are differentially expressed in PPARβ/δ-/- mice 
compared to wildtype mice in both fed (open bars) and fasted state (black bars). 
Pathways were identified with the Canonical pathways feature of Ingenuity Pathway Analysis. Only 
significantly regulated signaling pathways are shown. The –log(P-value) shown on the X-axis was 
calculated by Fischer’s exact t-test. The line indicates –log(P-value) = 1.3, which corresponds to a P-
value of 0.05. 
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Functional analysis of microarray data 
To investigate the functional role of PPARβ/δ in mouse liver, we used the pathway analysis 
tool GSEA, which determines whether an a priori defined set of genes shows statistically 
significant concordant differences between wildtype and PPARβ/δ-/- mice. The results 
from fed mice show that PPARβ/δ deletion is associated with induction of genes involved 
in various innate immunity and inflammation-related processes, including antigen 
processing and presentation, Toll-like receptor signaling pathway, and natural killer cell 
mediated cytotoxicity (Figure 6). These results were supported by Ingenuity pathway 
analysis, which pointed towards changes in innate immune system, and numerous other 
cytokine and inflammation related pathways (Figure 7). In agreement with the suggested 
role of PPARβ/δ in oxidative metabolism, the electron transport chain and oxidative 
phosphorylation pathways were decreased in PPARβ/δ-/- mice in fed state (Figure 6). 
Interestingly, in both fed and fasted state PPARβ/δ deletion was associated with a decrease 
in several pathways related to carbohydrate metabolism, including fructose and mannose 
metabolism, glycogen metabolism, glycolysis-gluconeogenesis and the pentose phosphate 
pathway, suggesting a role for PPARβ/δ in governing carbohydrate metabolism (Figure 6 
and data not shown). Similarly, the lipoprotein metabolism pathway was downregulated in 
PPARβ/δ-/- mice in fed and fasted state (Figure 6 and data not shown). These changes were 
corroborated by decreased expression of specific genes within the abovementioned 
pathways, including liver pyruvate kinase (Pklr), fructose-1,6-bisphosphatase 1 (Fbp1), 
Apoa4, Pcsk9, Pcsk6 (PACE4) and VLDL receptor (Vldlr) (Figure 8). Interestingly, the 
nicotinate and nicotinamide metabolism pathway was also downregulated in PPARβ/δ-/- 
mice in fed and fasted state. Within this pathway the gene most significantly downregulated 
was Sirt5 (Figure 8). 
 
Metabolic similarities and differences between PPARα and PPARβ/δ 
To assess whether changes in expression of genes involved in carbohydrate and lipoprotein 
metabolism functionally impacted nutrient metabolism, we studied the metabolic response 
to fasting. To enable comparison with the role of PPARα, a parallel analysis was performed 
in PPARα-/- and PPARβ/δ-/- mice. As expected, fasting plasma FFAs were increased in 
PPARα-/- mice while fasting plasma levels of β-hydroxybutyrate were dramatically 
reduced (Figure 9A and 9B). No changes in plasma FFA or β-hydroxybutyrate were 
observed in PPARβ/δ-/- mice. In agreement with reduced expression of numerous genes 
involved in lipoprotein metabolism, plasma triglycerides were significantly elevated in 
PPARβ/δ-/- mice compared to wildtype mice in fed state, which resembled the situation in 
PPARα-/- mice (Figure 9C). In the fasted state, plasma cholesterol levels were reduced in 
PPARβ/δ-/- mice, whereas no change was observed in PPARα-/- mice (Figure 9D). 
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Consistent with reduced expression of genes involved in glucose utilization such as 
pyruvate kinase and fructose 1,6 bisphosphatase, fasting plasma glucose levels were 
significantly increased in PPARβ/δ-/-mice, whereas they were decreased in fasted PPARα-
/- mice (Figure 9E). No effect of PPARβ/δ deletion on liver glycogen levels and 
triglyceride levels was observed (Figure 9F and 9G). In contrast, PPARα deletion gave rise 
to marked hepatic steatosis. Taken together, it is evident that PPARβ/δ deletion influences 
hepatic glucose and lipid metabolism, although the effects are less pronounced compared to 
PPARα deletion. The data support a functional role for PPARβ/δ in regulation of hepatic 
glucose and lipoprotein metabolism. 
 
 
 
 
 
 
Figure 8. Decreased expression of specific genes involved in several pathways 
related to carbohydrate- and lipoprotein metabolism. Expression of selected genes is shown 
in wildtype (+/+) and PPARβ/δ-/- mice. Grey bars = fed state; black bars = fasted state. Error bars 
represent SEM. n = 5 per group. * = significantly different from corresponding wildtype mice 
according to student’s t-test (P<0.05). 
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Figure 9. Metabolic similarities and differences between PPARα and PPARβ/δ. Plasma 
and liver metabolites were analyzed in fed and fasted wildtype, PPARα-/- and PPARβ/δ-/- mice. (A) 
plasma free fatty acids; (B) plasma β-hydroxybutyrate; (C) plasma triglycerides; (D) plasma 
cholesterol; (E) plasma glucose; (F) liver triglycerides; (G) liver glycogen. Grey bars = fed state; 
black bars = fasted state. n = 5 per group. * = significantly different from corresponding wildtype 
mice according to student’s t-test (P<0.05). 
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Discussion 
In this paper we have used PPARα and PPARβ/δ-/- mice in combination with Affymetrix 
microarray and analysis of plasma and liver metabolites to investigate the role of PPARβ/δ 
in liver. In fed liver, PPARα and PPARβ/δ expression levels are highly similar. Based on 
the number of genes differentially expressed between wildtype and PPARα or PPARβ/δ-/- 
mice, it can be argued that PPARα and PPARβ/δ are about equally important in the fed 
state. Upon fasting, however, the number of genes affected by PPARα deletion grows 
dramatically, whereas this is not the case for PPARβ/δ. These data suggest that in contrast 
to PPARα, PPARβ/δ does not mediate an adaptive response to fasting. Instead, PPARβ/δ is 
involved in basal regulation of a number of metabolic pathways. This notion is supported 
by analysis of several plasma metabolites. 
 
Previously it was shown that PPARβ/δ deletion leads to embryonic lethality due to a 
placental defect, which was found in three independent PPARβ/δ-/- mouse lines (130, 134, 
378). Despite embryonic lethality, breeding colonies could be created from surviving mice, 
enabling study of the role of PPARβ/δ in adult animals. It is unclear what type of 
mechanism allows the surviving mice to overcome the placental defects. However, we 
assume that this mechanism does not confound the data collected in adult PPARβ/δ-/- mice 
as presented here. 
 
So far the most extensively documented roles of PPARβ/δ are as regulator of cell 
proliferation, cell differentiation and inflammation in the gastrointestinal tract (reviewed in 
(405)), and as a critical intermediate in skin wound healing (reviewed in (406)). Research 
on the metabolic role of PPARβ/δ has focused on regulation of fatty acid oxidation in 
skeletal muscle. Numerous in vitro studies have shown a stimulatory effect of PPARβ/δ 
overexpression or activation on genes involved in fatty acid catabolism (93, 137, 157-159). 
Forced overexpression of PPARβ/δ in skeletal muscle was shown to alter muscle fiber type 
characteristics towards more oxidative fibers (160, 161). Consistent with these data, 
administration of a synthetic PPARβ/δ agonist induced fatty acid oxidation, decreased 
muscle lipid content, and improved exercise performance (137, 162, 407). Interestingly, a 
recent study using PPARβ/δ-/- mice does not support a role for PPARβ/δ in fatty acid 
oxidation in skeletal muscle, at least in normal physiology (163). The reason for this 
discrepancy is not clear but may reflect differences between the pharmacological and 
physiological function of PPARβ/δ in muscle. Using gain of function models, PPARβ/δ has 
also been shown to induce fatty acid oxidation in adipose tissue (155). Our data clearly 
suggest that the key regulator of fatty acid oxidation in liver is PPARα and not PPARβ/δ. 
Hepatic PPARβ/δ is also not able to compensate for the lack of PPARα in PPARα-/- mice. 
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Instead, the primary metabolic influence of PPARβ/δ in liver is at the level of carbohydrate 
and lipoprotein metabolism. We found that PPARβ/δ deletion leads to downregulation of 
numerous pathways of carbohydrate metabolism, including pentose-phosphate pathway, 
mannose and fructose metabolism and especially glycolysis. Genes in the latter pathway 
that were clearly decreased in PPARβ/δ-/- mice included pyruvate kinase (Pklr) and 
fructose 1,6 bisphosphatase (Fbp1). Whether Pklr and Fbp1 represent direct PPARβ/δ 
targets requires further investigation. Decreased flux of glucose through glycolysis might 
account for the elevated plasma glucose levels in fasted PPARβ/δ-/- mice as well as the 
reported impaired glucose tolerance (156). Overall, the data are consistent with previous 
data showing a stimulatory effect of the synthetic PPARβ/δ agonist GW510516 on glucose 
consumption and the pentose phosphate pathway (156). 
 
In addition to glucose metabolism, PPARβ/δ deletion was associated with decreased 
expression of a number of genes connected with lipoprotein metabolism, including Apoa4, 
Lipg, and very low density lipoprotein receptor (Vldlr). A similar observation was made in 
hearts of PPARβ/δ-/- mice (our unpublished data). Confirming a previous report and in line 
with the plasma triglyceride-lowering effect of PPARβ/δ agonists in primates, plasma 
triglyceride levels were elevated in PPARβ/δ-/- mice, at least in the fed state (136, 169). In 
contrast, plasma total cholesterol was reduced in PPARβ/δ-/- mice in the fasted state. 
Elevated plasma triglyceride levels in PPARβ/δ-/- mice have been suggested to be related 
to a combination of increased VLDL production and decreased plasma triglyceride 
clearance, as evidenced by a decrease in postheparin LPL activity and increased hepatic 
expression of LPL inhibitors Angptl3 and Angptl4 (169). Based on the data presented here, 
it can be speculated that elevated plasma triglycerides may also be due to decreased 
expression of VLDL receptor and/or changes in production of various apolipoproteins, 
including Apoa5, Apoa4, and Apoc1. Interestingly, Pcsk9 expression was decreased in 
PPARβ/δ-/- mice, which may contribute to the lowering of plasma cholesterol levels. 
Again, whether these genes represent direct PPARβ/δ target genes requires further 
investigation. 
 
The changes in hepatic gene expression in PPARβ/δ-/- mice reported here are the combined 
effect of absence of PPARβ/δ in numerous cell types including endothelial cells, 
hepatocytes and Kupffer cells, all of which express ample levels of PPARβ/δ (44). While 
the alterations in glucose and lipoprotein metabolism are probably related to absence of 
PPARβ/δ in hepatocytes, changes in innate immunity and inflammation-related pathways 
are likely explained by the absence of PPARβ/δ in Kupffer cells.  Recently, it was shown 
that PPARβ/δ is required for the acquisition of the metabolic and immune phenotypes of 
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alternatively activated macrophages in liver (184). Thus, PPARβ/δ appears to be a major 
modulator of Kupffer cell function. 
 
Since PPARα mRNA was about 38% decreased in fasted PPARβ/δ-/- mice compared to 
fasted wildtype mice (data not shown, p<0.05), downregulation of several genes in fasted 
PPARβ/δ-/- mice vs. fasted wildtype might reflect indirect regulation via PPARα. 
However, since typical, highly sensitive PPARα targets such as Cyp4a14 and Aldh3a2 were 
completely unaffected by PPARβ/δ deletion during fasting, the overall impact is likely to 
be modest. 
 
In conclusion, our data suggest that the roles of PPARα and PPARβ/δ in liver gene 
regulation only mildly overlap. While PPARα mediates the adaptive response to fasting, 
this is not the case for PPARβ/δ. Importantly, our study reveals that PPARβ/δ governs 
hepatic glucose utilization and lipoprotein metabolism. 
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Abstract 
PPARs are ligand-activated nuclear receptors that induce target gene expression by binding 
to specific response elements (PPREs) in the DNA. Based on chance alone, putative PPREs 
are expected to be present throughout the whole genome at reasonably high frequency. 
However, these PPREs can not all be functional and mediate PPAR-dependent gene 
regulation. Accordingly, it is unclear what sequence determinants or other genomic 
information are relevant for dictating whether a PPRE will be functional. Here we use an in 
silico screening method to identify putative PPARα binding sites in the mouse genome. In 
an attempt to investigate possible correlations between the putative PPREs identified and 
actual gene regulation, we compared the results from the in silico screen with results from 
microarray analysis of mouse livers and mouse primary hepatocytes treated with the 
PPARα agonist WY14643. 
 
Our results show that the presence of a PPRE close to the transcription start site (TSS) of a 
gene based on in silico screening correlates very poorly with induction of gene expression 
by PPARα agonist as measured by microarray. This result did not change when considering 
conservation of PPRE between species, the number of PPREs situated close to a gene, the 
binding strength of PPARα to the PPRE, or the proximity of the PPRE to the TSS. Our 
data, therefore, question the utility of in silico screening to predict gene regulation by 
PPARs and to identify novel PPAR target genes. Screening for conserved PPREs within 
genes known to be induced by PPAR may be a valuable tool to identify functional PPREs. 
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Introduction 
Peroxisome proliferator activated receptors (PPARs) are ligand-activated nuclear receptors 
that play a major role in the regulation of nutrient metabolism, including fatty acid-, 
glucose-, and amino acid metabolism (21, 217). Three different PPAR subtypes encoded by 
separate genes have been identified: PPARα, PPARγ and PPARβ/δ (20, 21). Each subtype 
has a distinct biological function related to a unique tissue expression pattern and a 
preferential activity towards specific target genes (24, 37, 38). PPARα is highly expressed 
in the liver where it governs metabolism of lipids including fatty acid uptake, mitochondrial 
and peroxisomal fatty acid oxidation, ketogenesis and fatty acid elongation (42, 72, 74, 
408). In addition, PPARα is involved in the regulation of glucose metabolism and inhibits 
expression of genes involved in inflammation (92, 94, 108). PPARγ is the subtype most 
highly expressed in white adipose tissue and plays a key role in adipogenesis. It is best 
known for its ability to stimulate adipocyte differentiation, fat storage, and glucose 
metabolism (217, 219, 221, 223). Finally, PPARβ/δ is expressed in a large number of 
tissues and has been shown to be involved in several biological processes including cell 
proliferation and differentiation, wound healing and fatty acid oxidation (122, 409, 410). 
 
PPARs, like many other nuclear receptors, bind to DNA as a heterodimer with the nuclear 
receptor RXR (retinoid X receptor). Gene activation by PPAR requires binding of the 
PPAR:RXR heterodimer to specific DNA sequences located in the promoter region of a 
target gene (24). These sequences, called peroxisome proliferator response elements 
(PPREs), are composed of a direct repeat of the consensus sequence AGGTCA with a 
single nucleotide spacer between the two repeats (24). 
 
Subsequent to DNA binding, transcriptional regulation by PPARs involves complex 
interactions between coactivators and corepressors. In the absence of ligand, compression 
of the chromatin is caused by corepressor proteins such as nuclear corepressors (NCoRs) 
and silencing mediator for retinoid and thyroid hormone receptor (SMRT) (28, 29). These 
corepressor proteins recruit enzymes expressing histone deacetylase activity, keeping the 
chromatin structure “closed” and inactive. When a ligand binds, the corepressor protein 
complexes dissociate and a recruitment of several coactivators occurs (29, 30), resulting in 
a more “open” and active chromatin structure which in turn leads to initiation of DNA 
transcription and upregulation of PPAR target genes. 
 
According to the traditional view, PPREs are located in the promoter region of target genes. 
Indeed, several PPAR target genes possess functional PPREs in close proximity to the 
transcriptional start site (TSS). However, recent studies suggest that functional PPREs are 
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also found in introns (97, 230, 411, 412). Furthermore, recent ChIP-on-chip experiments 
support the presence of PPREs and other nuclear receptor binding sites distant from the 
TSS (385-387). It is believed that nuclear receptors bound to distant response elements may 
access the TSS via formation of loop-like structures within chromatin units (413, 414). 
 
Based on chance alone, putative PPREs are predicted to be distributed throughout the 
whole genome at reasonably high frequency. However, these PPREs can not all be 
functional and mediate PPAR-dependent gene regulation. Accordingly, it is unclear what 
sequence or other genomic determinants are relevant for dictating whether a PPRE will be 
functional. Here we use an in silico screening method (295) to identify putative PPARα 
binding sites in the mouse genome. In order to investigate possible correlations between the 
putative PPREs and gene regulation, we compared the results from the in silico screen with 
results from microarray analysis of mouse livers and mouse primary hepatocytes treated 
with the PPARα ligand WY14643 for six hours. 
 
In conclusion, together with previous data (415), the results of our study imply that 
screening for conserved PPREs within genes that are induced by PPAR may be a valuable 
tool to identify functional PPREs. However, screening of putative PPREs cannot predict 
gene regulation by PPARα nor do we find that PPARα-induced genes are enriched with 
PPREs, regardless of the selection criteria employed. 
 
Materials and Methods 
 
Materials. WY14643 was purchased from ChemSyn Laboratories (Lenexa, KS, USA). 
Recombinant human insulin (Actrapid) was from Novo Nordisk (Copenhagen, Denmark). 
William's E medium, foetal calf serum and penicillin/streptomycin/fungizone were from 
Lonza Bioscience (Verviers, Belgium). All other chemicals were from Sigma (Zwijndrecht, 
the Netherlands). 
 
Animals. Pure-bred Sv129, BALB/C, C57BL6J, DBA, FVB and NMRI mice were 
purchased from Jackson Laboratories (Bar Harbor, ME) and bred at the animal facility of 
Wageningen University. All animal experiments were approved by the Local Committee 
for Care and Use of Laboratory Animals at Wageningen University. 
 
Experimental design. Two independent studies were performed. Study A: Male Sv129 
mice were given an intragastric gavage of 400μl WY14643 (10mg/ml in 0.5% 
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carboxymethyl cellulose) after a four hour fast. Six hours after gavage, mice were 
anaesthetized with a mixture of isofluorane (1.5%), nitrous oxide (70%) and oxygen (30%). 
Blood was collected by orbital puncture, after which the mice were sacrificed by cervical 
dislocation. Livers were removed, snap-frozen in liquid nitrogen and stored at -80°C until 
further analysis. For RNA analyses, tissue from the same part of the liver lobe was used. 
Study B: Primary hepatocytes were isolated from six different mouse strains (Sv129, 
BALB/C, C57BL6J, DBA, FVB and NMRI) by two-step collagenase perfusion as 
described previously (287). Cells were plated on collagen-coated six-well plates. Viability 
was determined by Trypan Blue exclusion, and was at least 75%. Hepatocytes were 
suspended in William's E medium supplemented with 10% (v/v) foetal calf serum, 
20mU/ml insulin, 50nM dexamethasone, 100U/ml penicillin, 100μg/ml of streptomycin, 
0.25μg/ml fungizone and 50μg/ml gentamycin. The next day, cells were incubated in fresh 
medium in the presence or absence of WY14643 (10μM) dissolved in DMSO for six hours, 
followed by RNA isolation. 
 
RNA isolation and quality control. Total RNA was isolated from both studies with 
TRIzol reagent (Invitrogen, Breda, the Netherlands) according to manufacturer’s 
instructions. RNA was further purified and DNAse treated using RNeasy micro columns 
(Qiagen, Venlo, the Netherlands). A NanoDrop ND-1000 spectrophotometer (Isogen, 
Maarssen, the Netherlands) was used to determine RNA concentrations. RNA quality was 
assessed on an Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, the 
Netherlands) with 6000 Nano Chips using the Eukaryote Total RNA Nano assay. RNA was 
judged as suitable for array hybridization only if samples showed intact bands 
corresponding to the 18S and 28S rRNA subunits, displayed no chromosomal peaks or 
RNA degradation products, and had a RIN (RNA integrity number) above 8.0. 
 
Affymetrix microarray. Five micrograms of RNA were used for one cycle cRNA 
synthesis (Affymetrix, Santa Clara, CA). Hybridization, washing and scanning of 
Affymetrix Mouse Genome 430 2.0 arrays was carried out according to standard 
Affymetrix protocols. Packages from the Bioconductor project (288), integrated in an in-
house developed online management and analysis database for multiplatform microarray 
experiments (Gavai AK, de Groot PJ, Lin K, Boekschoten MV, Liu Y, Nijveen H, 
Neerincx PBT, Hooiveld GJEJ, Muller M and Leunissen JAM. MADMAX - Management 
and analysis database for multi-platform microarray experiments (2009). Submitted.), were 
used to analyze the scanned microarrays. Quality control based on various advanced quality 
metrics, diagnostic plots, pseudo-images and classification methods was performed to 
assure only excellent quality arrays were included in further statistical analyses (8). Arrays 
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were normalized using quantile normalization, and expression levels were calculated using 
GC-RMA applying the empirical Bayes approach (416) and a remapped chip description 
file (CDF) (294). 
 
Comparisons were made between WY14643-treated and control animals (study A) and 
WY14643 and DMSO treated hepatocytes (study B). Differentially expressed genes from 
study A and B were combined to create one dataset. Genes with a P-value <0.01 and fold 
change >1.5 were considered significantly upregulated by treatment. 
 
In silico screening of putative PPREs. The in silico screening for putative PPREs 
was performed according to (295). Briefly, the consensus sequence of AGGTCA was used 
to create 39 different PPREs with single nucleotide variations. These variations were tested 
for the in vitro binding of PPAR-RXR heterodimers and subsequently used to calculate 
binding strength. The variations were divided into two categories based on medium (20-
38%) or strong (>39%) binding. Genomic sequences for the entire mouse genome were 
extracted from the Ensembl data base (Ensembl release 44, April 2007). These were 
screened for the varying PPREs using in-house software named RESearch. A list of all 
medium and strong PPRE variants can be found in (295). 
 
Conservation analysis of identified putative PPREs was carried out using cis-regulatory 
element annotation system (CEAS) (417). The CEAS model uses PhastCons (418) to 
assign conservation scores to each putative PPRE region. These scores are based on multiz 
alignment of human, chimp, mouse, rat, dog, chicken, fugu and zebrafish genomic DNA. 
PPREs with a conservation score >0.8 were considered to be conserved. 
 
Distance to closest gene was calculated using PinkThing (http://pinkthing.cmbi.ru.nl; F. 
Nielsen, M. Kooyman, M. Huynen; paper in preparation). PinkThing compares the position 
of each putative PPRE against the location of genes. 
 
Results 
 
In silico screening of putative PPREs 
Previously, we characterized the in vitro binding preference of PPARα on a panel of 39 
systematic single nucleotide variations of the consensus DR1-type PPRE 
(AGGTCAAAGGTCA). PPREs were subsequently classified according to strength of 
binding by PPARα and grouped into strong or medium binding strength PPREs. Putative 
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PPREs were identified throughout the mouse genome via an in silico screening method (see 
methods). 
 
For PPARα, we found a total of 113598 medium PPREs and 49373 strong PPREs. The 
number of PPREs identified within a chromosome was highly correlated with the size of 
the chromosome (Figure 1A). As it has been suggested that the functionality of nuclear 
receptor binding sites is determined by species conservation (415), we removed non-
conserved PPREs, which drastically reduced the number of PPREs to approximately 4% of 
the original search. Interestingly, conserved PPREs appeared to be a bit more abundant on 
chromosome 11 relative to other chromosomes (Figure 1B). 
 
We next examined the distance of the PPREs to the closest gene. The results indicated that 
most medium PPREs were situated 1-5KB up-or downstream from a TSS. Most strong 
PPREs were positioned more than 10KB from the TSS (Figure 2A). Interestingly, most 
conserved PPREs were situated more than 10KB from the TSS (Figure 2B), which was true 
for both medium and strong PPREs. 
 
 
 
Figure 1. Number of putative PPREs in the mouse genome. The graphs show the number 
of PPREs for PPARα per chromosome and in total for all chromosomes. Grey bars are medium 
PPREs, black bars strong PPREs. (A) All PPREs resulting from the in silico screen. (B) Conserved 
PPREs with a conservation score of >0.8. Conservation scores were calculated using the CEAS 
method (417). 
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Figure 2. Distance between PPREs and the closest gene. Pie graphs showing the distance 
between PPREs for PPARα and the closest gene. (A) All PPREs resulting from the in silico screen 
are included. (B) Conserved PPREs with a conservation score of >0.8. Conservation scores were 
calculated using the CEAS method (417). 
 
 
 
 
 
 
To better appreciate the number of PPREs present in and around an average single gene, for 
every gene we calculated how many putative PPREs were present within ±2KB, ±10KB or 
±50KB from TSS (Figure 3). The majority (80%) of all genes have no PPRE, medium or 
strong, within ±2KB from the TSS. In contrast, close to 100% of genes contain at least one 
medium PPRE within ±50KB from the TSS, and almost 90% of genes contain at least one 
strong PPRE within ±50KB from the TSS. Conserved PPREs, however, are much more 
rare. Indeed, around 80% of all genes contain no conserved PPRE within ±50KB from the 
TSS. 
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Figure 3. Percentage of genes with a certain number of PPREs within different ranges 
from TSS. Graph shows the percentage of all genes with a certain number of medium and strong 
PPREs for PPARα, according to scale, within ±2KB, ±10KB and ±50KB from TSS. (A) All PPREs 
resulting from the in silico screen are included. (B) Conserved PPREs with a conservation score of 
>0.8. Conservation scores were calculated using the CEAS method (417). 
 
 
 
 
 
 
No correlation between in silico screening and PPARα regulation in vivo 
By definition, functional PPREs mediate induction of gene expression by PPAR. To 
explore the connection between the presence of PPREs within a gene and gene regulation 
by PPARα, we first determined the set of genes upregulated by PPARα. To that end, 
Affymetrix microarray analysis was performed on liver samples from mice treated with the 
PPARα agonist WY14643 for 6 hours, as well as on primary hepatocytes treated with 
WY14643 for 6 hours. Out of 13935 genes included in the analysis, 598 genes were 
significantly upregulated (P<0.01, FC>1.5) upon WY14643 treatment in either mouse liver, 
primary hepatocytes, or both. 
 
We next examined whether genes upregulated upon PPARα activation are enriched with 
PPREs. This analysis was performed separately for PPREs within ±2KB, ±10KB or ±50KB 
from TSS, and also for conserved PPREs. Importantly, we found that PPREs were not more 
abundant in genes significantly upregulated by PPARα activation compared to all genes on 
the array (Figure 4). This result was obtained independently of the type of PPRE (medium, 
strong) and whether the PPRE was conserved. The results indicate that genes that are 
upregulated by PPARα activation and thus represent putative PPARα target genes are not 
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enriched with PPREs, irrespective of whether PPREs are conserved, suggesting that 
presence of PPREs is disconnected from gene induction. 
 
It can be hypothesized that not the presence of PPREs but rather their distance to the TSS is 
important for gene regulation. However, we found that upregulated genes were not 
specifically enriched with PPRE within ±2KB of TSS compared to nonregulated genes or 
all genes (Figure 4). In fact, there were hardly any regulated genes that contained a PPRE 
within ±2KB of TSS. Additionally, we did not find a relationship between the distance of 
gene to nearest PPRE and fold change in expression of the gene upon PPARα activation, 
again regardless of the type of PPRE and whether it was conserved (Figure 5). 
 
 
 
 
 
 
 
 
 
Figure 4. PPARα-regulated genes are not enriched with PPREs. Percent genes with certain 
number of PPREs (according to scale) within ±2KB, ±10KB and ±50KB from TSS. The X-axis 
compares all genes on the array with significantly upregulated genes upon PPARα activation (P<0.01, 
FC>1.5). (A) non-conserved medium PPREs; (B) non-conserved strong PPREs; (C) conserved 
medium PPREs; (D) conserved strong PPREs. 
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Figure 5. No correlation between in vivo gene regulation and distance to closest 
PPRE. Scatter plots showing the relationship between log fold change in gene expression (Y-axis) 
and log distance to closest PPRE for PPARα (X-axis). (A) medium PPREs, (B) strong PPREs, (C) 
medium conserved PPREs, (D) strong conserved PPREs. PPREs with a conservation score of >0.8 
are considered to be conserved. Conservation scores were calculated using the CEAS method (417). 
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Figure 6. Percentage of significantly upregulated genes with a certain number of 
PPREs. Graph shows the percentage of genes, compared to all genes, (Y-axis) that have a certain 
number of PPREs for PPARα within ±10KB (A: non-conserved; C: conserved) or ±50KB (B: non-
conserved; D: conserved) from TSS (X-axis). PPREs with a conservation score of >0.8 are 
considered to be conserved. Conservation scores were calculated using the CEAS method (417). 
Purple bars are medium PPREs, black bars are strong PPREs. 
 
 
 
 
No correlation between number of PPREs for each gene and regulation by 
PPARs 
Finally, we explored the possible correlation between the number of PPREs for each gene 
and gene regulation by PPARs. If gene regulation by PPARα requires several PPREs, one 
would expect that as the number of PPREs for a gene increases, the likelihood of regulation 
by PPARα increases accordingly. For non-conserved strong but not medium PPREs, there 
seems to be a minor trend that as the number of PPREs increases, the chance that a gene is 
regulated increases as well. No clear trend was observed for conserved PPREs. Our data 
argue against a clear relationship between the number of PPREs connected with a gene and 
its chance of being upregulated by PPARα activation (Figure 6). 
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Additionally, we explored the possible correlation between the number of PPREs for each 
gene and the fold change in expression of the gene upon PPARα activation. To quantify the 
number of PPREs and take into account the strength of predicted PPARα binding, we 
created a PPRE score for each gene. This PPRE score was calculated by giving each 
medium PPRE the value 0.5 and each strong PPRE the value 1. Then, by adding up the 
number of medium and strong PPREs for each gene within a certain distance from TSS 
(PPREscore = #strongPPREs * 1 + #mediumPPREs * 0.5), we obtained PPRE scores 
ranging from 0 to 16. We next plotted the PPRE score of a gene against the fold change in 
expression of the gene upon PPARα activation (Figure 7). The data show a lack of 
correlation between PPRE score and fold change in expression. In fact, the relationship 
between PPRE score and fold change resembled the overall frequency distribution of PPRE 
scores among all genes (compare left and right panels). This correlation was also not 
improved when only conserved PPREs were included. Taken together, our analysis does 
not support a correlation between the number of PPREs in proximity of a gene and its 
regulation by PPARα. 
 
 
 
 
 
Figure 7. No correlation between in vivo gene regulation and number of PPREs for 
each gene. A PPRE score was calculated for each gene within a certain distance from TSS 
(PPREscore = #strongPPREs * 1 + #mediumPPREs * 0.5). This PPRE score (X-axis) was put in 
relation to log fold change (Y-axis) in scatter plots (left panels). Right panels show PPRE score (X-
axis) in relation to percentage of genes (Y-axis). (A) PPREs within ±10KB from TSS, (B) PPREs 
within ±50KB from TSS, (C) conserved PPREs within ±10KB from TSS, (D) conserved PPREs 
within ±50KB from TSS. PPREs with a conservation score of >0.8 are considered to be conserved. 
Conservation scores were calculated using the CEAS method (417). 
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Discussion 
The primary aim of this paper was to investigate the utility of whole genome screening for 
PPAR binding sites to help identify target genes of PPARs in mouse. A secondary aim was 
to find out the properties that determine the functionality of putative PPAR response 
elements. The major outcome of this study was that presence of PPREs in the vicinity of 
the TSS of a gene based on in silico screening correlates very poorly with actual gene 
regulation as determined by microarray analysis. This is true regardless of the number of 
PPREs present around a gene, their predicted strength of PPAR binding, their proximity to 
the TSS, and their conservation between species. Our data question the utility of in silico 
PPRE screening for the identification of novel PPAR target genes. 
 
The applicability of an in silico screening method ultimately depends on setting appropriate 
criteria for screening in order to optimize sensitivity and selectivity. We screened the 
genomic region ±2KB, ±10KB and ±50KB from the TSS of a gene and performed separate 
analyses for medium and strong PPREs, the latter property being based on the predicted in 
vitro PPARα binding affinity of the PPRE. Indicating a lack of sensitivity, it was observed 
that 99% of all mouse genes carried at least one medium PPRE within ±50KB from the 
TSS. Setting more stringent criteria for PPREs in terms of location, predicted PPARα 
binding strength and number of PPREs, however, failed to improve matching with the data 
on gene regulation. 
 
As an additional criterion to sort out the functional PPREs from our screen, we addressed 
sequence conservation across species. Recently, it was shown that sequence conservation 
of putative glucocorticoid receptor binding sites across species predicted actual in vivo 
occupancy at glucocorticoid-induced genes (415). These findings imply that conservation 
may be helpful in determining the functionality of PPAR binding sites within PPAR-
regulated genes. However, whether the conservation of putative PPREs surrounding a gene 
may predict its upregulation remains unclear. In our study we assessed conservation using a 
method available online which is based on comparison between eight different species, 
including human, mouse and rat. While taking into account sequence conservation led to a 
dramatic decrease in the number of putative PPREs, it did not improve the correlation with 
the gene expression data. 
 
To compose a list of genes upregulated by PPARα we combined microarray data of livers 
from mice treated with the PPARα agonist WY14643 for 6 hours and microarray data of 
primary hepatocytes treated with WY14643 for 6 hours. Previously we established that the 
effects of WY14643 on gene regulation in mouse liver are exclusively (>99%) mediated by 
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PPARα (69). The time point of 6 hours was chosen to largely avoid inducing indirect 
mechanisms of gene regulation involving another transcription factor. Although our list of 
PPARα-induced genes will certainly not be complete nor be devoid of false positives, the 
list should be highly enriched with PPARα target genes compared to the set of genes not 
induced by PPARα activation. Consistent with this notion, careful inspection of the list of 
PPARα-induced genes allowed us to identify virtually all established direct target genes of 
PPARα. Nevertheless, no differences in the number of PPREs present around a gene and 
their proximity to the TSS were found between genes upregulated and not upregulated by 
PPARα. These results were not altered when taking into account sequence conservation. 
 
Our results raise the question to what extent upregulation of gene expression by PPARα is 
mediated by PPREs or may be achieved via an alternative mechanism. While several 
mechanisms have been put forward to explain downregulation of gene expression by 
PPARα (111), to our knowledge no evidence is available suggesting that PPAR can 
upregulate gene expression independently of PPRE binding. 
 
It should be emphasized that the discrepancy between actual gene regulation and in silico 
prediction of putative PPAR targets based on presence of PPRE does not imply lack of 
PPARα binding to the PPREs identified. It is conceivable that PPARα is capable of binding 
to the putative PPREs, yet for reasons that remain to be defined binding may not translate 
into transcriptional regulation. To assess whether PPARα is bound to the PPREs identified, 
our analysis should be coupled to direct measurement of in vivo binding of PPAR to DNA 
using ChIP-on-chip or ChIP-Seq. 
 
It is worth noting that conserved PPREs were absent in a number of well-known PPARα-
induced genes. These include Fgf21 and Cidec, both of which were recently shown to be 
transcriptional targets of PPAR (419-421). While promoter-reporter studies led to the 
identification of a functional PPRE in the mouse Fgf21 and Cidec promoters (419, 422), it 
is unclear whether these PPREs are conserved in human. 
 
One question that was not addressed in the present study is whether the presence of several 
PPREs in close proximity (so-called PPRE clusters) may be predictive of gene regulation 
by PPARα. An example of such a PPRE cluster consisting of four adjacent PPREs is 
present in intron 3 of the Angptl4 gene, which represents a highly sensitive PPAR target. 
However, it is difficult to assign criteria for a PPRE cluster. Furthermore, PPRE clusters 
are expected to be extremely rare. Another aspect that we did not address is the proximity 
of PPREs to other transcription factor binding sites. It is expected that functional PPREs 
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are primarily found in promoter regions characterized by the presence of numerous 
transcription factor binding sites. 
 
In the present paper we concentrated the analysis on PPARα. However, a parallel analysis 
was performed for PPARγ using microarray data from 3T3-L1 adipocytes and mouse 
adipose tissue treated with rosiglitazone which essentially yielded the same results. No 
enrichment of (conserved) PPREs was found among PPARγ-regulated genes. 
 
In conclusion, together with previous data (415), our study suggests that screening for 
conserved PPREs may be a valuable tool to identify functional PPREs within genes known 
to be induced by PPAR. However, screening of putative PPREs cannot predict gene 
regulation by PPARα nor do we find that PPARα-induced genes are enriched with PPREs, 
regardless of the selection criteria employed. 
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The objective of this thesis was to better characterize the roles and modes of activation of 
PPARα and PPARβ/δ in the liver. To achieve this aim, a nutrigenomics approach was 
pursued by combining microarray technology with several transgenic- and knockout mouse 
models in the context of a specific dietary intervention. 
 
The concept of nutrigenomics rests on the knowledge that diet is the most important 
environmental factor impacting the transcriptome. As a consequence, in the past few years 
transcriptomics has taken the field of molecular nutrition by storm. Since transcriptomics 
first became available in the late twentieth century, a huge number of studies have been 
published reporting on the effects of nutrients at the whole genome level. However, while 
this technology allows for a very large number of genes to be analyzed simultaneously, 
thus giving a comprehensive picture of changes in gene expression, the gain of insight into 
the underlying molecular processes is generally limited. To fully understand and interpret 
whole genome gene expression data, it is highly recommended to combine transcriptomics 
analysis with specific functional genomics tools, thereby giving more specific information 
about the mechanism of gene regulation. Thus, rather than merely studying the effect of a 
dietary compound or drug, functional genomics tools should be implemented to alter the 
expression of potential molecular mediators, whether it is a membrane receptor, 
transcription factor, or signaling kinase. This concept, while commonplace in biomedical 
science, is just gaining ground within nutritional science. This thesis represents a successful 
example of such an approach, based on a combination of microarray analysis and knockout 
mouse models. 
 
Since PPARα was first described in 1990 (20), its role in hepatic lipid metabolism has been 
extensively studied (42, 69, 73, 74). It is well established that PPARα is able to bind and be 
activated by dietary fatty acids. Indeed, several intervention studies in mice have 
demonstrated activation of PPARα in response to feeding with different fats. So far, 
however, only diets consisting of several types of fats have been used (such as a high fat 
diet, a Mediterranean diet, or a fish oil diet), which makes it impossible to distinguish the 
effects of the individual fatty acids on gene regulation by PPARα. In this thesis, we used a 
unique nutrigenomics design based on synthetic triglycerides composed of one single fatty 
acid. By feeding these synthetic triglycerides to wildtype and PPARα-/- mice, followed by 
determination of the gene expression profiles in the livers of these mice, we were able to 
investigate the effect of several types of dietary unsaturated fatty acids on hepatic gene 
expression and ascertain the specific role of PPARα in fatty acid-dependent gene 
regulation. This type of study can be considered a mixture between a nutritional and 
pharmacological intervention, since it concerns a dietary macronutrient yet is administered 
in relatively high dose in purified form. Whereas conventional nutrigenomics studies often 
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are based on a summary of effects by several components, in our study changes in gene 
expression can be traced back to one single fatty acid. In this thesis we successfully studied 
the effects of these synthetic triglycerides on gene expression in mouse liver. This approach 
can also be applied to other tissues such as heart and intestine, and may involve knockout 
models for transcription factors other than PPARα. 
 
Using PPARα-/- mice, it has been clearly established that PPARα governs the fasting-
induced upregulation of numerous genes involved in hepatic fatty acid oxidation, many of 
which have been identified as direct PPARα target genes (70-72). The PPARα-dependent 
induction of fatty acid oxidation during fasting, the ability of PPARα to be activated by 
fatty acids, and the increase in circulating FFAs during fasting have led to a generally 
accepted model in which the elevated plasma FFAs themselves are responsible for the 
induction of hepatic fatty acid catabolism via enhanced ligand-activation of PPARα (423). 
Although the evidence supporting direct activation of PPARα in liver by FFA is 
circumstantial, the model has been readily adopted since it makes sense physiologically and 
provides a mechanistic basis for the observation that the rate of fatty acid utilization is 
generally proportional to the plasma FFA concentration. We were able to show, however, 
that circulating FFAs are not able to ligand-activate PPARα in mouse liver. Since it is well 
established that dietary fatty acids are indeed able to bind and activate PPARα in liver (69, 
73, 338, 339), the question remains how the two fatty acid signaling pathways are separated 
within the hepatocyte. The basis for the physical separation within hepatocytes lies in 
differences in the mechanisms of cellular uptake between the two fatty acid sources. While 
plasma FFAs enter the hepatocyte as fatty acids, dietary fatty acids are predominantly taken 
up in the form of triglycerides as remnant particles, which are internalized and degraded to 
liberate free fatty acids. We envision that a different mechanism of uptake is linked to 
distinct pools of fatty acids inside the hepatocyte, which may serve as substrates or ligands 
for distinct metabolic or regulatory pathways. The exact mechanisms responsible for 
intracellular transport of fatty acids largely remain elusive, although an important role of 
fatty acid binding proteins (FABPs) is commonly assumed. Several studies using co-
immunoprecipitation and transactivation assays have indicated a direct interaction between 
liver FABP1 and PPARα (82, 424-426). Interestingly, a LXXLL domain characteristic to 
proteins that are capable of binding PPARs and other nuclear receptors has not been 
identified in FABP1 (82), suggesting that PPARα may interact with FABP1 through a 
domain yet to be identified. FABPs represent a large family of proteins that bind long chain 
fatty acids and LCFA-CoA with high affinity (427-429). Different members of this family 
are known to exist, each characterized by a specific pattern of expression among tissues. 
Although the various FABPs are still often referred to by the tissue in which they were 
originally identified (liver – FABP1, intestine – FABP2, heart – FABP3, adipose tissue – 
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FABP4, epidermis – FABP5 and brain – FABP7), several FABPs often co-exist in one 
single tissue. For example, different FABPs are known to be expressed in the liver. 
Recently, it was suggested that the nuclear receptor ligand retinoic acid is able to activate 
either retinoic acid receptor (RAR) or PPARβ/δ depending on whether it is bound to 
cellular retinoic acid binding protein (CRABP) or FABP5, respectively (83). In analogy it 
is conceivable that after uptake plasma FFAs bind to a different FABP compared to fatty 
acids derived from plasma triglycerides, which in turn is coupled to a different PPAR. 
According to this scenario, plasma free fatty acids might bind to FABP2 or FABP5 and 
interact with PPARβ/δ, while plasma triglyceride-derived fatty acids bind FABP1 and 
interact with PPARα. Future research will need to address whether this mechanism might 
explain the differential activation of the two PPAR subtypes by different fatty acids. 
 
Experimental approaches to characterize these mechanisms are hampered by the lack of 
appropriate in vitro hepatocyte model systems for studying gene regulation by fatty acids. 
For this thesis, several attempts were made to activate PPARα in primary hepatocytes by 
means of incubation with fatty acids. Although fatty acids efficiently upregulated gene 
expression in the FAO liver cell line, including upregulation of established PPARα target 
genes, we were not able to get a PPARα response in primary cells. Microarray analysis 
revealed that the fatty acids were indeed taken up by the hepatocytes, since the expression 
of many genes were changed upon treatment. None of these genes were known PPARα 
targets, however. Careful analysis of the genes regulated by fatty acids in primary 
hepatocytes did point to several target genes of HNF4a, which has previously been shown 
to bind LCFA-CoAs (340, 430-432). Although the reason for the lack of PPARα activation 
by fatty acids is not clear, there are a few possibilities that come to mind. First of all, it is 
possible that the unresponsiveness of PPARα is related to the fact that we incubated the 
cells with albumin bound FFAs, which based on our in vivo analysis were suggested to be 
unable to activate PPARα in liver. Alternatively, we found that expression of FABP1 and 
FABP2 in hepatocytes declined very quickly after culturing the cells. Finally, the lack of 
activation of PPARα targets by fatty acids might be connected to a high mitochondrial fatty 
acid oxidation activity, thereby limiting the amount of fatty acids available in the cell to 
activate PPAR. However, the latter speculation does not explain why our microarray 
analysis revealed hundreds of genes changed upon treatment with fatty acids. 
 
Overall, this thesis illustrates the power of using microarrays. This is especially true when 
microarrays are combined with other experimental tools, such as transgenic- and knockout 
mouse models, siRNA, metabolic measurements and measurement of DNA binding. One 
important remaining problem, however, is the lack of proper statistical tools to deal with 
the low signals typically achieved with nutritional interventions. Direct application of 
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standardized techniques used for stronger interventions, such as pharmacological studies, 
often results in major loss of information. Rather than performing statistics at the level of 
individual genes, nutritional interventions call for a more comprehensive type of analysis 
that takes into account parallel regulation of genes within a single biological pathway. 
 
This thesis illustrates that microarrays are not only useful for generating hypotheses but can 
be equally applied towards testing research hypotheses. Overall, the work described in this 
thesis has greatly expanded our understanding of the role of PPARα and PPARβ/δ in the 
liver. Furthermore, it has provided important new leads for future research. Finally, our 
nutrigenomics type of analysis has demonstrated the extremely important role of PPARs in 
gene regulation by fatty acids. 
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Summary 
 
Since obesity and its related metabolic diseases are rapidly increasing world-wide, studies 
aimed at uncovering the molecular mechanisms that control lipid metabolism are becoming 
more and more important. Within the field of nutrigenomics, researchers study how 
nutrition influences gene-, protein- and metabolite expression on a genome-wide scale. 
This type of research is mainly focused on preventing disease, rather than curing already 
developed illnesses and holds the expectation that nutritional intervention early on will 
prevent the need for pharmacological therapy. Common tools used within the field of 
nutrigenomics include gene expression microarrays, where the entire genome can be 
measured simultaneously on a small chip, and transgenic- and knockout mouse models, 
where a gene of interest can be either overexpressed or completely shut down. 
 
As indicated above, within the field of nutrigenomics there is special interest in 
understanding the effect of dietary components on gene expression. Effects of dietary 
components on gene expression are partially mediated by members of the nuclear receptor 
superfamily, including the peroxisome proliferator activated receptors (PPARs). Three 
PPAR isoforms are known to exist: PPARα, PPARβ/δ and PPARγ. PPARα has been well 
described as a major regulator of hepatic lipid metabolism and is of great importance in the 
liver during fasting. Much less is known about PPARβ/δ in liver, although some studies 
point to an involvement of this transcription factor in certain metabolic processes. 
 
The aim of the research carried out in this thesis was to determine the importance of 
PPARα in fatty acid dependent gene regulation in liver. Moreover, we set out to better 
characterize the functional roles of PPARα and PPARβ/δ in hepatic gene regulation and 
function. 
 
With the help of various nutrigenomics tools, we were able to gather several important 
results. Firstly, we were able to create a comprehensive list of PPARα target genes in the 
liver, and demonstrated that the role of PPARα in hepatic lipid metabolism is much more 
extensive than previously described. Furthermore, using a unique nutrigenomics design that 
involves feeding mice synthetic triglycerides composed of one single fatty acid, we were 
able to determine the effect of individual fatty acids on gene regulation in liver. By 
performing a parallel analysis in wildtype and PPARα-/- mice, we were able to show that 
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the effects of dietary unsaturated fatty acids on hepatic gene expression are almost 
completely mediated by PPARα. 
 
In the second part of this thesis we show that contrary to what has been generally assumed, 
circulating free fatty acids are not able to ligand-activate PPARα. We offer an alternative 
theory based on involvement of other transcription factors, especially PPARβ/δ. By using 
gene expression arrays in combination with analysis several metabolic parameters, we 
managed to appoint a role for PPARβ/δ in hepatic glucose utilization and lipoprotein 
metabolism. 
 
Finally, we utilized an in silico method to screen for putative PPAR binding sites in the 
mouse genome. In an attempt to investigate a possible correlation between the identified 
putative PPREs and actual gene regulation, we compared the results from the in silico 
screen with results from microarray analysis of mouse livers and mouse primary 
hepatocytes treated with the PPARα agonist WY14643. Our data, however, question the 
utility of in silico screening to predict gene regulation by PPARs and to identify novel 
PPAR target genes. Screening for conserved PPREs within genes known to be induced by 
PPAR may be a valuable tool to identify functional PPREs. 
 
In conclusion, this thesis demonstrates the power of microarray analysis in combination 
with specific knockout models to determine the impact and mechanisms of gene regulation 
by nutrients. This thesis extends our knowledge of PPARα as a dietary fatty acid sensor in 
liver and provides important new information on the role of PPARβ/δ in liver metabolism. 
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Samenvatting 
(Summary in Dutch) 
 
Wereldwijd neemt de prevalentie van obesitas en aan obesitas gerelateerde ziekten nog 
steeds toe. Het is daarom belangrijk dat er onderzoek gedaan wordt naar de moleculaire 
mechanismen die betrokken zijn bij de regulering van het vetmetabolisme. Het vakgebied 
van Nutrigenomics is erop gericht met behulp van grootschalige technieken de effecten van 
voeding op het niveau van gen, eiwit en metaboliet te onderzoeken. Dit type onderzoek wil 
uiteindelijk bereiken dat door middel van voedingsinterventies ziekten kunnen worden 
voorkomen. Belangrijke technieken die binnen nutrigenomics worden toegepast zijn 
microarrays, waarmee de mRNA expressie van vrijwel het hele genoom bepaalt kan 
worden, alsmede transgeen en knock-out diermodelen waarbij een gen tot overexpressie 
wordt gebracht of volledig wordt uitgeschakeld. 
 
Binnen nutrigenomics is er speciale aandacht voor de effecten van voedingsstoffen op de 
expressie van genen. Deze effecten komen voornamelijk tot stand via een groep van 
receptoren die bekend staan als nucleaire hormoon receptoren, en dan in het bijzonder de 
peroxisome proliferator activated receptors (PPARs). Er zijn 3 verschillende typen PPARs: 
PPARα, PPARβ/δ en PPARγ. PPARα reguleert het vetmetabolisme in de lever en is vooral 
van groot belang tijdens vasten. Over PPARβ/δ is veel minder bekend. Volgens een aantal 
studies is deze transcriptiefactor betrokken bij bepaalde metabole processen. 
 
Het doel van dit promotieonderzoek was om uit te zoeken welk belang PPARα inneemt bij 
de regulering van gen expressie door vetzuren in de lever. Tevens was het onderzoek erop 
gericht de rol van PPARα en PPARβ/δ in de lever op te helderen. 
 
Het onderzoek heeft een aantal belangrijke resultaten opgeleverd. Ten eerste zijn we erin 
geslaagd een uitgebreide lijst van PPARα target genen in de lever op te stellen die liet zien 
dat de rol van PPARα in de lever veel verder gaat dan tot dusver werd aangenomen. 
Daarnaast hebben we gebruik gemaakt van een uniek ontwerp waarbij muizen eenmalig 
werden blootgesteld aan synthetische triglyceriden bestaande uit één specifiek vetzuur. 
Door experimenten in parallel in wildtype and PPARα knock-out muizen uit te voeren 
konden we laten zien dat de effecten van onverzadigde vetzuren in de voeding op 
genexpressie in de lever vrijwel volledig tot stand kwamen via PPARα. 
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Het tweede deel van dit promotieonderzoek laat zien dat vrije vetzuren die in het bloed 
circuleren niet in staat zijn PPARα te activeren, in tegenstelling tot wat algemeen wordt 
aangenomen. Daarentegen kan PPARβ/δ in de lever wel door vrije vetzuren in het bloed 
worden geactiveerd. Door middel van microarray analyse in combinatie met meting van 
diverse metabolieten konden we laten zien dat PPARβ/δ in de lever betrokken is bij het 
metabolisme van lipoproteinen en glucose. 
 
Tenslotte beschrijft dit proefschrift de resultaten van een in silico screen voor 
bindingsplaatsen van PPARα in het genoom. De resultaten van de screen zijn vergeleken 
met de resultaten van analyse van gen expressie in muizen levers en primaire hepatocyten 
behandeld met de PPARα agonist WY14643. Onze analyse plaatst vraagtekens bij de 
voorspellende waarde van in silico screening voor het vaststellen van PPARα target genen. 
Daarentegen kan het zoeken naar geconserveerde PPARs van nut zijn om functionele PPAR 
response elementen te identificeren binnen genen waarvan bekend is dat ze door PPARα 
worden gereguleerd. 
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